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Abstract 
Carbamazepine (CBZ), an anticonvulsant and mood-stabilising drug, is 
known to cause delayed type hypersensitivity reactions. These reactions 
occur only in a minority of patients treated with the drug, but often result in 
severe clinical outcomes. Although an association between CBZ-induced 
hypersensitivity reactions and HLA alleles has been demonstrated, the 
underlying mechanism(s) of toxicity are poorly understood. 
Cell death caused by CBZ and one of its metabolites, 9-
acridinecarboxaldehyde (9-AC) was investigated. CBZ did not show cytotoxic 
effects in concentrations ranging from sub-therapeutic to supra-therapeutic. 
By contrast, 9-AC caused apoptosis in the lymphoblastoid cell line (50µM 
and 24 hours of exposure) and primary PBMCs (50 µM and 2 hours of 
exposure). PBMCs from 20 CBZ-naïve individuals showed significant inter-
individual variability in the susceptibility to the cytotoxic effect of 9-AC. 
To further investigate the observed inter-individual variability, 331 
immortalised lymphoblast cell lines of unrelated individuals from 4 
populations were exposed to CBZ, CBZ-10,11 epoxide or 9-AC and cell 
viability was measured after 24 hour exposure. Considerable inter-individual 
variability in the cytotoxic response was observed for all three compounds. 
The genome wide association study (GWAS) revealed two genetic 
polymorphisms in dual oxidase 1 (DUOX1) and RP11-354|13.2 that were 
linked to cell toxicity at low concentrations of all three compounds. 
A SNP in DUOX1 was investigated further because of its biological 
plausibility. Genotyping of 153 patients did not show an association between 
this SNP and CBZ-induced hypersensitivity in Caucasians. Due to the higher 
than normal frequency of the DUOX1 variant in non-Caucasian patients 
(20%), the involvement of DUOX1 in the predisposition to CBZ-induced 
hypersensitivity reactions in non-Caucasians could not be excluded. 
To elucidate how T cell activation occurs in CBZ-induced hypersensitivity 
reactions, the protein binding capability of CBZ and two of its metabolites, 
CBZ-10,11 epoxide (CBZE) and 9-AC, to human serum albumin and 
glutathione S-transferase π was assessed. Only CBZE was found to bind 
covalently to these proteins. For 9-AC, no covalent products were observed 
but an indication of reversible binding was detected. 
Finally, newly developed genotyping methods for HLA-A*31:01 were 
investigated in comparison to sequence based typing. The methods were 
based on SSP-PCR. One of the methods showed exact accordance with the 
current gold standard but PCR failed to amplify the gene of interest and the 
control gene in considerable amount of samples (13.1%), while the second 
SSP-PCR typing method showed less reliability. 
In conclusion, the mechanisms of CBZ hypersensitivity has been 
investigated using a number of approaches designed to elucidate 
bioactivation of the drug, and how cytotoxicity links with genetic factors. The 
genomic approach may have the potential to identify novel biomarkers, but 
needs further studies with larger sample size. 
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1.1 Adverse Drug Reactions 
 
Despite recent advances in science, adverse drug reactions (ADRs) still 
present a major clinical problem for modern medicine. ADRs can range from 
a mild skin rash to a severe life threatening systemic reaction, which affects 
multiple organs. ADRs can result in prolonged hospitalisation, which 
increases costs, and are a great concern to national health services [1]. A 
meta-analysis of data from the USA before 1990 extrapolated the number of 
deaths caused by ADRs to more than 100 000, making ADRs the fifth most 
common cause of death in hospitals [2]. Although this study was criticised for 
the heterogeneity of the data included and the methodology used [3], it still 
underlines the importance of understanding and preventing ADRs. A review 
from 2008 of over 25 studies conducted in the United Kingdom, revealed that 
out of 106 586 hospital admissions, 2 143 were related to ADRs, 
representing 5.3% of all hospital admissions.[4]. The cost of admissions to 
hospital due to ADRs was estimated to reach approximately £466m per year 
in the UK alone [1]. ADRs are also of great concern for pharmaceutical 
industry since they are the most common reason for withdrawal of marketed 
drugs [5]. Although ADRs are widespread, the underlying mechanisms are 
poorly understood and there are only a few genetic biomarkers available to 
predict a patient’s risk for developing ADRs. 
 
1.1.1 Definition of adverse drug reactions 
The World Health Organisation defines ADRs as ‘any response to a drug 
which is noxious, unintended, and occurs at doses normally used for 
prophylaxis, diagnosis, or therapy…’ [6]. This definition excludes effects 
resulting from overdose and misuse and multiple attempts have been made 
to bring forth a more precise definition for ADRs. In this thesis, the definition 
by Edwards and Aronson will be used, which states that an ADR is ‘an 
apparently harmful or unpleasant reaction, resulting from an intervention 
related to the use of medicinal product, which predicts hazard from future 
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administration and warrants prevention or specific treatment, or alteration or 
the dosage regimen, or withdrawal of the product.’ [7] 
 
1.1.2 Classification of adverse drug reactions 
ADRs can be divided into different types: type A, B, C, D, E, and F. The 
precise determination of an ADR allows for appropriate management and 
prevention of further harm to the patient. Misdiagnosing ADRs can lead to 
fatal consequences for the patient. Several classification systems have been 
developed. Two of these will be discussed in this introduction. 
 
1.1.2.1 Classification of ADRs by Rawlins and Thompson 
The classification of ADRs by Rawlins and Thompson is the predominant 
model utilised in clinics and throughout literature [8]. The classification has 
been modified over the years as the understanding of molecular mechanisms 
of ADRs has improved. In this classification system, the ADRs are divided 
into the following groups according to their dose dependence. 
 
Type A 
Type A (augmented or ‘ON TARGET’ ADRs) is the most common form 
accounting for over 80% of all ADRs [9]. Their outcome is related to the 
known pharmacology of the drug and the toxic effects occur as a result of an 
overreaction of the body to the drug, which can be avoided by adjustment of 
the dose. 
 
Type B 
Type B, also named “bizarre”, or ‘OFF TARGET’ ADRs, are less common 
(20%) [9]. They are also called idiosyncratic drug reactions as the reaction is 
not connected to the known pharmacological characteristics of the drug. 
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These ADRs are often more serious and account for many drug-induced 
deaths. A typical clinical feature is the lack of a clear dose-dependent 
relationship; the reactions can be observed at any dose within the 
therapeutic window. Type B ADRs generally do not have a high incidence 
rate and the risk factors for developing type B reactions are mostly unknown. 
 
Other Types 
Type A and B reactions were established to divide ADRs into dose-related 
and non-dose-related reactions. Over the years, this system left some ADRs, 
such as osteoporosis due to corticosteroid treatment, unclassified as they 
could not be placed into one of these two categories. Therefore, further 
categories were introduced to the ones proposed by Rawlins and Thompson, 
and should be briefly mentioned here for completeness of the current 
terminology [7, 10]. 
 Type C, or chronic ADRs, are less common. They are related to the 
cumulative dose of the drug. The best known example is 
hepatotoxicity caused by paracetamol [11]. 
 Type D, or delayed ADRs, are also uncommon but are usually related 
to the drug dose and occur a while after treatment with the drug, such 
as teratogenesis and carcinogenesis. Foetal hydantoin syndrome 
seen in children whose mothers were treated with phenytoin (an 
anticonvulsant) during pregnancy is an example [12]. 
 Type E, or end of use ADRs, are also uncommon. They occur soon 
after the drug treatment has been stopped. Such reactions can be 
observed after the withdrawal of opiate therapy [7]. 
 Type F, or failure ADRs, are common and dose-related. They can be 
caused by drug-drug interactions. An example of such reactions is the 
decreased effectiveness of oral contraceptives during treatment with 
antibiotics [13]. 
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1.1.2.2 Dose relatedness, timing, and patient susceptibility 
An alternative to the Rawlins and Thompson’s classification is the dose 
relatedness, timing, and patient susceptibility (DoTS) system developed by 
Aronson and Ferner [14]. One of the advantages is that it was developed 
much later and with greater knowledge of ADRs. The issue with this system 
is its rare utilisation as it has not been widely established in the clinic or in 
literature. 
Similar to the Rawlins and Thompson’s model, the DoTS system categorises 
ADRs by the dose at which they occur and is based on supratherapeutic 
doses (toxic effect), standard therapeutic doses, and subtherapeutic doses. 
Timing is subdivided into time dependent and time independent reactions. 
Time dependent reactions are further sub-divided into rapid, first dose, early, 
intermediate, late, and delayed reactions while time independent reactions 
can occur during any time of treatment. 
The last category is susceptibility. It divides patients into different risk groups 
depending on known factors associated with higher risk for ADRs. Known 
factors that increase the susceptibility of a patient include age, gender, 
disease state, exogenous factors, genetic variation and chemical properties 
of the drug involved. 
 
1.1.3 Risk factors for adverse drug reactions 
Certain risk factors, such as age, gender, disease state, environmental 
factors, genetic variation, and chemical properties, have been associated 
with ADRs in different populations with different drugs. 
The risk for most ADRs increases with age [15] but there are ADRs with a 
higher incidence in infants such as the liver injury caused by valproic acid 
[16]. Gender can also influence risk as many ADRs are more likely to occur 
in women [17-19]. Viral infections, especially HIV and herpes simplex virus, 
also increase the risk of ADRs [20-25]. The stage of the disease has also 
been shown to be important for the prediction of a patient’s risk [26-30]. The 
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chemical properties of a drug are also considered important for the prediction 
of the risk of ADRs [31]. 
Furthermore, genetic variation can influence the risk of an ADR. Single 
nucleotide polymorphisms (SNPs) are the most common genetic variants 
and are known to increase risk of ADRs caused by certain drugs. SNPs 
associated with ADRs have been identified in genes across the human 
genome. These genes can be related to the pharmacology of the drug or 
apparently unrelated to the known pharmacology of the drug [32]. 
The first group of genes are responsible for the pharmacokinetics of ADR-
causing drugs, including phase I and II metabolism genes, drug transporters, 
ion channels or receptors. A well-known example are the polymorphic genes 
that encodes the enzymes N-acetyltransferase type 1 and 2 (NAT-1, NAT-2) 
responsible for the detoxification of arylamine and hydrazine metabolites. 
SNPs in these genes cause amino acid substitutions in the protein 
sequence, which reduce their enzymatic activity [33]. It has been shown that 
the polymorphisms in these genes have clinical implications for the 
metabolism of drugs such as isoniazid and sulphonamides [34]. It has been 
reported that slow acetylators suffer from more side effects of certain drugs 
(e.g. dapsone and procainamide) while isoniazid treatment may fail in fast 
acetylators [35]. 
The second group of genes are mainly involved in the immune response 
(immunogenic genes). An increasing number of studies have shown a strong 
association between human leukocyte antigen (HLA) alleles and drug 
hypersensitivity reactions, which may allow prediction of ADRs (see Tab. 1.1) 
[36]. HLAs play an important role in the antigen presentation to T cells and 
two associations between HLA alleles and ADRs will be discussed in more 
detail in section 1.4.4.1 and 1.7.3 of this chapter. 
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1.2 Drug-induced Hypersensitivity Reactions 
 
Drug-induced hypersensitivity reactions (DHRs) are a form of idiosyncratic or 
type B ADRs that can be observed in susceptible patients. DHRs can be 
subdivided into allergic (immune-mediated) and pseudo-allergic (non-
immune-mediated) reactions. The majority of DHRs appear to be immune 
mediated and this work will focus on immune mediated DHRs [49]. 
DHRs do not show an observable dose-response relationship and are 
therefore considered dose independent [49]. The common understanding is 
that DHRs may occur at concentrations, well below therapeutic levels [50]. 
Another characteristic of most DHRs is the delayed onset of clinical 
symptoms, varying from one day to several weeks before the first 
manifestations [49, 51]. Symptoms of DHRs appear much quicker when the 
patient is re-challenged by the drug, consistent with the immune nature of the 
reactions [52, 53]. 
As DHRs only occur in a small minority of patients treated with the drug, they 
are rarely seen in phase I-III clinical trials and often only manifest in post-
marketing surveillance (Phase IV). Currently there are very few animal 
models that can be used to study DHRs [54-56]. DHRs present a major 
clinical problem as well as being the main reason for post-marketing drug 
withdrawal. Although the risk-benefit ratio of a drug associated with DHRs is 
difficult to assess, withdrawal of the drug would protect a minority, it also 
means denial of an otherwise safe, and maybe more efficient, drug to the 
majority of people. As the safety and drug efficacy to all patients is the main 
concern, it is important to study and understand the mechanisms of DHRs 
and thus find markers to distinguish between patients who will benefit and 
those who will suffer from the unwanted effects of a drug. 
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1.2.1 Classifications of hypersensitivity reactions 
According to Coombs and Gell, DHRs can be categorised, into four groups: 
type I, type II, type III and type IV reactions [57]. This system represents a 
sub classification of type B reactions in the system described by Rawlins and 
Thompson and is based on the mechanism of the immune response involved 
(see figure 1.1). This system has been utilised and has proven useful in 
clinical practice [58]. 
Some drugs have the ability to act as haptens. By binding covalently to host 
proteins, they form immunogenic complexes that elicit an immune response. 
In the case of type I hypersensitivity reactions, immunoglobulin (Ig) E, binds 
the hapten and the resulting complex promotes the activation of mast cells 
and basophils. Upon activation, these innate immune cells release a number 
of factors, such as histamine, leukotrienes, prostaglandins, and cytokines, 
which induce vasodilation, bronchoconstriction, vascular permeability, mucus 
production, and eosinophil recruitment [59]. The clinical features of an IgE-
mediated reaction can vary in severity from a mild skin rash to lethal 
anaphylaxis. 
Type II reactions are mainly IgG-mediated. In these reactions the hapten-
carrier complex consisting of IgG and the drug coats target host cells and 
leads to sequestration of blood cells by the reticuloendothelial system in the 
liver and spleen through complement-receptor binding [59]. Alternatively, the 
hapten-carrier complex can activate the classical complement pathway and 
lead to cell lysis through complement-fixing immune complex formation. 
Clinical features, such as haemolytic anaemia, granulocytopenia and 
thrombocytopenia can be observed in type II hypersensitivity reactions. 
Type III DHRs are similar to type II in the formation of immune complexes via 
IgG. Compared to type II, type III DHRs derive from an excessive formation 
of immune complexes, which are deposited in the basement membrane of 
blood vessels. Clinical manifestations of type III reactions include serum 
sickness and vasculitis [59]. 
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Type IV DHRs are T cell mediated reactions and are also referred to as 
delayed-type hypersensitivity reactions. T helper and cytotoxic T cells 
involved in the type IV DHRs can orchestrate different forms of inflammation, 
which leads to different clinical manifestations. Based on the subset of T 
cells involved in the delayed-type DHR, the type IV reactions are sub-divided 
into four classes: type IV a, type IV b, type IV c, and type IV d (see Tab.1.2) 
[60].  
The focus of this thesis is on the effect of the drug carbamazepine (CBZ) on 
inducing type IV reactions, which is discussed in more detail in section 1.7.3. 
 
Table 1.2: Classification of type IV hypersensitivity reactions  
 Type IV a Type IV b Type IV c Type IV d 
Type of T cells 
T helper 
cells type 1 
T helper cells 
type 2 
Cytotoxic T 
cells 
T cells 
Pathological 
mechanism 
Monocytic 
inflamation 
Eosinophilic 
inflamation 
Keratinocytes 
/ hepatocytes 
death 
mediated by 
T cells 
Neurophilic 
inflamation 
Clinical 
manifestation 
Eczema MPE 
Bullous 
exanthema 
(SJS, TEN), 
MPE and 
DRESS 
Pustular 
exanthema 
(AGEP), 
SJS, TEN 
and MPE 
     
MPE: maculopapular exanthema, SJS: Steven Johnson Syndrome, TEN: toxic epidermal 
necrolysis, AGEP: acute generalised exanthematous pustulosis, DRESS: drug rash with 
eosinophilia and systemic symptoms (adapted from Posadas and Pichler 2007 [60]) 
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In type IV a reactions, T helper 1 cells release cytokines (e.g. interleukin (IL)-
2, interferon-γ, and lymphotoxin-α) that activate macrophages and other 
phagocytes and increase their phagocytic activity [60, 61]. In addition, the T 
helper 1 cells stimulate the production of complement fixing antibodies (IgM 
and IgG) by plasma B cells and are pivotal in maintaining a proinflammatory 
response. 
In type IV b reactions, T helper 2 cells secret cytokines (e.g. IL-4, IL-10, and 
IL-13 ) that increase antibody titres and regulate the antibody class switch 
from IgG to IgE the production of IgE and IgG production in plasma B cells. 
Furthermore, T helper 2 cells regulate the deactivation of macrophages, and 
the response of mast cells and eosinophil granulocytes [60, 61]. 
Type IV c reactions are mediated by cytotoxic T cells that act as effector 
cells. They migrate to tissues and can destroy tissue cells by lysing them or 
by inducing apoptosis [60]. The cytotoxic effects of cytotoxic T cells are 
triggered either by the recognition of non-self antigens presented by HLA 
class I on the surface of target host cells or though antibody-depended 
cellular cytotoxicity (ADCC) [62]. 
Type IV d involves antigen driven T cells coordinating neutrophilic 
inflammation. T cells recruit neutrophilic leucocytes through the release of 
the chemokine interleukin 8 and prevent the apoptosis of these leucocytes 
through white blood cell growth factors (granulocyte-macrophage colony-
stimulating factors) [63]. A typical example for this is sterile inflammation of 
the skin, such as in acute generalised exanthematous pustulosis (AGEP). 
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1.2.2 Clinical manifestations of cutaneous drug reactions 
DHRs can occur in almost any tissue or organ of the body including skin, 
liver, and blood [52] with skin being most commonly affected and accounting 
for 2-3% of hospitalised ADR patients [64-68]. 
Manifestations of cutaneous DHRs vary from mild rashes, which require 
treatment cessation, to severe blistering forms, which can require intensive 
care and have a high mortality rate. The clinical manifestations caused by a 
specific drug can vary between patients [52]. The different forms of 
cutaneous DHRs show distinct clinical characteristics [51] and include 
maculopapular exanthema (MPE), acute generalised exanthematous 
pustulosis (AGEP), Steven Johnson Syndrome (SJS) and toxic epidermal 
necrolysis (TEN). 
The most common cutaneous reaction observed in DHRs is MPE, which 
accounts for 31-95% of all cutaneous DHRs [65, 66, 69]. The symptoms are 
usually observed during the first two weeks after the start of treatment and 
disappear after the treatment is discontinued [70, 71]. Initial manifestations 
include isolated patches of faint, pink or red macules. These then develop 
into maculopapular rashes in the extremities with moderate to severe itching 
and can be accompanied by fever. 
AGEP is less common, with an incidence rate between 1-5 per million each 
year [72, 73]. Typical characteristics for AGEP are small, numerous pustules 
arising widely spread all over the skin [63]. Symptoms appear within the first 
week of treatment [74]. The mortality rate from AGEP is approximately 5% 
without appropriate clinical treatment [71]. 
The most severe blistering skin reactions caused by drugs are SJS and TEN. 
SJS and TEN are considered to be forms of the same spectrum of skin 
reaction. The incidence rate is estimated between 1:100 000 and 
1:1 000 000, which makes them a very rare form of cutaneous DHRs [75]. 
The two forms are distinguished from each other by the percentage of skin 
detachment observed in the patient [76]. SJS is associated with up to 10% of 
skin detachment whereas TEN is associated with 30% or more of skin 
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detachment. Between 10-30% skin blistering is called SJS/TEN overlap 
syndrome. These reactions occur during the first eight weeks of treatment. 
After the first observed symptoms, the rash develops quite rapidly and 
withdrawal of the drug does not always stop the progression [52]. The most 
important clinical prognostic factors for the patient are percentage of skin 
detachment, age, and underlying disease. The mortality rate for SJS is 13%, 
for SJS/TEN overlap syndrome 21%, and for TEN ~30% [77]. 
Drug rash with eosinophilia and systemic symptoms (DRESS) is a severe 
DHR. Different terminologies are used in literature for drug reactions 
involving different organs, such as hypersensitivity syndrome (HSS) or drug-
induced hypersensitivity syndrome (DIHS) [78-80]. In this work this reaction 
will be referred to as DRESS. Clinical symptoms of DRESS usually occur two 
to eight weeks after the start of drug treatment and often include a 
combination of different symptoms including high fever, skin rash, and 
lymph-node swelling. In addition, multiple organs are involved including liver, 
kidneys, lungs, and heart, resulting in pneumonitis, lymphadenopathy, 
hepatitis, and nephritis [52]. The liver is the most commonly involved organ 
[81] and DRESS can lead to liver failure, which is the most common cause of 
death in DRESS with a 10% mortality rate [51]. DRESS can be easily 
misdiagnosed as an acute viral infection. This is due to the level of activated 
T-cells and virus specific antibodies in the blood which can be similar to 
those seen for viral infections [82-85]. The underlying mechanism of DRESS 
is poorly understood but it has been proposed that activated T cells cause 
the tissue damage [86]. 
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1.3 Immune system  
 
Multicellular organisms employ the immune system to defend themselves 
from pathogens and cancers. To fulfil this protective function, the immune 
system has evolved complex mechanisms enabling it to distinguish between 
self- and non-self-structures. Upon the detection of non-self-structures the 
immune system responds either with tolerance or an immune response 
through its two arms, namely the innate and the adaptive immune system. 
The innate immune system provides a fast response to structures common in 
many pathogens, such as specific glycolipid or certain forms of nucleic acid. 
Since the recognition repertoire of the innate immune system is limited, some 
pathogens have evolved to evade the innate immune response. In 
comparison the adaptive immune system is slower, however, it has a vast 
variety of highly specific antibodies and  receptors that is achieved through a 
complex gene rearrangement allowing it to adapt to the ever changing 
pathogens [87]. 
 
1.3.1 Innate immune system 
The innate immune system is the first line of defence of the organism and 
consists of physical barriers (e.g., skin, mucus, low pH) and effector immune 
cells and molecules. The innate immune responses are mediated by 
phagocytic cells (macrophages, monocytes, neutrophils and dendritic cells), 
mast cells, basophils and eosinophils [88] which are triggered by patterns 
associated with pathogens [87, 89, 90]. 
The recognition of pathogen-associated molecular patterns (PAMPs) by 
innate immune cells and the alternative and lectin complement pathways 
plays a crucial role in the initiation of the innate immune response [91]. 
PAMPs are conserved molecules, only associated with pathogens such as 
bacteria (e.g. lipopolysaccharide, flagellin, peptidoglycan and bacterial DNA), 
viruses (e.g. single- or double-stranded viral DNA and RNA), fungi (e.g. 
glucan) and parasites (e.g. chitin). PAMPs are detected by pathogen 
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recognition receptors (PRRs), such as toll-like receptors, which can be found 
in soluble form (e.g. complement) or expressed on the membrane of 
phagocytic cells such as macrophages and neutrophils [92, 93]. The binding 
of soluble PRRs to PAMPs results in the lysis of the pathogen, for example 
as a result of the activation of the alternative and lectin complement 
pathways [87]. The activation of the complement system leads to the 
formation of pores in the membrane of the pathogen and it subsequent lysis. 
Binding of membrane bound PRRs to PAMPs leads to the engulfment and 
phagocytosis of the pathogen, the release of inflammatory mediators and 
activation of the adaptive immune responses. 
PRRs can also detect damage-associated patterns (DAMPs). DAMPs, such 
as heat shock proteins, high-mobility group box 1 proteins, adenosine 
triphosphate, uric acid and cellular DNA, are released by the loss of 
membrane integrity of a host cell, which can be caused by rupture of the cell 
through physical damage or through certain pathways of cell death such as 
necrosis [94, 95]. Similar to the detection of PAMPs, recognition of DAMPs 
by PRRs results in the activation of the adaptive immune system through the 
release of pro-inflammatory mediators, by basophils, eosinophils, mast cells, 
natural killer cells (NK) [88, 94, 96]. 
The cytotoxic NK cells belong to the innate arm of the immune system. 
However, in contrast to the other innate immune cells, they recognise 
malfunctioning host cells, such as cancer or virus infected cells, by the 
abnormal expression of HLA class I molecules on the cell surface and induce 
their apoptosis [97]. 
The dendritic cells (DCs) play a central role in the immune response. They 
absorb extracellular components through phagocytosis and pinocytosis and 
display antigens on their surface, thus turning into antigen-presenting cells 
(APCs) [88]. The APCs then initiate the activation of the adaptive immune 
system and therefore play an important role in the crosstalk between the 
innate and the adaptive immune systems. 
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1.3.2 Adaptive immune system 
The adaptive immune system is more specific in its response but requires 
time before activation, during which the innate immune system keeps the 
pathogens at bay. The highly specialised cells of the adaptive immune 
system can be divided into two groups, namely cells involved in the humoral 
response (B-cells) and cells involved in the cell-mediated immune response 
(T cells) [98]. Like the cells of the innate immune system, they are derived 
from hematopoietic stem cells of the bone marrow, but maturate through 
distinct differentiation pathways in either the bone marrow (B cells) or thymus 
(T cells) [99-101]. The B and T cells can be activated and must be carefully 
controlled to prevent damage to healthy cells, while dealing with pathogens 
or malfunctioning host cells [87]. The B and T lymphocytes express specific 
B or T cell receptors on their cell membrane which can bind complementary 
antigens thus leading to their activation. 
B cells detect antigens through B cell receptors which represent membrane 
bound antibodies. Upon recognition of pathogenic structures, B cells 
transform into plasma cells mostly under the influence of an activated T 
helper cell [102]. The differentiated plasma cells then produce and secrete 
soluble antibodies which can then bind to an antigen and thus mark it for 
digestion by phagocytic cells. Furthermore, antibodies specifically bound to 
an antigen can activate the classical complement pathway or stimulate 
antibody-dependent cytotoxicity (ADCC) carried out by NK, neutrophils and 
monocytes [103]. 
In contrast to B cells, the T cells are incapable of detecting foreign antigens 
directly: they require a presentation of antigens by APCs such as dendritic 
cells, macrophages, neutrophils and B cells. These phagocytes internalise 
and process the pathogenic proteins into peptides (epitopes) for presentation 
on the HLA class II. T helper lymphocytes express an antigen specific T cell 
receptor (TCR), which interacts with the peptides presented on the HLA at 
the surface of APCs. If the peptide is recognised as non-self, the T cells are 
activated [87, 104-107]. This results in proliferation and differentiation of a 
particular set of T cell into effector T cells. 
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The TCR is a heterodimer anchored in the outer membrane of T cells 
consisting of two polypeptides linked via disulphide bonds. The majority of 
the TCR polypeptides are highly variable α and β chains. Each of these 
chains is composed of four domains, namely, the N-terminal variable region, 
the constant region, a hydrophobic transmembrane domain followed by the 
cytoplasmic tail [108]. The variable region is responsible for the antigen 
recognition. Specific peptide recognition is achieved through gene 
rearrangement during gene expression. This process results in a variety of 
genes, which would not be possible to be encoded for in the genome. The 
naïve T cells undergo two selection processes in the thymus to ensure their 
functionality [88]. The first of these is a positive selection which selects for T 
cells capable of detecting self-peptides on HLA molecules. This is followed 
by a negative selection during which apoptosis is induced in T lymphocytes 
interacting too strongly with the self-peptides. This selection prevents the 
induction of autoimmune reactions initiated by T cells [109]. 
The T lymphocytes can be grouped into two functionally different types 
depending on the cluster of differentiation (CD) expressed on their surface. 
The function of the CD molecules is to recognise HLA molecules and assist 
during the TCR recognition of epitopes presented by HLA [87]. T cells 
expressing CD4 only detect epitopes presented by HLA class II molecules on 
APCs and are called T helper cells. These T cells mediate the activation of 
other innate and adaptive immune cells by secreting a variety of cytokines. 
As mentioned earlier (section 1.2.1), depending on the cytokines released, 
the T helper cells can be further subdivided into Th1 and Th2 which regulate 
the function of different immune cells. T cells expressing CD8 interact with 
HLA class I molecules and are referred to as cytotoxic T cells. These T 
lymphocytes are capable of killing infected cells by inducing apoptosis. 
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1.4 Major histocompatibility complex 
 
The MHC is located on the short arm of chromosome 6 (6p21.3) and more 
than 220 genes that regulate innate and adaptive immune functions are 
encoded in this region [110, 111]. MHC encodes transmembrane 
glycoproteins expressed on the surface of every nucleated cell in the human 
body and possess an immunoglobulin-like region for the presentation of 
endogenous and exogenous peptides to T cells [112]. 
The MHC was first described in 1936 when it was found that antigenic 
molecules in the blood of mice are responsible for the rejection of 
transplanted tumours [113]. It was later discovered that similar antigenic 
structures are present on the cell surface of human leukocytes which is why 
human MHC molecules were named HLAs in humans [114]. 
 
1.4.1 Classification and structure 
The MHC molecules are divided into three major classes, MHC I, MHC II and 
MHC III, based on their molecular structure and function. The first two 
classes of MHCs present peptide fragments to T cells and subcategorised 
into HLA-A, HLA-B and HLA-C for MHC I and HLA-DQ, HLA-DP and HLA-
DR for MHC II. The HLA genes are generally inherited in blocks, one block 
from each progenitor, called haplotypes. These haplotypes are co-
dominantly expressed in the individual. Frequencies of these haplotypes 
show large variability in different ethnicities [115]. MHC III genes encode 
proteins of the complement system and inflammatory cytokines including 
tumour necrosis factor α and heat shock proteins. These are however, not 
membrane proteins and have no role in the antigen presentation. A diagram 
of the MHC region depicting the three gene clusters is shown in figure 1.2. 
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Figure 1.2: Localisation of genes in major histocompatibility complex 
(MHC) region (adapted from Klein and Sato, 2000 [112]) 
 
Class I and class II HLA molecules are related structurally and functionally 
and are expressed as glycosylated membrane bound heterodimers. Although 
HLA class I and HLA class II molecules share a number of functional 
similarities , differences exist in the source of protein fragments they present 
as well as in the subset of T cells they present these peptides to [116]. 
The HLA class I molecule consists of a 45 kDa α subunit (heavy chain), 
which is encoded by the HLA class I gene, and a 12 kDa β2-microglobulin 
polypeptide (light chain) encoded on chromosome 15 [117]. The polymorphic 
α chain contains three extracellular domains (α1, α2 and α3), a 
transmembrane region and a cytoplasmic tail. The α1 and α2 domains form 
the peptide-binding groove of HLA class I molecules, which presents 8 to 11 
amino acids long peptide fragments [118]. HLA class I molecules can be 
found on the surfaces of all nucleated cells in the body. The peptides they 
present derive from the cytosolic antigen processing [119]. 
In contrast, HLA class II molecules are only expressed on APCs and the 12 
to 25 amino acids long peptides fragments they present derive from the 
endocytic antigen processing [120]. The HLA class II molecule consists of a 
33 kDa α chain and a 28 kDa β chain [117]. The each of the chains consists 
of two extracellular domains (α1 and α2 or β1 and β2), a transmembrane 
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region and a cytoplasmic tail. The peptide-binding groove is formed by α1 
and β2 domains [112]. 
 
1.4.2 Polymorphism and nomenclature 
The HLA genes are highly polymorphic, with a large number of HLA alleles 
reported and with the HLA-B locus being the most polymorphic [121, 122]. In 
the case of HLA class I alleles, single nucleotide polymorphisms (SNPs) that 
distinguish the different alleles located in the second and third exon and are 
most commonly typed, as these parts code for the antigen-binding groove of 
the HLA protein. For HLA class II, SNPs in the second exon are routinely 
typed, since most of these SNPs are non-synonymous and lead to changes 
in the amino acid sequence as well as in the peptide-binding groove [122]. 
The determination of HLA polymorphisms or HLA typing has evolved 
significantly since the first discovery of HLA antigens in human blood [114]. 
The first method used for HLA typing was based on serology utilising 
antibodies directed against HLA molecules on the cell surface [123]. Since 
then, the application of DNA-based methods increased the repertoire of 
available methods, especially after the discovery of sequence-based typing 
which applies PCR or next generation sequencing technology [124]. 
Due to the large number of known HLA alleles, systematic nomenclature has 
been introduced. The standardised nomenclature system was established in 
1968 by the International Histocompatibility Working Group (IHW) [125]. This 
system is still used today and constantly maintained and updated by the 
WHO Nomenclature Committee for Factors of the HLA System [126]. 
The HLA allele name consists of the name of the gene locus followed by an 
asterisk and a number that identifies the gene variant (see Fig. 1.3). The 
identification number of the gene variant can consist of four fields, which are 
separated by colons. The first field identifies the type of allele and 
corresponds to the serological type in most cases. The next field is the 
subtype of the HLA allele. The field is assigned in sequential order, which 
allows the incorporation of further alleles. The third field describes 
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synonymous mutations while the last field identifies mutations in the non-
coding regions. The identification number of the gene variant can be followed 
by an optional letter describing the expression status of the allele. 
 
 
Figure 1.3: Nomenclature of HLA alleles 
 
1.4.3 Antigen processing and presentation 
As mentioned earlier (section 1.3.1), APCs play a central role in the 
activation of the adaptive immune response by engulfing, processing and 
presenting extracellular antigens on HLA class II to T helper cells in the 
lymph nodes [87]. 
HLA class I molecules present intracellular epitopes that are degraded in the 
cytosol by the proteasome. During this cytosolic (endogenous) antigen 
processing, the peptide fragments are translocated into the endoplasmic 
reticulum (ER) by a transporter associated with antigen processing (TAP). 
The peptides are then mounted onto HLA class I molecules by the peptide 
loading complex in the ER. After the formation of a stable peptide-HLA 
complex, the HLA class I complexes are released from the ER and proceed 
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through the Golgi apparatus to the surface of the cell for antigen presentation 
to cytotoxic T lymphocytes [127]. 
In contrast to HLA class I, HLA class II complexes present extracellular 
antigens. In the endocytic (exogenous) antigen processing, extracellular 
proteins are internalised by phagocytosis in endosomes. The endosomes 
merge with lysosomes to form the phagolysosome. The acidic conditions 
within this structure promote the activation of proteases, which digest 
proteins in the phagolysosome into peptide fragments. After the 
fragmentation of the proteins, the phagolysosome merges with vesicles 
containing HLA class II molecules and the peptide fragments are mounted on 
the HLA molecules [127]. The newly formed peptide-HLA complexes are 
then transported to the cell surface. The HLA class II α and β chain 
molecules are assembled in the ER and bind a third protein (invariant chain) 
that temporarily occupies the peptide-binding groove [128]. HLA class II 
molecules binding the invariant chain are transported to late 
phagolysosomes, where the invariant chain is degraded by proteases to a 
short peptide, class II-associated invariant chain peptide (CLIP). A chaperon, 
HLA-DM, alters the structure of HLA class II molecule, which results in the 
exchange of CLIP for a peptide fragment derived from the protein digestion 
in the phagolysosome [129]. 
Dividing the antigen processing pathways for HLA class I and class II in 
exclusively intracellular and extracellular proteins is a simplified model of the 
processes found in living cells. The process of cross-presentation has been 
described after it was shown that epitopes derived from extracellular proteins 
can be presented on HLA class I molecules, while HLA class II molecules 
presented intracellular epitopes through the fusion of autophagosome and 
vesicles containing HLA class II molecules [130, 131]. 
The HLA class I complexes are more restrictive during the protein loading 
due to the closed confirmation of the binding groove. The ends of the 
peptide-binding groove interact with the free N and C termini of the peptides, 
which limits the length of the presented peptide [132]. HLA class II 
complexes do not have this length restriction as the peptide-binding possess 
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open ends [133, 134]. The length of the peptide on HLA class II results from 
the peptide processing of proteases. The peptide-binding groove of a HLA 
complexe stabilises the peptide through a series of interactions with the 
peptide backbone and limited interactions with particular side chains of the 
peptide. Two or more residues (anchor residues) of the peptide dock in 
pockets of the peptide-binding cleft and ensure the correct positioning of the 
peptide in the HLA peptide-binding groove [135]. 
 
1.4.4 HLA associations with adverse drug reactions 
HLA alleles play a key role during the activation of T cells thus initiating 
immune responses. The importance of the HLA in the pathogenesis of 
various diseases has been demonstrated by associations between HLA 
alleles and autoimmune disease, infectious disease and cancer [136]. 
However, the precise mechanism of pathogenesis in most diseases remains 
unknown. Furthermore, most of these diseases have multifactorial etiology, 
including environment, life style, and genetics, which complicates matters 
even further. 
More and more discoveries of HLA associations with hypersensitivity 
reactions caused by various drugs are being reported, suggesting that HLA 
molecules may be of crucial importance in at least some drug-induced 
hypersensitivity reactions [137]. However, it is not clear however, what role 
HLA molecules have in the pathogenesis of drug-induced hypersensitivity 
reactions. Furthermore, the fact that HLA molecules are found to be 
associated with specific phenotypes of hypersensitivity reactions caused by a 
certain drug and the HLA molecule varying between different populations 
complicates the analysis of their role [137]. 
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1.4.4.1 Abacavir 
An overview of drug-induced hypersensitivity reactions with known 
association to HLA alleles is shown in table 1.1. Abacavir (ABC) will be 
discussed in more detail as an example of how the knowledge has advanced 
after the discovery of HLA associations and drug hypersensitivity. 
ABC is a nucleoside analogue reverse transcriptase inhibitor and acts as an 
antiretroviral drug used for the treatment of human immunodeficiency virus 
(HIV). One of the most common side effects of the drug is ABC-induced 
hypersensitivity, manifesting in about 70% of the patients through a mild or 
moderate skin rash. More serous forms of ABC-induced hypersensitivity 
reactions, such as DRESS, can be observed in 5-8% of patients treated with 
the drug [36]. The symptoms of DRESS include fever, gastrointestinal 
manifestations and internal organ involvement. Two independent research 
groups have found a strong association between HLA-B*57:01 and ABC-
induced DRESS [39, 40]. Utility of pre-treatment HLA-B*57:01 testing for 
reducing the incidence of hypersensitivity reactions in individuals prescribed 
ABC has been demonstrated in a randomised controlled clinical trial 
conducted in Australia [36]. Further research revealed the presence of 
activated CD8+ T lymphocytes in the skin of patients who had suffered from 
ABC-induced hypersensitivity [138]. Additionally, a T-cell response could be 
triggered in T cells derived from patients as well as from ABC-naïve healthy 
volunteers carrying the HLA-B*57:01 allele [139]. The T cell response was 
found to be HLA-B*57:01 restricted, as even highly similar HLA types were 
unable to induce T cell activation in the presence of ABC. 
The mechanism of T cell activation caused by ABC has been discovered 
recently by three groups who independently reported an interaction of ABC 
with certain amino acids within the binding groove of HLA-B*57:01 [140-142]. 
ABC seems to bind in a non-covalent fashion to one pocket of HLA-B*57:01. 
The preference of the peptide mounted on the HLA molecule during the 
antigen processing is altered through this occupation of one of the pockets in 
the peptide-binding groove. The new peptides preferred for presentation 
possess smaller residues in the position where the peptide interacts with the 
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F-pocket. Based on this observation, a new mechanism for drug mediated T 
cell activation was proposed, the so called “altered self-peptide hypothesis” 
(discussed in section 1.5.3). 
Screening for HLA-B*57:01 in patients before the start of ABC therapy was 
shown to reduce the incidence of ABC-induced hypersensitivity and also was 
proven to be cost effective [143]. Therefore pharmacogenetic testing for 
HLA-B*57:01 in patients is recommended by both the US Food and Drug 
Administration and the European Medicine Agency before the start of 
treatment. ABC is an example for the success of personalised medicine, 
where the discoveries made in the laboratory are transferred into health care 
to the bedside of the patient. 
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1.5 T cell activation in hypersensitive reactions 
 
The activation of T cells plays an important role in the initiation of an adaptive 
immune response. Two signals are required for the full activation of T cells. 
The first signal involves the presentation of peptides on HLA molecules by 
APCs. T cells interact with the peptide-HLA complexes through the TCR and 
co-receptors such as CDs [87]. Mature T cells possess either the co-receptor 
CD4 or CD8 for the interaction with HLA class II or HLA class I molecules, 
respectively. During the recognition, the TCR binds directly to the peptide 
presented, while the co-receptors interact with the HLA-molecule to stabilise 
the TCR-peptide-HLA complex. This process is termed “signal 1” and in 
instances where signal 1 is generated alone, the induction of immune 
tolerance will occur [144]. 
The second signal (signal 2) derives from the detection of primal and 
feedback danger signals in the organism [144]. Primal danger signals consist 
of two subclasses: (i) exogenous and (ii) endogenous danger signals. 
Exogenous danger signals are molecules produced by pathogens (PAMPs), 
while endogenous danger signals are molecules released by cells that 
undergo stress or abnormal cell death (DAMPs) (see section 1.3.1). The 
detection of primal danger signals by resting APCs results in the activation of 
APCs, which trigger T cell activation through the presentation of 
costimulatory signals [95, 145]. For example, immature DCs express low 
levels of HLA class II and costimulatory molecules, while surveying the tissue 
for danger signals. Through the detection of exogenous or endogenous 
danger signals, DCs become activated and turn into APCs with increased 
expression of HLA class II and costimulatory molecules (e.g. B7, OX40L and 
4-1BBL) [146]. The activated DCs then migrate to the lymph nodes where 
they prime naïve T cells. 
Feedback danger signals are proinflammatory cytokines (e.g. IL-2, 
interferon-γ, or TNF α), which are secreted by activated cells of the immune 
system [147]. The detection of feedback danger signals increases the 
presentation of costimulatory signals on the surface of APCs. The 
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costimulatory signals, such as B7, on APCs can interact with CD28 on T 
cells. The interaction of the costimulatory molecules in the presence of signal 
1 results in the full activation of T cells by amplifying the signalling cascade 
triggered through TCR-peptide-HLA interaction, thereby promoting antigen-
specific T cell proliferation, differentiation and survival as well as cytokine 
production [148]. 
The TCR forms a complex with two CD3 heterodimers (CD3εγ and CD3εδ) 
and one CD3 homodimer (CD3ζ) for the activation of intrinsic cell signalling 
pathways [87]. Each of the dimers possesses two intracellular tyrosine-based 
activation motifs (ITAMs). Upon binding of TCR to the antigen and either 
CD4 or CD8 to the HLA molecule, associated Src family kinases, proto-
oncogene tyrosine-protein kinase (Fyn) and lymphocyte-specific protein 
tyrosine kinase (Lck), become activated and phosphorylate tyrosines in the 
ITAMs [149]. Phosphorylated ITAMs recruit zeta-chain-associated protein 
kinase 70 (ZAP-70), which becomes activated through the phosphorylation 
by Lck. ZAP-70 phosphorylates the linker for activation of T cells (LAT) and 
LAT in turn activates transcription factors through the Ras-Erk and 
phosphoinositide 3-kinase (PI3K) pathways [150]. The PI3K pathway 
activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) and Ca2+ flux from the ER, which both result in the transcription of genes 
related to T cell proliferation and effector function [151]. The costimulatory 
signalling (e.g. from B7 bound to CD28) intensifies PI3K signalling and 
increases the expression of pro-survival genes [148]. 
The isolation of drug-specific T cells from blood and tissue of hypersensitivity 
patients clearly showed that T cells are involved in delayed hypersensitivity 
reactions [83, 152]. The above described mechanism of T cell activation 
requires the processing of large molecules, with a mass greater than 
1 000 Da. Drug molecules are too small and would only become 
immunogenic after interacting with larger molecules such as proteins [49, 
153, 154]. Therefore the hapten hypothesis has been developed as a model 
to explain how drugs can be involved in the activation of T cells through 
covalent binding to proteins. Several other models of T-cell activation which 
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do not involve covalent binding of drugs to proteins, have been proposed 
recently, and will be discussed below. 
 
1.5.1 Hapten hypothesis 
The first model to describe the activation of T cells by drugs was the hapten 
hypothesis. A hapten is a small exogenous molecule, which as such is 
unable to initiate an immune response. Only through covalent binding to 
larger endogenous molecules, such as proteins, can haptens become 
immunogenic. In 1935, Landsteiner and Jacobs formulated this hypothesis 
after they showed in experiments that small molecules (< 1 000 Da) can 
induce skin rashes in guinea pigs by binding to proteins [155]. In their 
experiments, Landsteiner and Jacobs showed that reactive molecules of 
dinitrochlorobenzene can cause T cell activation. They demonstrated in vitro 
that the compound used in the experiments could modify proteins. From 
these observations, they hypothesised that small, reactive molecules 
(haptens) can modify proteins and through this trigger an immune response. 
It was later proven that covalent binding of haptens to proteins is required for 
T cell recognition [156]. 
The observation that metabolites but not the parent drug can bind to proteins 
and act as haptens lead to the introduction of the term pro-hapten [157]. This 
bioactivation of the pro-hapten would occur predominantly in the liver through 
cytochrome P450 but can also take place in the skin or in blood, however, at 
a lower rate [60, 158]. If these hapten metabolites are not detoxified, they 
can damage the metabolising host cell, activate the immune system, and 
form protein adducts, which are also capable of evoking an immune 
response [52]. The haptenization of proteins can lead to the formation of anti-
drug antibodies as the hapten-modified proteins can be also processed by 
the antigen-presenting machinery of APCs to haptenised peptides, which are 
then displayed to T cells [100]. The hapten hypothesis is depicted in figure 
1.4. 
 
31 
 
 
Figure 1.4: Hapten hypothesis 
A reactive drug or metabolite binds covalently to an endogenous peptide. The hapten-
modified protein is taken up, processed and presented on the human leukocyte antigen 
(HLA) by an antigen presenting cell (APC). This can then be recognised by a T cell through 
the T cell receptor (TCR), which leads to an immune reaction (adapted from Uetrecht, 2007 
[49]). 
 
Examples of drugs acting as haptens are β-lactam antibiotics, such as 
penicillin, which covalently bind to lysine residues of many proteins, including 
serum albumin. It has been shown that anti-penicillin antibodies and 
penicillin-conjugate specific T cells are found in the serum of hypersensitive 
patients [52]. 
Sulfamethoxazole (SMX) is an example of a prohapten. SMX is metabolised 
by cytochrome P450 in the liver to SMX hydroxylamine. This hydroxylamine 
can then undergo autooxidation resulting in nitroso-SMX, which is highly 
reactive and reacts with the cysteine residues of various proteins [52]. 
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1.5.2 Pharmacological Interaction Concept 
The observation of T cell activation by drugs that are not capable of forming 
adducts with peptides, led to the proposal of an alternative theory that 
focuses on the pharmacological interaction of drugs with immune receptors 
(p-i) [159, 160]. In contrast to the hapten hypothesis where reactive drugs 
form covalent bonds with proteins, it has been proposed that chemically inert 
drugs directly interact with TCR or HLA molecules through non-covalent 
bonds, such as electric, van der Waals, hydrophobic, and hydrogen bonding 
forces, thus leading to the activation of T cells. The T cell activation is 
thought to result from previously primed effector cells and memory T cells, 
which possess a lower activation threshold [159]. The p-i concept is 
supported by experimental evidence showing that T cells could be activated 
via a HLA-dependent mechanism in the presence of glutaraldehyde-fixed 
APCs and nonreactive drugs [161, 162]. These chemically fixed APCs are 
unable of processing proteins for antigen presentation, which suggests that 
the drug interacts with the peptides on HLA molecules of APCs. Additionally, 
T cell activation, measured through visualisation of calcium influx, after the 
exposure to the drug occurred too fast for antigen processing and 
presentation to have taken place [161, 163]. Figure 1.5 depicts the 
mechanism of the p-i concept.  
Drugs found to activate drug-specific T cells include carbamazepine, 
lamotrigine, lidocaine, and sulfamethoxazole [83, 162-164]. Experiments with 
T cells isolated from SMX-hypersensitivity patients showed that the cells 
were activated by the parent drug, SMX, as well as the metabolites, 
suggesting that both mechanisms (the hapten and p-i hypothesis) are 
important in the development of SMX-induced hypersensitivity [165]. T cells 
isolated from SMX hypersensitivity patients reacted only to the parent drug in 
the presence of APCs [163]. It was also shown that covalently SMX-modified 
peptides mounted on HLA molecules did not activate SMX-specific T cells 
[166]. Recent modelling of SMX and TCR interaction revealed a possible site 
for interaction [167]. This suggests that the peptide is not involved in the HLA 
binding and activation of SMX-modified TCR. 
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Figure 1.5: Pharmacological interaction (p-i) hypothesis 
A chemically inert drug binds in a reversible manner to the peptide presented on the human 
leukocyte antigen (HLA). This modified peptide is recognised as a non-self structure by T 
cell receptor (TCR) of a T cell, triggering an immune response (adapted from Bharadwaj et 
al., 2012 [168]). 
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1.5.3 Altered self-peptide hypothesis 
The discovery of the mechanism of ABC-induced hypersensitivity reaction 
resulted in the postulation of a novel hypothesis, the altered self-peptide 
hypothesis [141]. The antiviral drug ABC causes hypersensitivity reactions in 
patients expressing HLA-B*57:01 [40, 169]. It was shown that ABC interacts 
with a specific pocket in HLA molecule, changing the configuration of the 
groove and resulting in the presentation of different self-peptides by HLA-
B*57:01 [140-142]. The different self-peptide presented by the APCs 
activates cytotoxic CD8+ T cells, which mediate the clinical manifestation of 
the ABC hypersensitivity syndrome. 
Based on this observation the hypothesis states that drug molecules bind in 
a non-covalent fashion to pockets within the binding groove of HLA 
molecules. This interaction changes the shape and the chemical properties 
of the pocket, altering the repertoire of self-peptides presented by the 
affected HLA molecule, thus resulting in the presentation of different 
peptides. These new HLA complexes do not take part in the negative 
selection of T cells in the thymus. Therefore, the self-peptides which can only 
bind to the HLA molecule in the present of the drug are capable of activating 
T cells, which presents a mechanism of drug-induced autoimmunity since the 
recognised protein is not modified. Another example of a drug interacting 
with the binding groove of HLA is CBZ [140]. It was shown that CBZ can 
occupy a certain pocket in HLA*B-15:02, which alters the presented peptide. 
The altered self-peptide hypothesis is schematically illustrated in figure 1.6. 
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Figure 1.6: Altered self-peptide hypothesis 
A drug binds to the binding groove of the human leukocyte antigen (HLA) in a reversible 
manner. This changes the properties of the pocket resulting in the binding of novel peptides. 
These peptides are recognised by the T cell receptor and trigger an immune response 
(adapted from Bharadwaj et al., 2012 [168]). 
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1.5.4 Danger Hypothesis 
The danger hypothesis was proposed in 1994 and is based on the 
observation that the activation of T cells requires more than one signal [170]. 
It has been shown that at least two signals are necessary for triggering T cell 
activation [171]. As discussed at the beginning of this section, the recognition 
of non-self peptides presented on HLA molecules by T cells via the TCR is 
termed signal 1 and alone this signal results in immune tolerance [172]. 
The second signal is derived from the interaction of various costimulatory 
molecules on the surface of APCs (e.g. B7) and the receptors on T cells (e.g. 
CD28) and leads to proliferation, differentiation, and survival of the T 
lymphocytes [173]. Signal 2 on APCs is modulated by the detection of 
PAMPs and DAMPs [95, 145]. The first model to describe costimulatory 
signalling for T cell activation assumed that the signals derive from 
pathogens (PAMPs) [174]. The danger model added another source for 
costimulatory signals, which are derived from cells of the body (DAMPs) 
[170]. In the danger model, the detection of non-self structures is not the 
important signal that triggers an immune response. Only the simultaneous 
presence of danger signal initiates the full activation of T cells [175].  
According to the danger hypothesis drugs require costimulatory signals to 
activate naïve T cells. Reactive drugs or metabolites, which cause cellular 
damage, function as antigenic stimuli (see 1.5.1 hapten hypothesis) and also 
lead to the presence of danger signals, which are detected by APCs and 
result in the full activation of naïve T cells [154, 176]. Depending on the 
damaged tissue as a source of danger signals, the hypothesis could explain 
the localised occurrence of DHRs phenotypes [49]. This theory also explains 
why not all reactive drugs or metabolites cause hypersensitivity as not all 
reactive drugs cause cellular damage, thus avoiding the release of danger 
signals [49]. Alternative sources for danger signals are ongoing infections, 
such as HIV and herpes simplex virus, as seen for certain drugs [20, 21]. 
The principle of the danger hypothesis is shown in figure 1.7. 
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It has been shown that ABC, amoxicillin and metabolites of SMX can lead to 
danger signalling [177-179]. For ABC, it was found that the redistribution of 
heat shock proteins in APCs is induced by the drug and that this 
redistribution is accompanied by the expression costimulatory molecules on 
the surface of APCs [177]. 
 
 
Figure 1.7: Danger hypothesis 
Signal 1 occurs as described above for the hapten hypothesis (see Fig. 1.4). Signal 2 is 
present on the surface of antigen presenting cells (APCs) after the detection of danger such 
as infection or tissue damage. Only if both signals are present on the surface of the APC will 
the T cell be activated, resulting in an immune response. The absence of the second signal 
results in tolerance (adapted from Uetrecht, 2007 [49]). 
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1.6 Cell Death 
 
To maintain and ensure the functioning of tissues, the body needs to renew 
cells as well as dispose of infected, malfunctioning or old cells. Different 
modes of cell death have been described [180]. The best known forms of cell 
death are apoptosis and necrosis. Due to different definitions for these cell 
death pathways, the Society of Toxicologic Pathologists formed a committee 
on the Nomenclature of Cell Death, which first made recommendations for 
the definition and use of the terms apoptosis and necrosis [181]. This 
committee later included other forms of cell death and provided definitions 
and recommendations for the newly discovered cell death pathways [180, 
182]. In the beginning, the cell death pathways were defined by 
morphological changes observed during the cell death. In 2012, the 
committee proposed a change of the definitions from the system based on 
morphological characteristics to a system based on functional aspects 
(quantifiable biochemical properties) [183]. The two main advantages of the 
new system are: (1) the observed effect is quantifiable and (2) the 
interpretation of the results is not dependent on the experimenter. According 
to the definition on functional aspects, cell death pathways can be classified 
as accidental or regulated, with programmed cell death presenting a 
subcategory of regulated cell death. The biochemical properties, which 
define the cell death pathway include, enzymes activated during the process 
and immunological characteristics. The enzymes activated during cell death 
include proteases and nucleases. The definition based on the immunological 
characteristics focuses on whether the death of the cell results in an immune 
reaction in the surrounding tissue or not [184]. 
The most important forms of cell death for the work carried out in this thesis 
are apoptosis and necrosis, which will be discussed in greater detail. Other 
cell death pathways will be mentioned in brief. 
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1.6.1 Apoptosis 
Apoptosis plays an important role during the development of organs and 
tissues and is essential for maintaining the functionality of an organism [185-
187]. For example, apoptosis is the central process leading to the elimination 
of activated immune cells and termination of the immune response [188]. 
During bacterial or viral infections, the apoptosis of infected cells acts as a 
defensive mechanism as it destroys the pathogen and the source of 
pathogen production. Apoptosis is a highly regulated process and does not 
disturb the surrounding tissue. 
Morphological characteristics of apoptosis include detachment from 
neighbouring cells, shrinkage of the cell, condensation of chromatin, 
fragmentation of the nucleus, membrane blebbing resulting in the shedding 
of apoptotic bodies, and phagocytosis of the apoptotic bodies [189]. A 
important feature of apoptotic cell death is that the process does not cause 
inflammation (immunologically silent) [190]. 
Apoptosis was first described as programmed cell death by Currie in 1972 
[189]. In mammals, there are two major pathways by which apoptosis can be 
initiated in response to a variety of signals. These apoptotic pathways are the 
extrinsic (death receptor) and the intrinsic (mitochondrial) pathway. The 
extrinsic apoptotic pathway is initiated by extrinsic signals such as the 
binding of death-inducing ligands to death receptors on the cell surface. In 
contrast, the intrinsic pathway is activated through intrinsic signals, such as 
DNA damage, and the mitochondria play a central role [191]. 
The activation of the extrinsic pathway is initiated by the binding of death-
inducing ligands to death receptors. These receptors belong to the tumour 
necrosis factor (TNF) receptor family, such as the TNF receptor, TNF-related 
apoptosis-inducing ligand receptor and Fas receptor. These receptors are 
involved also in other cellular processes, including proliferation and 
differentiation [192]. The best studied pathway is the Fas pathway, which 
also plays an important role in immune responses. For example, the 
elimination of infected cells by cytotoxic T cells as well as the deletion of 
activated T cells after an immune response is mediated via the Fas pathway 
40 
 
[193]. After Fas ligand binding, activated Fas receptors trimerize and a 
death-inducing signalling complex (DISC) is formed [194]. The trimerization 
allows Fas-associated death domain adaptor proteins to be recruited, 
through interactions between the death domains of the adaptor proteins and 
DISC. The adaptor proteins contain death effector domains, which bind 
procaspase-8 and -10 [195]. Caspase-8 is the main initiator in the Fas 
signalling of apoptosis. The clustering in the death-inducing complex 
composed of Fas, Fas-associated death domain and procaspase-8 leads to 
the cleaving of prodomain in procaspase-8, its dimerization, and the release 
of the active caspase. The activated caspase-8 subsequently initiates a 
caspase cascade reaction which leads to the activation of the executioner 
caspase. Additionally, caspase 8 cleaves Bcl-2-homology 3-only protein, a 
member of the protein family responsible for controlling apoptosis via the 
mitochondrial apoptosis [196], and thus also initiates the mitochondrial 
apoptotic pathway [197, 198]. 
The activation of caspase is an important indication for apoptosis as the 
caspase cascade orchestrates various processes [199]. Active caspase can 
be detected as early as 10-15 min. after triggering apoptosis by the extrinsic 
pathway [200, 201]. There are 14 different caspases known in mammals 
which all share important features. Caspases are expressed as inactive 
proenzymes consisting of a prodomain followed by a large and a small 
subunit. Cleaving of the prodomain and dimerization of caspase result in its 
activation. All caspases cleave substrates at an Asp-XXX motif and their 
catalytic triad consists of Cys285, His237 and a carbonyl group at residue 
177 [202]. The 14 caspases can be divided into three groups based on their 
function. The first group consists of inflammatory caspases and includes 
caspase-1, -4, -5, -11, -12, -13, and -14. These caspases are involved in 
inflammation rather than apoptosis. The second group represents the initiator 
caspases and contains caspase-2, -8, -9, and -10. These caspases have 
long prodomains, which contain motifs that allow their recruitment to the 
complexes formed during the initiation of the apoptosis. Caspase-8 and -10 
are the initiator caspases in the extrinsic pathway and possess a death 
effector domain [203]. This domain is needed for the interaction and 
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activation by the death-inducing signalling complex. Caspase-2 and -9 are 
involved in the initiation of the intrinsic pathway and their prodomain contains 
a caspase activation and recruitment domain, responsible for the interaction 
and activation by the apoptosome [204]. The last group of caspases are the 
apoptotic effector caspases and includes caspase-3, -6, and -7. Experiments 
with caspase-3 knockout mice suggest that caspase-3 is the most important 
of the executioner caspases, while caspase-6 and -7 appear to be rather 
redundant [205-207]. Their prodomain is short and they are generally 
activated by initiator caspases. After activation, they cleave multiple cellular 
substrates including apoptotic regulators, structural proteins, proteins 
involved in DNA repair, and regulators of the cell cycle [208]. DNases, such 
as the DNA fragmentation factor 45 kD subunit, are cleaved by caspase and 
thus activated, which results in the DNA fragmentation in the nucleus [209, 
210]. The activation of pro-apoptotic kinases results in the formation of 
apoptotic bodies [211], which is supported by the cleaving of the structural 
proteins, such as fodrin and gelsolin (actin filament network) [212, 213]. The 
inactivation of DNA repair mechanisms serves the purpose of saving energy 
needed for the completion of apoptosis, while cleaving cell cycle regulators 
promotes apoptotic signalling [214]. 
The mitochondria are the main regulator of the intrinsic pathway of 
apoptosis. The most important event in the intrinsic pathway is the 
permeabilisation of the mitochondrial membrane (MMP), which is controlled 
by members of the B cell lymphoma-2 (Bcl-2) protein family. Through MMP, 
pro-apoptotic molecules are released while the essential functionality of 
mitochondria is lost, and thus production of energy within the cell is 
impossible [215]. The members of the Bcl-2 protein family belong either to 
the pro-survival (e.g. Bcl-2) or the pro-apoptotic group (e.g. Bax and Bak). 
Proteins of the Bcl-2 family are expressed in the cell and localised in the 
membrane of mitochondria and endoplasmic reticulum [216]. Members of the 
pro-survival group can inhibit apoptosis by neutralising members of the pro-
apoptotic group. The proportion of anti- to pro-apoptotic proteins is important 
for the survival and the susceptibility to intrinsic apoptosis of the cell [217]. 
Various stimuli, such as DNA damage or cytotoxic insult, can trigger the 
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transcription of pro-apoptotic Bcl-2 proteins inside the cell inducing the 
intrinsic apoptotic pathway. Upon the detection of DNA damage for example, 
p53 regulates the transcription of Bax [218]. The higher proportion of pro-
apoptotic Bcl-2 proteins (e.g. Bax and Bak) in the outer membrane of the 
mitochondria induces the formation of pores in the outer membrane, resulting 
in its permeabilisation, and the initiation of apoptosis. The permeabilisation of 
mitochondria leads to the release of cytochrome c into the cytosol [215]. In 
the presence of ATP, cytochrome c binds to apoptosis protease activating 
factor 1, which leads to the formation of the apoptosome [219]. The 
apoptosome then recruits procaspase-9 that becomes activated and forms 
dimers. Caspase-9 cleaves and activates the executioner caspases. 
Besides the mitochondria, the endoplasmic reticulum (ER) can also initiate 
the intrinsic apoptotic pathway. The ER hosts mechanisms, which control 
and ensure that proteins are folded in the right confirmation. Oxidative stress 
and chemical toxicity can lead to misfolded proteins, which have to be 
unfolded. To prevent accumulation of unfolded proteins and to refold them, 
the protein synthesis is decreased, chaperons and folding catalysts are 
induced, and ER-associated protein degradation is activated to eliminate 
possible aggregates [220, 221]. If these countermeasures do not resolve the 
problem of misfolded proteins, cell death is initiated by calcium ions release 
from the ER [222]. The released calcium ions are then taken up by the 
mitochondria, resulting in cytochrome c release, which in turn increases the 
release of calcium ions by the ER. The cytochrome c release leads to the 
formation of the apoptosome, resulting in the activation of the executioner 
caspases. It has been shown that ER-mediated apoptosis plays a pathogenic 
role in neurodegenerative disorders such as Alzheimer’s disease and 
Parkinson’s disease [223]. 
The clearance of apoptotic bodies through phagocytosis before these lose 
membrane integrity and cellular content leaks into the surrounding tissue, is 
important to prevent an immune response in the surrounding tissue. This 
also presents a protective mechanism from potentially cytotoxic or 
pathogenic contents by preventing them from spreading further in the body 
[224]. The process of this clearance itself is also important for the prevention 
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of an immune response, as during the consummation of apoptotic cells, 
phagocytes release anti-inflammatory mediators, including transforming 
growth factor β, interleukin-10 and prostaglandin E2, while the release of pro-
inflammatory mediators such as TNF α is inhibited [225]. The migration of 
phagocytes to the site of apoptosis is accomplished through attraction 
signals. Apoptotic cells secrete chemo-attractants, such as 
lysophosphatidylcholine, which lead to the migration of monocytes and 
macrophages to the apoptotic cells. After the migration, the phagocytes 
recognise and consume the apoptotic cells via the so called ‘eat-me’ signal 
[226]. The apoptotic cell undergoes surface changes during apoptosis. Early 
on during apoptosis, phosphatidylserine (PS), which is normally localised on 
the inner side of the outer membrane, is exposed on the cell surface. PS can 
be found in discrete patches on the outer membrane and present the ‘eat-
me’ signal [227]. Bridging molecules from the serum, such as β2 glycoprotein 
I, serum protein S, and growth arrest-specific 6, bind to PS exposed on the 
outer membrane and link the apoptotic cell to phagocytes, which leads to 
uptake and phagocytosis [228]. 
 
1.6.2 Necrosis 
Necrosis was long considered an accidental and uncontrolled pathway of cell 
death [229]. According to this theory, necrosis happens as a result of the 
inability of the cell to undergo apoptosis [230] or as a result of physical or 
chemical damage [231, 232]. Growing evidence changed the few of necrosis 
being only accidental and suggests that a regulated, caspase-independent 
pathway of cell death with the morphologic characteristics of necrosis exists, 
which contributes to the development of the body as a backup mechanism of 
cell death [233]. 
The controlled form of necrosis was named necroptosis. It was first observed 
in cells in which the caspase cascade was inhibited, but where TNF α and 
Fas ligand were found to cause cell death [234, 235]. In in vitro experiments 
utilising caspase inhibitors, such as Carbobenzoxy-valyl-alanyl-aspartyl-(O-
methyl)-fluoromethylketone (Z-VAD-FMK), cells have been shown to die via 
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an organised pathway displaying morphological characteristics resembling 
necrosis [236, 237]. Even though the precise mechanism of necroptosis is 
not completely understood, it is clear that receptor-interacting protein kinase 
(RIPK) 1 and 3 play an important role [238]. During extrinsic apoptosis, the 
formed death-inducing signalling complex activates caspase-8, which then 
cleaves RIPK1 and leads to the activation of the executioner caspases thus 
resulting in apoptosis. During the absence of caspase-8 activity, RIPK1 is not 
cleaved and forms a complex with the death-inducing signalling complex and 
procaspase-8. This complex recruits RIPK3 and is called necrosome. Mixed 
lineage kinase domain-like (MLKL) protein is phosphorylated by the 
necrosome and activates a protein phosphatase located in the mitochondria, 
which then inactivates a dynamin-related GTPase and leads to mitochondrial 
fragmentation [239]. It was also observed that MLKL transfers to the cell 
membrane where it activates non-voltage-sensitive ion channels, which 
results in an increased concentration of calcium ions in the cell [240]. 
Calcium ion overload leads to the opening of large nonselective pores in the 
mitochondria, which results in the rupture of the mitochondria. Furthermore, 
calcium ion overload activates phospholipases, proteases, and neuronal 
nitric oxide synthase, which all contribute to the execution of necroptosis 
[241]. 
Necrosis can be best distinguished from apoptosis through the morphology 
of the cell during the process (see Fig. 1.8). Characteristics include swelling 
of the cell, dysfunction of mitochondria, and rupture of the cellular 
membrane. In contrast to apoptosis, no DNA degradation is observed. The 
cell rupture leads to the leakage of cellular content into the extracellular 
space and act as DAMPs, which causes inflammation in the surrounding 
tissue [242]. Necrosis of a cell disturbs the function of the surrounding cells 
greatly and can even force them to undergo cell death. 
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Figure 1.8: Cell death. Difference between apoptosis and necrosis  
Necrosis: after the initial cell damage, the cell and the organelles start swelling. In 
mitochondria this can lead to the loss of membrane integrity and the release of cytochrome 
c. Further swelling of the cell will lead to cell rapture and cause the spillage of cytosolic 
content into the extracellular space which leads to inflammation in the surrounding tissue. 
Apoptosis: Triggered either through extrinsic or intrinsic pathway which leads to the 
activation of caspases, which in turn causes the digestion of cytosolic components, including 
the cytoskeleton, and the fragmentation of the DNA. This is followed by budding where 
apoptotic bodies containing components of cell are formed out of the cell membrane. During 
the whole process the integrity of the membrane is maintained and no inflammation occurs 
in the surrounding tissue. 
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1.6.3 Other cell death pathways 
Autophagy is a cellular mechanism with the purpose to dismantle and recycle 
proteins and organelles. At normal levels, autophagy ensures the function of 
the cell by digestion of malfunctioning proteins or organelles [243]. It is still 
debated whether autophagy alone is the cause of cell death or accompanies 
apoptosis or necrosis. However, it has been shown that increased levels or 
incomplete autophagy can lead cell death [244]. Mammalian target of 
rapamycin (mTOR) plays a central role in autophagy. Upon inhibition of 
mTOR, an autophagosome, a double membrane vesicle, is formed around 
the organelle or protein and is transported to a lysosome [245]. The 
lysosome and the autophagosome merge and the engulfed structure is 
degraded. In the case of autophagic cell death, the mitochondria release 
cytochrome c through pores formed by Bax and Bak. In contrast to 
apoptosis, the formation of pores is mediated either by products of the 
autophagy related genes or by proteases, leaked out of the lysosome [246, 
247]. 
Mitotic catastrophe has been defined as another cell death pathway, which 
can happen during or shortly after unsuccessful mitosis. It has been mainly 
observed in cells display micronuclei or multiple nuclei after mitosis [248]. 
This feature is seen as the main difference between mitotic catastrophe, and 
apoptosis and necrosis [249]. However, the cell death that occurs after 
unsuccessful mitosis activates pathways for apoptosis or necrosis and shows 
morphological characteristics of either of these processes [250]. These 
observations suggest that mitotic catastrophe is a different way of triggering 
either apoptosis or necrosis. 
 
In the last two decades many new cell death pathways have been 
discovered [251-254]. However, further research is required to determine 
whether these are novel cell death pathways or different modes of already 
known pathways as they exhibit similar morphological characteristics [180]. 
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Anoikis was first described in 1994 [255]. It describes an apoptotic response 
as a result of the loss of cell-cell interaction. The molecular cascade initiated 
in anoikis is triggered by the lack of signalling that normally derives from 
interaction between neighbouring cells within the tissue [256, 257]. It is 
important to point out, that the cell death is executed by the same 
mechanism as intrinsic apoptosis. 
Entosis describes a cell death mechanism in which cells can be found 
engulfed in cells that are not phagocytes and was previously described as 
‘cell cannibalism’ [253, 258, 259]. It was shown that the downregulation of 
proteins needed for the formation of junctions between the cells lead to the 
engulfment of cells [260]. After the engulfment, entosis progresses following 
a non-apoptotic pathway, thus distinguishing entosis from anoikis [253, 261].  
Parthanatos has been introduced as a cell death pathway mediated by DNA 
damage-responsive enzymes. Under normal physiological conditions of mild 
DNA damage, these enzymes interact with the DNA repair enzymes to 
restore DNA [262]. Extensive activation of DNA repair enzymes leads to 
several toxic effects in the cell including energy depletion and MMP [263-
265]. Due to the energy depletion, parthanatos is a caspase-independent 
programmed cell death pathway. 
Pyroptosis is a caspase-1 dependent form of cell death, which exhibits 
morphological characteristics of apoptosis and necrosis [266]. One necrotic 
characteristic of pyroptosis is the formation of pores in the cell membrane, 
which results in the rupture of the cell. Apoptotic characteristics include MMP 
and DNA fragmentation. Pyroptosis is triggered by the recognition of PAMPs 
through toll-like receptors or DAMPs through NOD-like receptors. This leads 
to the formation of a large signalling complex referred to as inflammasome 
[267]. The inflammasome activates procaspase-1, which is the main caspase 
in the execution of pyroptosis. Activated caspase-1 forms pores in the 
plasma membrane of the cell, which leads to water influx and the lysis of the 
cell [268]. 
Netosis is a cell death mode that can be only observed in granulocytes. 
Granulocytic cells undergoing netosis show vast vacuolisation of the 
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cytoplasm, and fast chromatin decondensation as well as degradation of 
cellular membranes leading to the formation of neutrophil extracellular traps 
[269]. It was shown that inhibitors of apoptosis and programmed necrosis do 
not prevent netosis, suggesting that a different mechanism for the execution 
is involved [270]. 
Cornification describes a physiological cell death pathway that only appears 
in keratinocytes [269]. Through cornification, the stratum corneum is formed. 
The stratum corneum is a layer of dead keratinocytes containing various 
proteins and lipids needed for different characteristics of the skin including 
structural stability, mechanical resistance, elasticity and hydrophobia. 
Experiments suggested that caspase-14 plays an important role in the 
process of cornification [271]. 
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1.7 Carbamazepine 
 
CBZ is one of the most commonly prescribed drugs for the treatment of 
epilepsy in patients with partial and generalised seizures. It is also prescribed 
for the treatment of neuropathic pain syndromes or as a mood stabiliser in 
bipolar disorders [272, 273]. 
It was first synthesised in the late 1950s in Switzerland. The synthesis was 
first described by Schindler in 1954 [274] and its antiepileptic effect was 
discovered by Theobald and Kunz in 1963 [275]. 
The chemical name of CBZ according to the International Union of Pure and 
Applied Chemistry (IUPAC) is either 5H-dibenzo[b,f]azepine-5-carboxamide 
or 5-carbamyl-5H-dibenzo[b,f]azepine. It is a derivative of iminostilbene and 
has a tricyclic structure [276]. The antiepileptic properties derive from the 
carbamyl group in the 5-position as 5H-dibenzo[b,f]azepine and its 
derivatives show only modest antiepileptic activity. This antiepileptic activity 
is further enhanced by the double bond at the 10 and 11 position. 
 
 
 
 
 
 
 
Figure 1.9: Chemical structure of carbamazepine 
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The mechanism of action for CBZ is not well understood. The many functions 
that have been discovered can be divided into two general mechanisms 
[277]: 
1. Effects on neuronal ion channels 
2. Effect on synaptic and postsynaptic transmission 
The antiepileptic effect is believed to result from effects on neuronal ion 
channels. It reduces high-frequency repetitive firing of action potentials which 
occur during seizures by stabilising the inactive state of the voltage-gated 
sodium channels. This decreases the sodium influx into the neuron and 
makes the neurons less likely to prolong the action potential shortly after 
another one has been prolonged [278]. 
 
1.7.1 Pharmacokinetics 
CBZ is slowly absorbed in the digestive tract. The reason for this is the rate 
with which CBZ dissolves in the gastrointestinal fluid, due to its nonpolar 
structure, which also increases its gastrointestinal transit time. 
Peak plasma concentration is reached between four to eight hours after 
administration but it has been reported that in some cases, peak plasma 
concentration was only observed after as long as 26 hours [279]. Absolute 
bioavailability of CBZ is hard to determine because of the lack of an 
injectable formulation. The estimate however, ranges from 75% to 85%. After 
absorption, CBZ is distributed rapidly in all tissues and 73%-81% of CBZ in 
blood is bound to proteins, including albumin [280, 281]. 
CBZ is extensively metabolised in vivo with more than 30 known metabolites 
of CBZ many of which also have antiepileptic activity [282, 283]. CBZ is 
mainly metabolised in the liver by CYP enzymes. The main metabolic 
pathway is the oxidation of the double bond at the 10 and 11 position. This 
results in an epoxide, CBZ-10,11 epoxide [284]. The main CYP isoform 
involved is CYP 3A4 [285]. CBZ induces its own metabolism by increasing 
the activity of CYP 3A4 [286]. Up to 50% of CBZ-10,11 epoxide can be found 
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in plasma compared to concentrations of CBZ. The epoxide is then 
hydrolysed to a dialcohol, CBZ-10,11 diol. This diol is then conjugated and 
excreted by renal clearance.  
Different metabolic pathways have been described, which include a 
hypothesised arene oxide and a ring contraction of CBZ (see Fig. 1.10). The 
hypothetical arene oxide is highly reactive and has not been found in vivo 
[287]. Detoxification products have been found in rat bile that can only be 
explained with an arene oxide intermediate [288]. The structure is then 
further metabolised. This results in a single or a double alcohol group at one 
of the benzene rings. The single alcohol can be further metabolised into 
iminoquinone, via iminostilbene, before being excreted. The dialcohol gets 
transformed into a quinone.  
Another metabolic pathway leads to a ring contraction, catalysed by the 
myeloperoxidase. This reaction is assumed to take place predominantly in 
the blood. The ring contraction results in an acridine structure, which is then 
conjugated and excreted [289]. 
The half-life of CBZ ranges from 18 to 55 hours. As CBZ induces its own 
metabolism by increasing the activity of CYP 3A4, the half-life on long term 
treatment decreases to 5 to 6 hours. The half-life for the main metabolite 
CBZ-10,11 epoxide is six to seven hours, and therefore much shorter than 
that of CBZ. 
Because of the auto-induction of CBZ, treatment is normally started with a 
lower daily dose of 100 to 200 mg to avoid toxic effects. It is then adjusted 
according to the response and plasma concentration of the patient. The 
therapeutic dose ranges from 4 to 15 µg/ml plasma concentration. 
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Figure 1.10: Metabolism of carbamazepine 
Carbamazepine (CBZ) is extensively metabolised. This is a brief overview of several 
pathways. The main pathway, via the CBZ-10,11 epoxide to the CBZ-10,11 dialcohol, is 
catalysed by cytochrome P450 (CYP). In addition, the pathway via the single alcohol group 
on the benzene ring or the theoretical arene oxide is catalysed by CYP. These alcohols can 
be further metabolised to the 2,3-dialcohol of CBZ, which can then be transformed into CBZ 
quinone. The 2-alcohol of CBZ can be metabolised into iminoquinone via an iminostilbene 
alcohol. 
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1.7.2 Carbamazepine-induced adverse effects 
Patients treated with CBZ can suffer from several adverse effects, which 
could be dose-dependent and dose-independent. CBZ also causes 
teratogenic effects during pregnancy [290]. 
Dose-dependent CBZ-induced toxicity can commonly be observed during the 
start of treatment within hours after administering a dose. The symptoms 
include blurred vision, dizziness, nausea, ataxia, sedation, and diplopia. 
Higher concentrations are associated with reduction in alertness and 
diminished pain sensation. The effects are reversible by dose reduction. 
During acute intoxication, seizures, impairment of consciousness, coma and 
death can be observed [291-293]. For this reason, treatment is started at a 
low dose and then continuously increased until the desired level is reached. 
 
1.7.3 Hypersensitivity reactions 
The dose-independent side effects are less frequent. They include skin 
rashes and abnormal organ function, mostly seen in the liver [294, 295]. Mild 
skin rashes are the most common form of hypersensitivity reactions and can 
be observed in up to 10% of patients treated with CBZ [296]. These can 
develop into severe CBZ-induced hypersensitivity reactions. The most 
severe forms comprise SJS, TEN and DRESS as described under the 
clinical manifestations of cutaneous drug reactions (see section 1.2.2). 
DRESS associated with rash, fever, eosinophilia and internal organ 
involvement, generally occurs during the first eight weeks of therapy with an 
estimated frequency of 4 in 10 000 [80, 297]. The most severe skin reactions 
SJS and TEN occur in Caucasians rarely with an estimated frequency of 1 in 
10 000 [298]. In Han Chinese, the occurrence of SJS and TEN is roughly 
ten-fold higher [299]. These severe DHRs often cannot be predicted and 
require close monitoring of the patient. 
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1.7.3.1 Pharmacogenetics 
CBZ-induced hypersensitivity reactions were thought to have a genetic 
origin. This theory was supported by reports of hypersensitivity reactions 
observed in members of the same family and in monozygotic twins [300]. 
These studies have suggested that reactive metabolites of CBZ, such as 
arene oxides, cause cytotoxicity and thus trigger an immune response. Case 
reports supported that the DHRs of CBZ have a genetic association and that 
genetic polymorphisms in metabolising enzymes might be involved [300, 
301]. For example, a case report demonstrated that a patient that had 
developed DHRs during treatment with CBZ possessed a less active form of 
an epoxide hydroxylase which is necessary for the metabolism of CBZ 
epoxide to the CBZ diol [302]. Therefore studies have focused on genetic 
differences in metabolising enzymes, particularly enzymes involved in the 
detoxification of CBZ such as microsomal epoxide hydroxylase, glutathione 
transferase, catechol-O-methyl transferase, and quinone reductase [300]. 
However, the results failed to show any association [303, 304]. Furthermore, 
antibodies against CYP isoforms involved in the metabolism of CBZ have 
been detected in patients with DHRs [305]. This observation led to the 
suggestion that reactive metabolites of CBZ bind to CYP enzymes, act as 
haptens and activate the adaptive immune system as per the hapten 
hypothesis. However, a genetic association between isoforms of CYP and 
CBZ-induced hypersensitivity reactions has not been found [44, 306]. 
The first evidence of an association between genetic polymorphism in genes 
with immune function in epileptic patients on CBZ was found by Pirmohamed 
and colleagues [307]. They showed that a polymorphism in TNF α at position 
308 together with HLA-DR3 and HLA-DQ2 increased the risk of Caucasian 
patients developing DRESS but not of any other forms of DHRs. 
A major breakthrough was the identification of an association between 
particular HLA alleles and specific clinical phenotypes observed in patients 
suffering from CBZ-induced hypersensitivity reactions. In 2004, a strong 
association between CBZ-induced SJS/TEN and HLA-B*15:02 in Han 
Chinese has been reported [44]. All patients, which had suffered from SJS or 
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TEN were carriers of the HLA allele while it was only present in 3% of CBZ 
tolerant patients and in 8.6% of healthy volunteers [44]. The association was 
also found in other Southeast Asian populations, including Indians, 
Malaysians, and Thai [45, 308-310]. Other studies showed that HLA-B*15:02 
is only associated with CBZ-induced SJS/TEN and not with other forms of 
CBZ-induced hypersensitivity reactions, including MPE and DRESS [306, 
311]. The association between HLA-B*15:02 and DHRs was not found in 
Europeans, possibly due to the low frequency of the HLA-B*15:02 allele in 
Caucasians [312]. Due to the evidence for a strong association between 
HLA-B*15:02 and SJS/TEN, genetic testing for this allele is recommended by 
the regulatory committees in patients with Asian ancestry before the start of 
CBZ therapy [313]. 
Recently an association was discovered between HLA-A*31:01 and all 
clinical phenotypes of CBZ-induced hypersensitivity reaction. This 
association was found by two independent research groups in Japan and 
Europe [46, 314]. In Europeans, the presence of HLA-A*31:01 increased the 
risk of developing ADRs from 5 to 26%, while the absence decreased the 
risk from 5 to 3.8%. In Japanese patients, HLA-A*31:01 was found in 60% of 
the patients who had suffered from DHRs. It has been reported that this HLA 
allele is also associated with CBZ-induced MPE in Han Chinese [306]. Based 
on the evidence, the association of HLA-A*31:01 and CBZ-induced 
hypersensitivity reactions is included in the label of the drug [315]. 
 
1.7.3.2 Functional studies 
The clinical phenotypes of CBZ-induced hypersensitivity reactions led to the 
assumption that these DHRs are immune-mediated. The detection of CBZ-
specific T cells in patients with CBZ-induced hypersensitivity reactions 
supported the hypothesis [152, 316]. The discovery of the above mentioned 
genetic association suggests a direct involvement of specific HLA alleles in 
presenting CBZ to cytotoxic T cells, leading to a T cell mediated immune 
response. 
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The role of HLA-B*15:02 in the role of CBZ-induced SJS in patients has been 
well studied and described: the immune reaction is mediated by cytotoxic T 
cells, which interact with HLA-B*15:02 [317, 318]. One in vitro study showed 
that CBZ activated drug-specific T cells directly, without the need of drug 
metabolism [164]. It was also shown that the parent drug CBZ does not 
modify peptides presented by the HLA [319]. Furthermore, T cell stimulation 
by CBZ in the presence of chemically fixed APCs, incapable of antigen 
processing, has been demonstrated [316]. All these observations led to the 
assumption that CBZ interacts with HLA or the TCR, thus activating the 
cytotoxic T cells, as described in the p-i concept. Recently, it has been 
shown that CBZ binds directly but non-covalently to HLA-B*15:02 [317]. 
Computer modelling revealed that the 5-carboxamide group on the tricyclic 
ring of CBZ is responsible for the interaction and identified three possible 
sites for interaction in the binding grove of HLA-B*15:02. These findings are 
supported by another study in which the non-covalent binding of CBZ to 
HLA-B*15:02 was also observed [140]. Furthermore, the analysis of the 
peptides mounted on HLA-B*15:02 in the presence of CBZ showed a change 
towards peptides with increased hydrophobicity. This shift in preferred self-
peptides in the presence of CBZ implies that drug-specific T cell stimulation 
occurs according to the altered self-peptide hypothesis. 
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1.8 Aims of Thesis 
 
Case reports of patients suffering from CBZ-induced hypersensitivity 
reactions have found an involvement the adaptive immune system in DHRs. 
Additionally, experimental findings have shown strong evidence for an 
association between HLA class I genes and CBZ-induced DHRs. The 
discovery that CBZ changes the self-peptide repertoire by binding in the 
grove of HLA-B*15:02 shows that the altered self-peptide hypothesis is 
important during CBZ-induced hypersensitivity reactions [140]. It has been 
observed, that memory T cells have a lower threshold for activation and 
therefore do not require costimulatory signals for their activation [320, 321]. 
However, a considerable amount of patients carrying the risk allele do not 
suffer from hypersensitivity reactions when treated with CBZ. These 
experiments have used drug-specific T cells from hypersensitive patients. 
Therefore, the mechanism of drug-specific T cell formation in patients 
remains unclear. Furthermore, the discovery of antibodies against CBZ in 
sera of hypersensitive and tolerant patients suggests that other factors are 
necessary for the activation of T cells [322-325]. 
Following this observation, other possible mechanism for the formation of 
drug-specific T cells in vitro were investigated in this work, not only 
considering the parent drug CBZ but also metabolites of the drug. 
The aims of this work were to: 
1. Explore the involvement of the mechanism defined by the danger 
hypothesis in the induction of CBZ-induced hypersensitivity reactions by 
investigating the possible release of danger signals by cells exposed to 
CBZ and one of its metabolites. 
2. Investigate the capability of CBZ and its metabolites to covalently modify 
proteins, leading to the formation of potentially immunogenic peptides, as 
described in the hapten hypothesis or signal 1 according to the danger 
hypothesis. 
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3. Discover new biomarkers for the assessment of a patient’s risk to suffer 
from CBZ-induced hypersensitivity reactions by finding genetic 
association with susceptibility of drug-caused toxicity and verifying these 
biomarkers in patient samples. 
4. Validate different newly developed methods for HLA-A*31:01-typing and 
their possible application for patient screening in hospital. 
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2.1 Introduction 
 
Carbamazepine (CBZ) is extensively metabolised in the human body. 
Different studies have found more than 30 metabolites of CBZ in vivo (see 
section 1.7.1 in the general introduction). Phase I metabolism takes place 
mainly in the liver. Highly reactive metabolites would therefore react with 
proteins in the liver. Furst and colleagues found that metabolism of CBZ can 
take place in human blood [1]. This metabolism was shown to result in 
reactive metabolites for other drugs [2-4]. 
Peripheral blood mononuclear cells (PBMCs) are the main component of the 
blood and consist of T cells, B cells, and macrophages. They play an 
important role in the induction of a response from the immune system. 
PBMCs also express metabolic enzymes although to a lesser extent than 
liver cells [5]. 
Previous work, using a cytotoxicity assay with an in vitro metabolising system 
[6], found that cells from CBZ-hypersensitive patients are more susceptible to 
cytotoxic metabolites of CBZ, than cells from CBZ-tolerant patients [7-9]. The 
underlying mechanism of these observations has not been further 
investigated. The findings support the hypothesis of CBZ-induced 
hypersensitivity reactions being the result of an imbalance in the 
detoxification process. Tissue damage caused by cytotoxic metabolites could 
result in the presence of danger signal and together with other protein bound 
metabolites lead to an immune responses. 
There are many assays available to investigate cell death. The difficulty is 
finding assays that are specific to the mode of the cell death being 
investigated. This is because of the overlap of some phenomena occurring 
during the different types of cell death [10]. 
Cell death assays can be divided into two distinct groups. The first is to 
measure the morphological changes and therefore the cell death directly. 
These include staining for intracellular proteins and use of vital dyes such as 
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Trypan blue. The other group is measuring cell death in an indirect manner 
such as the degree of cell attachment for adherent growing cell lines or loss 
of metabolic functions as in the MTT assay. 
Apoptosis manifests generally through shrinkage of the cell followed by the 
condensation of the chromatin, activation of cysteine aspartases (caspases), 
fragmentation of the chromosomal DNA as well as nuclear fragmentation 
before the blebbing of apoptotic bodies [11]. These apoptotic bodies are then 
cleared by phagocytes in vivo [12]. Cells undergoing necrosis show different 
morphological and pathological characteristics during the process. The 
common morphological features that can be observed include swelling of 
organelles, condensation of chromatin and an increase in the cell volume 
which results in the rupture of the cell. Due to this, cell membrane integrity is 
not maintained, as in the case of apoptosis, and the cell contents leak into 
the surrounding tissue [13]. In contrast to apoptosis, necrosis has been 
regarded as accidental cell death, but recent findings revealed a regulated 
form of necrosis, necroptosis [14]. 
The discovery of the two different cell death mechanisms led to increased 
investigations of the mechanistic differences involved in both pathways. This 
resulted in a large expansion of the methods used to distinguish between the 
two. It was found that the activation of caspases, mitochondrial membrane 
permeabilisation (MMP), DNA fragmentation and the exposure of 
phosphatidylserine (PS) on the cell surface are characteristic of apoptosis 
[12]. Nevertheless, these characteristics can also occur during other 
physiological states of the cell. These can include other modes of cell death 
but also in states that do not lead to the death of the cell [15-21]. Due to 
these findings, apoptotic cell death is commonly determined by the results of 
at least two different assays [22]. 
Universal assays for the measurement of apoptosis detect morphological 
changes typical for apoptosis in the cell. This includes the detection of DNA 
fragmentation such as the terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labelling (TUNEL) [20]. Other assays measure pathway-
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specific processes such as the activation of the caspase cascade, exposure 
of phosphatidylserine (PS) on the surface of the cell or MMP [17, 20, 23, 24]. 
The factors found to be specifically characteristic of necroptosis but not 
necrosis include activation of receptor-interacting protein kinase 1 and 3, 
metabolic burst with overproduction of reactive oxygen species, MMP and 
lysosomal membrane permeabilisation [13]. 
Experimental findings suggest an involvement of the adaptive immune 
system in CBZ-induced DHRs. Although, as described in the general 
introduction (see 1.7.3.1), there is strong evidence for associations between 
HLA alleles and CBZ-induced DHRs, many carriers of risk alleles do not 
suffer from DHRs. This suggests that there may be other, as yet 
undetermined, factors responsible for CBZ-induced DHRs. Still, many 
aspects of the pathogenesis of CBZ-induced DHRs are poorly understood, 
such as the sensitisation of hypersensitive patient. The hypothesis behind 
the work in this chapter was that the drug or its metabolite can damage cells, 
which results in the release of costimulatory signals for the activation of T 
cells, as described by the danger hypothesis (see general introduction 1.5.4). 
Therefore, the aim was to determine whether cells exposed to the drug and 
its metabolite, die via an apoptotic or necrotic pathway. 
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2.2 Material and Methods 
 
2.2.1 Chemicals 
CBZ (TOCRIS bioscience, Bristol, UK) and 9-acridinecarboxaldehyde (9-AC, 
Life Chemicals, Braunschweig, Germany) were used in the cell death 
assays. A 20 mM stock solution was made for each compound using 
methanol (MeOH, Sigma-Aldrich Co, Poole, UK) as a solvent. 
Staurosporine and cytochalasin B (STS, CytB, Sigma-Aldrich Co.) were used 
as apoptotic and necrotic positive controls in the assays. 
Carbobenzoxy-valyl-alanyl-aspartyl-(O-methyl)-fluoromethylketone (Z-VAD-
FMK) from Enzo Life Sciences Inc. (Exeter, UK) was used as a broad 
caspase inhibitor in the measurement of cellular caspase activation. 
 
2.2.2 Cell line and culture medium 
CCRF-CEM cells (ATCC CCL-19), a T lymphoblastoid cell line derived from 
a four year old female Caucasian with acute lymphoblastic leukaemia, were 
used. CCRF-CEM cells were cultured at 37°C (5% CO2) in RPMI-1640 with 
10% (v/v) foetal calf serum (FCS) and 2 mM L-glutamine obtained from 
Invitrogen Ltd (Paisley, UK). 
 
2.2.3 Peripheral blood mononuclear cell isolation 
PBMCs were isolated from fresh heparinised venous blood taken from CBZ-
naïve healthy volunteers. The isolation was conducted by centrifugation on 
Lymphoprep® density gradient (Axis-Shield, Dundee, UK). Blood was placed 
on top of Lymphoprep® and centrifuged at 600 g for 15 min (Heraeus 
Megafuge 11R, Thermo Fisher Scientific Inc., Loughborough, UK). During 
this step, the blood was divided into three components (see Fig. 2.1). The 
79 
 
erythrocytes aggregate and sediment to the bottom of the tube. The next 
layer consists of the Lymphoprep®. Above the layer of Lymphoprep® were 
the PBMCs and on top of them, plasma was found [25]. The layer of PBMCs 
was collected and washed twice with Hanks’ balanced salt solution (HBSS, 
Invitrogen Ltd, Paisley, UK). 
 
 
Figure 2.1: Blood separation over density gradient 
 
The resulting pellet of PBMCs was resuspended in HBSS buffered with 15 
mM HEPES (pH 7.5). Isolated PBMCs were counted and viability measured 
using the Trypan blue exclusion method [26]. Only samples with a viability ≥ 
90% were used for the experiments. The cell count was adjusted to the 
required concentration using media. 
 
2.2.4 Cell death assays 
The adjusted cell suspension was then placed into wells of the plate. 
Compound dilutions were prepared out of the stock solution. The dilutions 
were made using methanol. 5 µl of these concentrations were then added to 
495 µl of media. The same volume of the diluted compounds was added to 
the wells with plated cells. The methanol concentration in each sample was 
less than 1%. The resulting final concentrations for the assay were 0, 10, 50, 
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100 and 200 µM. For the 0 µM concentration, pure methanol was added to 
media before being added to the cell suspension. 
The cells were then incubated for either 2 or 24 hours. In case of the 2 hour 
incubation, the cells were centrifuged after 2 hours, the compound containing 
medium was removed and replaced with drug free medium before placing 
the cells back in the incubator for the rest of the 24 hours. 
 
2.2.4.1 Measuring cell viability using MTT 
In this assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT, Sigma-Aldrich Co.) was transformed by dehydrogenases in cells into 
its purple formazan form. The absorption was then measured to calculate the 
amount of living cells in the sample with the amount of formazan formed 
proportional to the amount of living cells in the sample [27]. 
The concentration of cells was adjusted to 500 x 105 cells/ml. 50 µl of cell 
suspension was added into each well of a clear flat bottom 96 well plate. 
Compound dilutions were prepared as described above. 50 µl of these were 
added to the plated cell suspension. Each concentration of each compound 
was plated in triplicate. 
24 hours after the start of the incubation, 20 µl of MTT solution (5 mg MTT in 
1 ml HBSS) was added to each well and the plate was incubated in the dark 
for 2 hours. 100 µl of lysis buffer (50% v/v Dimethylformamide, 20% w/v 
sodium dodecyl sulphate in dH2O) was added to each well. The plate was 
incubated for at least 4 hours in the dark at 37°C. The absorbance was then 
measured at 595 nm using a plate reader (DTX 880 Multimode Detector, 
Beckman Coulter Ltd., High Wycombe, UK).  
 
 
 
81 
 
From the absorbance (A595), the cell viability was calculated using the 
following formula: 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 [%]  =  (
∑ 𝐴595,𝑆𝑎𝑚𝑝𝑙𝑒 − ∑ 𝐴595,𝐵𝑙𝑎𝑛𝑘
∑ 𝐴595,𝐶𝑜𝑛𝑡𝑟𝑜𝑙
) × 100 
 
The data were expressed as the mean with the error bars representing the 
standard deviation (SD) of the mean from three independent experiments. 
 
2.2.4.2 Measurement of Mitochondrial Depolarisation using TMRE 
Tetramethylrhodamine, ethyl ester, perchlorate (TMRE, Sigma-Aldrich Co.) is 
a fluorescent dye. It can accumulate in mitochondria when the membrane is 
not depolarised. The loss of fluorescence was measured in cells by flow 
cytometry. The depolarisation of the mitochondrial membrane is 
accompanied by the death of the cell [28]. 
Cell concentration was adjusted to 1 x 106 cells/ml. 500 µl of cell suspension 
was added into each well of a clear flat bottom 12 well plate. 
The different concentrations were prepared as described above. 500 µl of the 
dilution was added into wells with cells. An apoptotic control STS was used 
at a final concentration of 4 µM [29]. 
24 hours after the start of the incubation, cells were washed 2 times with 
HBSS. After the second wash, pellets were dissolved with 500 µl of 50 nM 
TMRE in HBSS. Samples were then incubated at 37°C in the dark. Samples 
were measured in the fluorescence activated cell sorting machine (BD 
FACSCantoTM, Becton Dickinson, Oxford, UK). An unstained sample was 
used for adjustment of the forward and side scatter. The data were analysed 
using Cyflogic software. It was gated for the cell population to remove debris. 
From this population, the gating was conducted to derive the percentage of 
cells with depolarised mitochondria (see Fig. 2.2). The data were expressed 
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as the mean and the error bars represented the SD of the mean from three 
independent experiments. 
 
A:            B: 
 
 
 
 
 
 
 
 
Figure 2.2: Gating for the analysis of depolarised mitochondria.  
Plot A shows the forward against side scatter. To remove the debris for further analysis, only 
events in the area surrounded with the dashed line were selected and analysed further. Plot 
B shows the forward scatter against red fluorescence. Events in the area surrounded with 
the dashed line were identified as cells with depolarised mitochondria, due to their lack of 
red fluorescence. 
 
2.2.4.3 Measurement of apoptotic and necrotic cells 
Annexin-V-Fluorescein (Roche, Burgess Hill, UK) is a conjugate of Annexin 
V and a fluorescent dye. Annexin V binds to PS that is only present on the 
outer membrane of a cell, if this cell is undergoing apoptosis. Propidium 
iodide (PI, Roche) is a fluorescent dye that can bind to DNA. PI cannot 
penetrate the membrane of a living cell and therefore, it only binds to the 
DNA of necrotic cells as these cells have lost cell membrane integrity [30]. 
83 
 
Cell concentration was adjusted to 1 x 106 cells/ml and 500 µl of cell 
suspension was added into each well of a clear flat bottom 12 well plate. The 
different concentrations were prepared as described above. 500 µl of the 
dilutions were added to wells with cells. STS (4 µM final concentration) and 
CytB (50 µM final concentration) were used as apoptotic and necrotic 
positive controls respectively [31]. 
24 hours after the start of the incubation, the samples were prepared as 
described in the manual of the Annexin-V-FLUOS Staining Kit from Roche 
[32]. A master mix of Annexin-V-Fluorescein and PI was prepared and 100 µl 
of it were added to each sample plus 400 µl of incubation buffer. Samples 
were then incubated for 15 minutes at room temperature. 500 µl of 
incubation buffer from the kit was added to the samples before measuring it 
in the fluorescence activated cell sorting machine (BD FACSCantoTM, Becton 
Dickinson). An unstained sample was used for the adjustment of the forward 
and side scatter. Two single stained samples, either staurosporine and 
Annexin-V-Fluorescein or cytochrome B and PI were used for compensation. 
The data were analysed using Cyflogic software, gating for the cells to 
remove debris. From this population, gating was conducted to derive the 
percentage apoptotic and necrotic cells (see Fig. 2.3). Results were 
expressed as the mean and the error bars represent the SD of the mean 
from three independent experiments. 
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A:            B: 
 
 
 
 
 
 
 
Figure 2.3: Gating for the measurement of apoptotic and necrotic cells  
Plot A shows the forward and side scatter. To remove the debris for further analysis, only 
events in the area surrounded with the dashed line were selected and analysed further. Plot 
B shows the green fluorescence against red fluorescence after compensation. Events in the 
upper area surrounded with the dashed line were considered necrotic cells. Events in the 
lower right area surrounded with the dashed line were considered apoptotic cells. 
 
2.2.4.4 Measurement of caspase activation 
The Caspase-Glo® 3/7 assay (Promega) was used to detect caspase 
activation. In this assay, a mixture of a luminogenic substrate for caspase 3 
and 7, luciferase, and cell lysis buffer is added to the samples. The substrate 
is then be cleaved by activated caspase 3 or 7. Luciferase can then generate 
a luminescent signal from the fragment. The amount of luminescence 
measured is proportional to the activated caspase in the sample. 
Cell concentration was adjusted to 1 x 106 cells/ml. 50 µl of cell suspension 
was added into each well of a clear flat bottom 96 well plate. Compound 
dilutions were prepared as described above. 50 µl of these were added to 
the plated cell suspension. Staurosporine was used as an apoptotic control. 
Z-VAD-FMK was used as a broad caspase inhibitor [33]. Z-VAD-FMK (50 
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µM) was added together with 50 µM 9-AC to determine if the effect was 
reversible. Each concentration of compounds was plated in triplicate. 
24 hours after the start of the incubation, samples were mixed and 50 µl of 
sample was added into separate wells of a white flat bottom 96 well plate. 50 
µl of the freshly prepared reagent were added to each well. Contents were 
mixed for 30 seconds at 300 rpm using a plate shaker. Plates were then 
incubated for 2h at 37°C in the dark. The luminescence was measured using 
a plate reader (DTX 880 Multimode Detector, Beckman Coulter Ltd.). 
From the luminescence measured, the value for the blank sample (medium, 
reagent) was subtracted and the mean of all three replicates for that 
concentration calculated. The results are expressed as the mean and the 
error bars represent the SD of the mean from three independent 
experiments. 
 
2.2.3 Statistical analysis 
Data were statistically analysed using one-way ANOVA with a Dunnet’s post-
hoc test. The different compound concentrations were compared with the 
untreated control. 
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2.3 Results 
 
To investigate the role of cell death, different cell death assays were used 
after exposing CCRF-CEM cells or PBMCs, of CBZ-naïve volunteers, to CBZ 
and 9-AC, a metabolite of CBZ. 
 
2.3.1 Evaluation in CCRF-CEM cell line 
For the assessment of a toxic effect in CCRF-CEM cells, the MTT assay, a 
cell viability assay, was conducted after exposing the cell line to different 
concentrations of CBZ and 9-AC. 
For CBZ overall, no cytotoxic effect was observed (see Fig. 2.4). The only 
exception to this was a statistically significant decrease in cell viability of 
CCRF-CEM cells after 2 hour exposure to the lowest concentration (10 µM) 
in the experiments which may be artefactual. In the 24 hour exposure a 
dose-dependent decrease in cell viability could be observed but the effect 
was not statistically significant except for the highest concentration (200 µM). 
9-AC in comparison showed a dose-dependent effect after a 2 hour 
exposure (see Fig. 2.4 A). This effect was found to be statistically significant. 
The cytotoxic effect was also observed after a 24 hour exposure. Here the 
effect was more significant compared to the 2 hour exposure (see Fig. 2.4 
B). 
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Figure 2.4: Cell viability in CCRF-CEM cells after exposure to compounds 
CCRF-CEM cells were exposed to different concentrations of CBZ and 9-AC for 2 (A) and 
24 (B) hours. 24 hours after the start of the incubation, MTT solution and lysis buffer were 
added and absorbance was measured (n=3, error bars: standard deviation of the mean, and 
p-value: *: <0.05-0.01, **: <0.01-0.001, ***: <0.001). 
 
After the finding of cytotoxicity caused by 9-AC, further investigation was 
undertaken. MMP was assessed using TMRE for staining mitochondria. 
CCRF-CEM cells exposed to CBZ did not show an increase in the number of 
cells with MMP (see Fig. 2.5). 
CCRF-CEM cells exposed to 9-AC for 2 hours showed a small increase in 
cells with depolarised mitochondria. By contrast, cells exposed for 24 hours 
to 9-AC showed a statistically significant increase in the number of cells in 
which the mitochondrial membrane was depolarised (see Fig.2.5). 
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Figure 2.5: MMP in CCRF-CEM cells after exposure to compounds 
CCRF-CEM cells were exposed to different concentrations of compounds for 2 (A) and 24 
(B) hours. Cells were stained with TMRE 24 hours after start of incubation and fluorescence 
measured using flow cytometer. % shows amount of cells with MMP in whole population 
(n=3, error bars: standard deviation of the mean, and p-value: *: <0.05-0.01, **: <0.01-0.001, 
***: <0.001). 
 
This provided evidence of an apoptotic pathway involved in the cytotoxic 
effect caused by 9-AC. To validate that evidence, the percentage of cells 
exposing PS on the cell surface while possessing an intact cell membrane 
was determined. 
In the Annexin V and PI experiment, a small increase in dead CEM cells was 
observed after exposure to CBZ but only at the highest concentration (200 
µM) over 24 hours (see Fig. 2.6). 
For 9-AC, as observed in the previous experiments, there was a dose-
dependent cytotoxic effect observable after just 2 hours of exposure of CEM 
cells (see Fig. 2.6 A). After exposure of cells for 24 hours, the percentage of 
dead cells was statistically significant. The amount of apoptotic and necrotic 
cells increased with the amount of drug in the media. More apoptotic cells 
were found than the necrotic cells. Only for the highest concentration were 
more necrotic cells detected than apoptotic (see Fig. 2.6 B). 
89 
 
 
Figure 2.6:  Apoptotic and necrotic cells in CCRF-CEM cells after exposure 
CCRF-CEM cells were exposed to different concentrations of CBZ and 9-AC for 2 (A) and 
24 (B) hours. Cells were stained with Annexin V and PI 24 hours after the start of the 
incubation and fluorescence measured in flow cytometer. Percentage gives the amount of 
different stained cells in comparison to the whole population (n=3, error bars: standard 
deviation of the mean, and p-value: *: <0.05-0.01, **: <0.01-0.001, ***: <0.001). 
 
In the caspase activation assay, CCRF-CEM cells exposed to CBZ showed 
no increase in the activation of caspase except for the highest concentration 
and at 24 hours exposure (see Fig. 2.7). Cells exposed to 9-AC showed a 
significant increase in caspase activation. This effect was observable at the 
50 µM concentration and 2 hour exposure (see Fig. 2.7 A). After the 
exposure of the cells for 24 hours, at the highest concentration, the cells 
showed a drastic drop in caspase activity. The amount of active caspase 
dropped below the caspase activity of unexposed cells. 
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Figure 2.7:  Caspase activity in CCRF-CEM cell line after exposure to 
compounds 
CCRF-CEM cells were exposed to different concentrations of CBZ and 9-AC for 2 (A) and 
24 (B) hours. 24 hours after the start of the incubation, the assay was stopped by adding 
reagent and luminescence was measured (n=3, error bars: standard deviation of the mean, 
and p-value: *: <0.05-0.01, **: <0.01-0.001, ***: <0.001). 
 
Samples treated with 9-AC and Z-VAD-FMK (caspase inhibitor) showed a 
drop in caspase activity (see Fig. 2.8). The utilisation of the caspase inhibitor 
showed the dependence of the observed apoptosis upon caspase activation. 
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Figure 2.8:  Caspase activity in CCRF-CEM cell line after exposure to 
single concentration of compounds 
CCRF-CEM cells were exposed to 50 µM of CBZ and 9-AC, 50 µM 9-AC plus 50 µM Z-VAD-
FMK, and 4 µM of STS for 2 (A) and 24 (B) hours. 24 hours after the start of the incubation, 
the assay was stopped by adding reagent and luminescence was measured (n=3, error 
bars: standard deviation of the mean,  and p-value: *: <0.05-0.01, **: <0.01-0.001, ***: 
<0.001). 
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2.3.2 Evaluation of cytotoxicity in PBMCs 
The finding that 9-AC caused apoptosis was demonstrated in a T 
lymphoblastoid cell line. The effect of 9-AC was further assess in primary 
cells, for which PBMCs from CBZ-naïve volunteers were used. 
As shown in the T lymphoblastoid cell line, PBMCs treated with CBZ showed 
only a non-significant decrease in cell viability. The exception to this was the 
highest concentration of CBZ (200 µM) after a 24 hour exposure (see Fig. 
2.9 B). 
By contrast, cells exposed to 9-AC showed a dose-dependent decrease in 
cell viability. This effect was observable at both 2 and 24 hours. This 
decrease was found to be statistically significant starting from 50 µM for the 2 
hour exposure and from 100 µM for the 24 hour exposure (see Fig. 2.9). 
 
 
Figure 2.9: Cell viability in PBMCs after exposure to compounds  
PBMCs were exposed to different concentrations of compounds for 2 (A) and 24 (B) hours. 
After 24 hours of incubation, MTT solution and lysis buffer were added and absorbance was 
measured (n=3, error bars: standard deviation of the mean, and p-value: *: <0.05-0.01, **: 
<0.01-0.001, ***: <0.001). 
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Following this observation, the MMP of PBMCs exposed to the compounds 
was assessed. Therefore cells were stained with TMRE after exposure to the 
compounds. A high percentage of PBMCs with MMP were observed in the 
control samples. 
Cells exposed to CBZ for 2 or 24 hours did not show an increase in the 
number of cells with MMP. Cells exposed to 9-AC showed a dose-dependent 
increase in cells with MMP (Fig. 2.10). 
 
Figure 2.10: MMP in PBMCs after exposure to compounds  
PBMCs were exposed to different concentrations of compounds for 2 (A) and 24 (B) hours. 
PBMCs were stained with TMRE 24 hours after start of incubation. Cells with MMP were 
expressed as percentage of whole population (n=3, error bars: standard deviation of the 
mean, and p-value: *: <0.05-0.01, **: <0.01-0.001, ***: <0.001). 
 
To further investigate the nature of the cytotoxic effect, the amount of cells 
presenting PS on the cell surface, while the cell membrane is still intact, was 
assessed. The data from the flow cytometric analysis did not show precise 
populations of apoptotic and necrotic cells, which made the interpretation 
difficult (Fig. A2.1 in the appendix). A high percentage of cells showing signs 
of cell death, were found in the unexposed samples. Nevertheless it 
distinguished between dead and living cells. 
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The percentage of cells showing signs of cell death did not increase when 
exposed to CBZ. For 9-AC, the number of PBMCs, showing signs of cell 
death, rose with the increase in concentration (see Fig. 2.11). 
 
Figure 2.11: Apoptotic and necrotic cells in PBMCs after exposure  
PBMCs were exposed to different concentrations of compounds for 2 (A) and 24 (B) hours. 
PBMCs were stained with Annexin V and PI 24 hours after the start of the incubation and 
fluorescence measured in flow cytometer. Percentage gives the amount of different stained 
cells in comparison to the whole population (n=3, error bars: standard deviation of the mean, 
and p-value: *: <0.05-0.01, **: <0.01-0.001, ***: <0.001). 
 
Since the previous assay only confirmed that the cells were dying but could 
neither support nor dismiss the possibility of apoptosis or necrosis, the 
caspase activation assay was utilised. This assay can provide clear evidence 
of either apoptosis or necrosis since it has been shown to be cell type-
independent [34]. 
The activity of caspase did not significantly increase in PBMCs exposed to 
CBZ. In PBMCs exposed to 9-AC, increased activation of caspase was 
observed after the 2 hour exposure in a dose-dependent manner. Only for 
200 µM was the caspase activation found to be at the same level as in the 
unexposed cells (see Fig. 2.12). 
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For the 24 hour exposure, the activation of caspase decreased with an 
increase in 9-AC concentration below the level of caspase activity observed 
in unexposed cells. 
 
Figure 2.12:  Caspase activity in PBMCs after exposure to compounds  
PBMCs were exposed to different concentrations of compounds 2 (A) and 24 (B) hours. 24 
hours after the start of the incubation, the assay was stopped by adding reagent and 
luminescence was measured (n=3, error bars: standard deviation of the mean, and p-value: 
*: <0.05-0.01, **: <0.01-0.001, ***: <0.001). 
 
9-AC dependent caspase activation was observed in PBMCs exposed for 2 
and 24 hours but was reduced by Z-VAD-FMK. This observation shows that 
9-AC induces caspase-dependent cell death (see Fig. 2.13). The caspase 
activation in the 24 hour incubation was significantly higher than the caspase 
activation in the control. This contradicts the previous observation, where the 
caspase activation of the PBMCs treated with 9-AC was significantly lower 
than the control (see Fig. 2.12). 
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Figure 2.13:  Caspase activity in PBMCs after exposure to single 
compound concentration 
PBMCs were exposed to 50 µM of CBZ and 9-AC, 50 µM 9-AC plus 50 µM Z-VAD-FMK, 
and 4 µM of STS for 2 (A) and 24 (B) hours. 24 hours after the start of the incubation, the 
assay was stopped by adding reagent and luminescence was measured (n=3, error bars: 
standard deviation of the mean, and p-value: *: <0.05-0.01, **: <0.01-0.001, ***: <0.001). 
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2.3.2.1 Evaluation of interindividual variability 
 
The variability in the outcome of the previous experiments with PBMCs 
suggested that there might be interindividual variability in susceptibility to the 
cytotoxic effect of 9-AC. Therefore PBMCs from 20 CBZ-naïve, healthy 
volunteers were isolated and exposed to a single dose (50 µM) of CBZ and 
9-AC. The PBMCs were only exposed to the drug for 2 hours and replaced 
for the rest of the 24 hours with drug-free medium as this showed the 
strongest cytotoxic effect in previous experiments. Measurement of apoptotic 
and necrotic cells was not conducted as the data obtained in experiments 
were not interpretable and therefore provided no further information on 
apoptotic and necrotic cell death. 
PBMCs from 20 healthy volunteers exposed to a single dose of CBZ showed 
no sign of cell death. The cell viability measured via the metabolic activity of 
the cells did not show a decrease. Additionally no increase of cells with MMP 
was observed nor was the activity of caspase significantly increased (see 
Fig. 2.14). 
PBMCs exposed to 50 µM of 9-AC showed a decrease in their viability. Also 
the amount of cells exhibiting MMP increased in a statistically significant 
manner and caspase activation was seen after exposure to 9-AC when 
compared with control incubation. 
The cytotoxic response to the single concentration of CBZ and 9-AC from 
different individuals showed variation. The strongest variation was observed 
in the caspase activation after exposure to the compounds. 
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Figure 2.14: Cell viability (A), MMP (B), and caspase activity (C) in PBMCs 
after exposure to single compound concentration for 2 hours  
PBMCs from 20 different individuals were exposed to 50 µM of CBZ, 9-AC, 9-AC plus the 
caspase inhibitor Z-VAD-FMK (for caspase activation) and STS (for MMP and caspase 
activation) for 2 hours. After 24 hours of incubation, reagent according to specific assay was 
added (error bars: standard deviation of the mean and p-value: *: <0.05-0.01, **: <0.01-
0.001, ***: <0.001). 
99 
 
2.4 Discussion 
 
CBZ is one of the most widely prescribed anticonvulsants for the treatment of 
partial seizures. 10% of patients treated with CBZ develop skin rashes [35]. 
These can develop further into more severe forms of CBZ-induced 
hypersensitivity reactions. An association between HLA-A*31:01 and CBZ-
induced hypersensitivity reactions has been found and represents a 
prediction method for risk evaluation for the development of idiosyncratic 
reactions during treatment with CBZ [36]. It is therefore of utmost importance 
to understand the underlying mechanisms involved and through this, find 
other predictive markers for the development of CBZ-induced 
hypersensitivity reactions. 
The underlying pathological mechanisms involved in the development of 
CBZ-induced adverse drug reactions are still unknown. Patients treated with 
CBZ can have antibodies against CBZ in their blood [37-40]. This was found 
for CBZ-tolerant as well as CBZ-hypersensitive patients. It has also been 
shown that T cells play a role in hypersensitivity reactions and can be found 
in cutaneous blisters [41, 42]. T cells are thought to be responsible for the 
cytotoxic effects observed. How these T cells are primed against CBZ is 
unclear. 
The hypothesis behind the work in this chapter was based on the danger 
hypothesis, as described in the general introduction (see section 1.5.4). In 
brief, the danger hypothesis takes into consideration that T cell activation is 
not based on just one signal, non-self proteins, but on the presence of at 
least one additional signal, expressed by APCs in the presence of danger 
signals. Additionally, it was shown that certain drugs or their metabolites can 
damage cells and thus induce the presentation of costimulatory signals for T 
cell activation on APCs [43-45]. The leakage of cytosolic content, which 
would lead to the presentation of costimulatory signals, could be the result of 
cells undergoing necrosis after exposure to the compounds. Therefore the 
aim was to identify the type of cell death caused by the exposure of cells to 
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CBZ and one metabolite, 9-AC, thus testing the hypothesis that cell death 
can lead to danger signalling and to the activation of the immune system. To 
achieve this, different methods for assessing cell death and distinguishing 
between apoptosis and necrosis were utilised. The variation in cytotoxic 
response of PBMCs from CBZ-naïve healthy volunteers was also assessed. 
The assays utilised for this project were: cell viability assay, MMP assay, PS 
exposure combined with vital dye assay and caspase activation assay (for 
more details, including advantages and disadvantages of the assays used, 
see Tab. 2.1) 
The results from the assays revealed that 9-AC causes the CCRF-CEM cell 
line to undergo apoptosis in a dose-dependent manner since the cytotoxic 
effect increases with the concentration of 9-AC. For the 2 hour exposure of 
cells to 9-AC, not all assays were able to detect signs of cell death. A more 
distinct apoptotic effect was found for cells that were exposed for 24 hours to 
9-AC. The first statistically significant effect for all assays was observed for 
50 µM of 9-AC and 24 hour exposure. 
The results of the cell viability assay and the MMP assay of CCRF-CEM 
showed different sensitivity for cytotoxicity caused by 9-AC (Fig. 2.4 and 2.5). 
The cell viability measured through MTT transformation correlates the 
metabolic activity with viability of the cell [20]. This metabolic activity is 
generally attributed to the mitochondria [46-48]. Therefore, the depolarisation 
of the mitochondrial membrane should occur before the decrease in 
metabolic activity of the cell during cell death. However, the dehydrogenases 
which transform MTT are not only present in mitochondria but can also be 
found in the cytosol [49]. Furthermore, the conversion of MTT reflects 
metabolic alteration which can be influenced by other factors, e.g. medium 
overconsumption or excessive cell density [20]. This may explain the 
observed discrepancy between the metabolic activity and the MMP of the 
CCRF-CEM cells. 
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In the PS exposure and vital dye assay, a large number of necrotic cells 
were observed after 24 hours of exposure at the highest concentration of 9-
AC. A continuous increase in apoptotic and necrotic cells was observed, with 
the apoptotic cells representing the dominant population. The necrotic cells 
seen after exposure to 200 µM of 9-AC were probably a result of secondary 
necrosis [50]. Cells undergo complete apoptosis and after blebbing, the 
apoptotic bodies stay in the culture media. Due to the fact that there are no 
macrophages in the media, unlike the in vivo situation, apoptotic bodies are 
not cleared through phagocytosis. The apoptotic bodies are unable to 
maintain membrane integrity and start rupturing resulting in necrosis like 
spillage of the contents into the culture media [50]. In certain assays, this will 
be detected as cells that appear to have undergone necrosis. This 
assumption is supported by the caspase activation assay. 
The activation of caspase increases with higher concentrations of 9-AC. For 
the highest dose, however, the activity of caspase drops even below the 
caspase activity level in untreated cells suggesting that the ATP content of 
the cells is completely depleted and apoptosis completed. 
This decrease in caspase activation below the caspase activity of unexposed 
cells was also observed in cells that were exposed to 9-AC and the caspase 
inhibitor Z-VAD-FMK. It was reported that cells exposed to a toxin in the 
presence of a caspase inhibitor still undergo cell death as the caspase 
inhibitor only prevents apoptosis but not necrotic cell death [51]. Cells 
undergo apoptosis and the process stops at the point where the activation of 
caspase would start. As the process cannot continue, the cells become 
necrotic, meaning that the cell membrane integrity will not be upheld. Similar 
observations were made for cells with depleted ATP reservoirs. Also in this 
case, cells are not able to proceed with apoptosis until the formation of 
apoptotic bodies and therefore become necrotic [52]. 
CBZ did not show a cytotoxic effect in the T lymphoblastoid cell line for most 
of the concentrations used in the experiments. A statistically significant 
increase of cells displaying signs of cell death was detected after 24 hour 
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exposure to 200 µM of CBZ. However, these findings were not confirmed by 
all assays. Furthermore, it should be noted that this concentration also 
exceeds the therapeutic concentration by more than twofold [53]. 
The experiments conducted in this work showed that 9-AC also causes 
apoptosis in PBMCs of CBZ-naïve healthy volunteers. The apoptotic effect 
was found to increase with higher dose. The difference could not be shown 
to be statistically significant in all assays used, as the variability in the 
response of different individuals was too large. Signs of apoptosis were 
detectable in PBMCs after 2 hours of exposure to 9-AC, which suggests that 
PBMCs are more susceptible to the cytotoxic effect of 9-AC than CCRF-CEM 
cells, for which a significant increase of apoptotic signs were detected after 
24 hours of exposure. The difference observed could be explained by the 
fact that the CCRF-CEM cell line is derived from blood of a patient with acute 
lymphoblastic leukaemia [54]. It is known that cancer cells develop 
mechanism to escape the elimination by the immune system through 
resistance against apoptosis [55]. It has been shown that both alleles of 
tumour suppressor gene p53 are mutated in CCRF-CEM cells, which leads 
to a defect of p53 inducing apoptosis [56, 57]. This reported impairment of 
apoptosis may explain the observed difference in viability between CCRF-
CEM cells and PBMCs. 
PBMCs did not show any signs of cytotoxicity when exposed to CBZ. This 
was expected, as it has been reported previously by Furst and Uetrecht that 
CBZ does not cause cell death [58]. In their experiments, it was observed 
that 9-AC but not CBZ caused cytotoxicity in human blood cells in vitro. The 
results presented in this chapter support these findings. 
For the MMP assay, it was found that a large percentage (>20%) of cells 
showed signs of MMP without being exposed to any of the compounds. 
PBMCs consist of different cell types and these different cell types might 
occur at variable frequencies while being stained with TMRE. The different 
cell types could also possess varying sensitivities towards the process of 
purification. The assay still showed an increase in cells with MMP with higher 
concentrations of 9-AC. 
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In the PS exposure and vital dye assay, data form flow cytometry did not 
allow a distinction between the apoptotic and necrotic cell populations. 
Nevertheless, distinguishing between living and dead cells was possible. 
Here, again the reason could lie in the different cell types in the PMBC 
population. To overcome the issue of undistinguishable populations of 
necrotic and apoptotic cells, cells were triple stained, including a dye for 
CD3+ T cells. This showed that less than 10% of cells in the samples were 
CD3+ and the amount of CD3+ cells decreased with higher concentration of 
9-AC suggesting that this marker was lost during the process of cell death 
and therefore not suitable in solving the problem (Fig. A2.2 in appendix). 
Triple staining with annexin V, PI and CD3+ of human PBMCs has been 
described for analysis of apoptosis and necrosis in freshly isolated PBMCs 
from patients but not for PBMCs in culture [59].  
The assumption that the problems experienced during the flow cytometric 
assays is the result of different cell types making up the PBMC population is 
indirectly supported by the fact that no such difficulties were experienced 
with the viability assay and caspase activation assay, which are known to 
assess the signs of cell death in a cell type-independent manner [34]. 
Besides the problems experienced with the flow cytometry assays, the 
contradictory findings of the caspase activation assay revealed another 
limitation of the experiments. Due to the limited access to healthy volunteers 
and the complexity of the study design (four assays, two compounds, and 
four concentrations per compound), it was only possible to measure the 
viability of PBMCs from each individual once with each assay. A better 
approach would have been to obtain and measure PBMCs from each 
individual at least three times and use the mean of these results. This would 
have delivered more robust and reproducible data for each individual. 
The experiments with PBMC samples of 20 healthy volunteers exposed for 2 
hours to 50 µM CBZ or 9-AC showed that only 9-AC induces cell death in 
PBMCs. The difference between the untreated control and 9-AC was 
statistically significant. The extent of the cytotoxicity observed in the samples 
of the different individuals showed variability. This suggests that some 
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individuals are more susceptible to the cytotoxic effect of 9-AC. The low level 
of activated caspase in some PBMCs exposed to 9-AC suggests that the cell 
death in these samples might not be caspase dependent. It has been 
reported that the dose of cytotoxic drugs can determine the cell death 
pathway [60, 61]. At low doses, cells undergo apoptosis, while higher doses 
result in necrosis. Therefore, the susceptibility of cells to the cytotoxic effect 
of 9-AC might lead to different pathways of cell death, which could result in 
the release of danger signals. Further investigation of this mechanism in 
CBZ-induced hypersensitivity reactions is required. 
Studies, using the lymphocyte toxicity assay after Spielberg, found that 
lymphocytes from patients [6], which had experienced CBZ-induced 
hypersensitivity reactions, were more susceptible to cytotoxicity of oxidative 
metabolites generated by hepatic microsomes than lymphocytes from CBZ-
tolerant patients or CBZ-naïve volunteers [8, 9]. It was also suggested that in 
vitro cytotoxicity assays could be used before the treatment of patients to 
evaluate their risk [9]. The finding of inter-individual variability in cell viability 
in this chapter, however, was made in CBZ-naïve volunteers. Therefore, the 
extent of the variability between patients who had suffered from CBZ-induced 
hypersensitivity reactions and CBZ-tolerant patients would be an interesting 
point for further investigations. 
In the experiments included in this chapter, only the parent drug, CBZ, and 
one metabolite, 9-AC, were used. However, more than 30 metabolites of 
CBZ have been found in patients treated with the drug. Furthermore, it has 
been speculated that a highly reactive arene oxide is generated during the 
metabolism of CBZ, which could lead to cellular damage [62]. Therefore, the 
cytotoxicity of other metabolites would need to be tested. The type of cell 
death caused by these toxic metabolites would then need to be examined to 
further investigate the possibility of CBZ metabolites causing danger 
signalling. 
The focus of the experiments conducted for this work lay on differentiating 
between apoptosis and necrosis. As mentioned in the general introduction, a 
number of cell death pathways have been described, some of which are 
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controlled forms of cell death. However, not all of these controlled forms take 
place under maintenance of the outer cell membrane integrity. It has been 
shown that these pathways can play an important role in the cytotoxicity 
caused by xenobiotics [63]. Therefore, the involvement of other cell death 
pathways would need to be examined, as they could lead to costimulatory 
signalling by leakage of cytosolic content into the surrounding tissue, similar 
to the leakage of necrotic cells. 
In conclusion, the results show that only the metabolite 9-AC causes 
cytotoxicity, while CBZ was not toxic in the concentration range used. 
Furthermore, it was found that 9-AC causes apoptotic cell death. Therefore, 
neither the parent drug CBZ nor its metabolite 9-AC would cause danger 
signalling as a result of cellular damage, which is necessary for T cell 
activation according to the danger hypothesis. However, danger signalling 
could be caused through other modalities, such as different forms of cell 
death or different metabolites. The inter-individual variability in cell viability 
observed in the experiments could indicate that cells exposed to 9-AC die via 
different cell death pathways, some of which might result in the release of 
danger signals. Additionally, an infection during the treatment with the drug 
could also induce the expression of costimulatory signals on APCs. These 
other possibilities need to be investigated before dismissing the danger 
hypothesis as an important mechanism during T cell activation in 
hypersensitivity reactions. Taken together, many factors which could explain 
danger signalling in the initiation of hypersensitivity reactions in patients 
remain unknown. 
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3.1 Introduction 
 
Carbamazepine (CBZ) is known to cause hypersensitivity reactions in up to 
10% of patients treated with the drug [1]. As CBZ is extensively metabolised 
in the human body [2, 3], it is unclear whether the parent compound is 
causing these reactions or one of the more than 30 metabolites found in vivo. 
Several studies showed that antibodies against CBZ can be found in sera 
from patients on CBZ treatment [4-7]. These antibodies were not only found 
in the sera of patients developing CBZ-induced ADRs but also in CBZ 
tolerant patients. The role of CBZ-specific antibodies in CBZ-induced 
hypersensitivity reactions is unknown. Generally, antibodies are secreted by 
B cells and bind to the surface of antigens, thus inducing the complement 
system or marking them for the clearance by phagocytic cells of the innate 
immune system [8, 9]. As CBZ-specific antibodies were found in CBZ 
hypersensitive as well as CBZ-tolerant patients this seems not to be the 
underlying mechanism. Other studies detected specific autoantibodies 
against human liver microsomal proteins in the blood of a patient that had 
suffered from CBZ-induced hepatotoxicity but it was not demonstrated 
whether these antibodies are immunogenic [10, 11]. 
The activation of the immune system can be caused through the production 
of reactive metabolites [12, 13]. The metabolites are predominantly 
generated by the cytochrome P450 CYP3A4 in the human liver. In the case 
of CBZ, a highly reactive arene oxide was hypothesised. Due to its high 
reactivity, the arene oxide has never been observed in humans but evidence 
of its existence was found in rat bile [14]. 
Pirmohamed and colleagues investigated the possibility of the formation of 
protein-reactive, unstable metabolites in vitro [15]. Following this 
investigation, Pearce and colleagues extensively assessed the role of 
different cytochrome P450 enzymes in the formation of different CBZ 
metabolites (see Fig. 3.1) [16-18]. 
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Figure 3.1: Isoforms of cytochrome P450 (CYP) responsible for 
metabolism of Carbamazepine (CBZ)  
 
Furthermore, Furst and colleague showed that activated leukocytes can 
metabolise CBZ to reactive forms in vitro. The enzyme responsible for this 
metabolism was myeloperoxidase which can be also found in the skin. The 
postulated metabolites resulting from this metabolism included acridine 
derivatives such as 9-acridinecarboxaldehyde (9-AC) [19]. 
In the experiments for the previous chapter, lack of cytotoxicity from 9-AC, 
was observed when peripheral blood mononuclear cells were cultured in 
protein rich medium (Fig. A2.3-A2.5 in appendix). Furst and colleagues have 
reported that 9-AC can bind to proteins. Their experiments suggested that 
the binding occurs via a Schiff base [20]. In their experiments they used 
radiolabeled molecules for the detection of the binding. This approach does 
not allow the determination of the exact binding in the protein. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) platforms 
are a major tool in the identification of protein modification. LC-MS/MS allows 
the use of intact proteins or enzymatic digested proteins [21, 22]. The 
fragments of the digested peptide are first separated from each other using 
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HPLC. The eluted analytes are then ionised before the mass/charge ratio is 
detected. The resulting list can then be compared with a theoretical list of 
fragments that would be expected. 
Ma and colleagues showed that reactive metabolites of drugs can be trapped 
and thus detected by MS. In their experiments, the parent drug or one 
metabolite was co-incubated with protein in the presence of metabolising 
enzymes [23, 24]. Due to its reactive cysteine residue, glutathione is used as 
a trapping agent [25]. Cysteine is the most common binding partner. 
Nevertheless compounds binding to other amino acids have been reported 
[26-29]. 
 
As mentioned above, drug-specific antibodies in the sera of hypersensitive 
patients, as well as in tolerant controls, were detected. For the production of 
antibodies by the immune system, the drug would need to modify proteins in 
the body. Therefore, the hypothesis in this chapter was that CBZ and its 
metabolites, carbamazepine-10,11 epoxide (CBZE) and 9-AC, bind 
covalently to proteins. Therefore, the aim of this work was to investigate the 
ability of the drug and its metabolites to modify proteins, as well as to identify 
the type of modification (covalent or non-covalent binding). Covalently 
modified proteins could play a role in the T cell activation according to the 
hapten hypothesis (see general introduction 1.5.1). The hapten hypothesis 
might not be sufficient to explain naïve T cell activation in hypersensitivity 
reactions but would still induce signal 1 as described in the danger 
hypothesis (see general introduction 1.5.4). 
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3.2 Material and Methods 
 
3.2.1 Chemicals 
CBZ (TOCRIS bioscience, Bristol, UK), CBZE (Toronto Research Chemicals 
Inc., Ontario, Canada) and 9-AC (Life Chemicals, Braunschweig, Germany) 
were investigated in the experiments. Dimethyl sulfoxide (DMSO) and 
methanol (MeOH, Sigma-Aldrich Co, Poole, UK) were used as solvents. 
Human serum albumin (HSA), N-α-acetyl-lysine, and N-ԑ-acetyl-lysine (NAL, 
Sigma-Aldrich Co) were used as protein or amino acids for the experiments. 
Sodium cyanoborohydride (NaBH3CN, Sigma-Aldrich Co) was used to 
reduce the Schiff base that results from binding of 9-AC to terminal N groups 
of amino acids such as lysine. 
Phosphate buffer was obtained by diluting 8 g NaCl, 0.2g KCl, 1.44 g 
Na2HPO4, and 0.24g KH2PO4 (Sigma-Aldrich Co) in 1 l distilled water. The 
pH was adjusted to 7.4 with HCl. 
 
3.2.2 Bradford assay 
Calibration dilutions (0.2, 0.25, 0.4, 0.5, 0.7, 0.8, 1.0, 1.2 mg/ml) were 
prepared in phosphate buffer using bovine serum albumin (BSA, Sigma-
Aldrich). 5 µl of each dilution were plated into 4 wells of a 96 well plate. 
Samples were plated into 3 different wells of the plate. 250 µl of Bradford 
reagent (Bio-Rad Laboratories Ltd., Hertfordshire, UK) was added to each 
well. The content was mixed and air bubbles were removed. Absorbance 
was measured at 570 nm using a plate reader. The mean was calculated for 
the values obtained for the calibration dilutions. The mean was plotted and a 
standard curve was fitted. With the equation for the standard curve, the 
protein content of each sample was calculated using Excel. 
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3.2.3 Incubation of compounds with N-acetyl-lysine 
A solution of 1 mM N-α-acetyl-lysine or N-ε-acetyl-lysine was made in 
phosphate buffer. 9-AC was dissolved in DMSO (100 µM final concentration) 
and incubated with N-α-acetyl-lysine or N-ε-acetyl-lysine (1 mM), in the 
presence of sodium cyanoborohydride (1 mM), in phosphate buffer at room 
temperature [20]. 
Aliquots of the incubation were removed immediately after mixing and 
analysed by LC-MS. The incubation time was approximately 10 minutes. 
Other aliquots were measured at 40 min, 2 h, 4 h and 6 h after the start of 
the incubation. 
Aliquots of the solutions were chromatographed at room temperature on an 
Agilent 5-µm Zorbax Eclipse XDB-C8 column (150 mm x 4.6 mm; Agilent 
Technologies, Santa Clara, CA, USA). Analytes were eluted with an 
isocratic-gradient system of acetonitrile (ACN) in 0.05% formic acid: 15% for 
5 min; 15% to 40% over 10 min; 40% to 15% over 0.1 min; 15% for 4.9 min. 
The eluent flow rate was 1.0 ml/min. The retention time of authentic 9-AC 
was 4 min. 
Eluent was delivered by a PerkinElmer series 200 HPLC system (pump and 
autosampler; PerkinElmer, Norwalk, CT, USA). The column was connected 
to the Turbo V electrospray source of an API 4000 Qtrap hybrid quadrupole 
mass spectrometer (AB Sciex, Warrington, UK) via a Valco flow-splitting T-
piece (Valco Instruments Co. Inc., Houston, TX, USA). The flow rate of 
eluate to the mass spectrometer was approximately 150 µl/min.  
The standard operating parameters of the mass spectrometer (Q1 operation) 
were as follows: source temperature, 450 °C; ionspray (electrospray 
capillary) voltage, 4 500 V; desolvation potential (DP), 100 V; entrance 
potential (EP), 10 V; curtain gas setting, 15; spray gas (Gas-1) setting, 50; 
heater gas (Gas-2) setting, 50. To obtain greater in-source analyte 
fragmentation, the DP was uprated to 120 V. All of the source gas 
requirements were met by a nitrogen/zero-grade air generator. The 
instrument was set up for full-scanning acquisitions in the positive-ion mode 
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over a scan range of  m/z 100-1 000 with a scan time of 5 s. Instrument 
management and data processing were accomplished through Analyst 1.5.1 
software. 
 
3.2.4 Isolation of His-tagged GSTPi on nickel beads 
Hexahistidine-tagged human glutathione S-transferase π (GSTPi) was 
expressed in Escherichia coli [30]. His-Select nickel affinity gel (Sigma-
Aldrich Co) was used for the purification of GSTPi [31]. The gel was 
suspended in 900 µl of phosphate buffer and 100 µl of lysate from GSTPi 
expressing Escherichia coli was added. The mixture was incubated for 10 
min at room temperature with agitation. After that, beads were washed 5 
times with phosphate buffer. The Bradford assay (Bio-Rad Laboratories Ltd.) 
was performed to determine the concentration of protein. According to the 
Bradford assay, protein compound ratios were created using the procedure 
as described below. 
 
3.2.5 Incubation of protein with compounds 
Different compound to protein mixtures were prepared using either CBZ, 
CBZE or 9-AC. For GSTPi, the used amount of protein depended on the 
yield from the isolation. For HSA, a 66 mg/ml solution was prepared. 
For concentration-dependent experiments, the following compound to protein 
ratios were used: 1:1, 10:1, and 25:1. The incubations were carried out at 
37°C for 24 h. 
The time-dependent experiments were conducted using a 10:1 compound to 
protein ratio. The samples were incubated for 1, 4, and 24 hours at 37°C. 
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3.2.6 Incubation of 9-AC and HSA with NaBH3CN 
For the incubation of 9-AC with HSA in the presence of the reducing agent 
NaBH3CN, the compound to protein ratios were: 10:1, 1:1, and 0.5:1. 
NaBH3CN (0.2 mM) was added after the samples were incubated at 37°C for 
30 min and the samples were incubated at 37°C for 16 h. 
 
3.2.7 Preparation of samples for LC-MS/MS analysis 
At the end of the incubation, the protein was precipitated using 9 volumes of 
cold MeOH. The mixture was then centrifuged at 14 000 RPM for 20 min at 
4°C. The supernatant was removed and the protein pellet was washed 3 
times with ice cold MeOH before being resuspended in 80 µl of PBS. The 
protein was denatured by adding 8.8 µl of dithiothreitol (100 mM) and 
incubating the sample for 15 min at room temperature. After that, 11 µl of 
iodoacetamide (500 mM) was added and the sample incubated for 15 min at 
room temperature. The protein was then precipitated using MeOH as 
described before. The pellet was reconstituted in 50 µl of ammonium 
bicarbonate solution (50 mM) and the concentration was determined utilising 
the Bradford assay. The protein was digested by trypsin (200 µg protein per 
µg trypsin). Samples were incubated at 37°C overnight. The digestion was 
stopped by acidifying the samples with trifluoroacetic acid (TFA, 1%). To 
desalt the peptide mixture, C18 Zip-Tips (Millipore, Waterford, UK) were 
used according to specifications provided by the manufacturer. The bed of 
the C18 Zip-Tip was humidified with ACN and equilibrated with TFA (0.1%). 
The sample was then loaded on the column and washed with TFA (0.1%). 
After that the samples were eluted with a mixture of ACN (50%) and TFA 
(0.1%). After the elution, the samples were dried and stored at 4°C before 
being analysed in the LC-MS/MS. 
For the LC-MS/MS analysis, the samples were reconstituted in 2% 
ACN/0.1% formic acid (FA, v/v). Samples of 2.4 to 5.0 pmol were delivered 
into a QTRAP 5500 mass spectrometer (AB Sciex, Framingham, MA, USA) 
fitted with a NanoSpray II source by automated in-line liquid chromatography 
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(U3000 HPLC System, 5 mm C18 nano-precolumn and 75 μm × 15 cm C18 
PepMap column [Dionex, California, USA]) via a 10 μm inner diameter 
PicoTip (New Objective, Massachusetts, USA). A gradient from 2% 
ACN/0.1% FA (v/v) to 50% ACN/0.1% FA (v/v) in 60 min was applied at a 
ﬂow rate of 300 nL/min. The ion spray potential was set to 2 200−3 500 V, 
the nebulizer gas to 19, and the interface heater to 150 °C. Spectra were 
acquired automatically in positive ion mode using information-dependent 
acquisition powered by Analyst 1.5 software, using mass ranges of 
400−1 000 amu in MS and 100−1 000 amu in MS/MS. The 5 most intense 
ions were selected for MS/MS, using a threshold of 5 000 counts per second, 
with dynamic exclusion for 30 s and rolling collision energy. Data were 
analysed using PeakView 1.2.0.3 (AB Sciex) or ProteinPilotTM 4.2 beta. 
The sequence and the theoretical mass of the the tryptic digestion were 
generated by the PeptideMass software, available on the ExPASy website, 
allowing for one cleavage site to be missed. 
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3.3 Results 
 
3.3.1 Binding of 9-AC to N-acetyl-lysine 
To detect the Schiff base formed between 9-AC and amine, 9-AC was 
reacted with N-α-acetyl-lysine in the presence of a reducing agent. A 
molecule with a mass of 380.20 amu was detected after 2.43 min. The 
intensity of that molecule increased over time up to 6 h after the start of the 
measurement (Fig. 3.3). The mass spectrometric analysis revealed the 
adduct as a reduced Schiff base from the reaction of 9-AC and N-α-acetyl-
lysine (Fig. 3.2). 
 
Figure 3.2: Mass spectrometric analysis of 9-AC-modified N-α-acetyl-
lysine 
An ion at m/z 380.20 corresponding to a reduced 9-AC-NAL adduct was detected and 
characteristic fragment ions were interpreted as the inserted structure. 
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Figure 3.3: Liquid chromatographic spectrum for fragments with a mass of 
380 amu 
Spectrum shows increase in the intensity of product peak (2.43 min) over time. No internal 
standard was used. Identity of the product was confirmed using mass spectrometric analysis 
(Fig. 3.2). 
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The experiment was repeated with 9-AC and N-ε-acetyl-lysine. An 
experimental error resulted in an excessive amount of reducing agent 
(100 mM compared to 0.1 mM). The HPLC and the mass spectrometric 
analysis showed molecule with the mass of 382.20 amu, suggesting that two 
reductions occurred (see Fig. 3.4). The analyses of several mass peaks lead 
to the conclusion that the second reduction must have taken place in the N-
acetyl-lysine. The results show the formation with the Schiff base with the α-
nitrogen group of lysine. 
 
 
Figure 3.4: Mass spectrometric analysis of 9-AC-modified N-ɛ-acetyl-lysine 
An ion at m/z 382.20 was detected and interpreted as an adduct of 9 
acridinecarboxaldehyde and N-ɛ-acetyl-lysine that had under two reductions. Characteristic 
fragment ions were interpreted and as the structure found next to the peaks. 
 
 
123 
 
3.3.2 Characterisation of compound modified HSA 
The most abundant protein in human blood, HSA, was used to observe 
possible covalent binding of CBZ and its metabolites through an addition in 
human blood. The mass spectrometric analysis of the tryptic digests of HSA 
in the presence of CBZ did not reveal any conjugates. The analysis detected 
only binding of 9-AC to the N-terminal α-amino group of HSA (Fig. A3.1 in 
appendix). The samples of HSA incubated with 9-AC exhibited lower protein 
coverage compared to all the other samples including HSA alone and HSA 
incubated with compounds. 
For CBZE, the analysis revealed two modified peptides that both contained a 
histidine residue. The first one was found on His146-containing peptide 
145RHPYFYAPELLFFAK159. The adduct was eluted at 37.78 min and 
identified as a triple charged ion at m/z 547.28, which had an additional mass 
of 253 amu to the parent peptide. The MS/MS analysis confirmed the identity 
of the peptide and the binding of CBZE to His146 (m/z 547.28) (Fig 3.5 A). 
The peptide sequence was confirmed by the observation of a series of b ions 
and y ions. The modification site was located at His146 by the observation of 
CBZE-modified b2 ions. The presence of characteristic fragment ions derived 
from CBZE provided further evidence of the modification (see Fig. 3.6). The 
second adduct was found in the His338-containing fragment 
337RHPDYSVVLLLR348. This peptide eluted after 28.25 min and was 
detected as a triple charged ion at m/z 574.22. Again the peptide sequence 
was confirmed by the observation of b and y ions. The modification site was 
found by the observation of CBZE-modified b2 ions and the binding was 
supported by fragment ions of CBZE. 
The peptide and the binding of CBZE to His338 were confirmed in the 
MS/MS analysis (Fig 3.5 B). Both fragments were found at a 10:1 drug: 
protein ratio and after a 24 hour incubation. The amount of additional mass 
corresponds to the expected amount of adduct from a nucleophilic addition of 
CBZE and HSA. 
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Figure 3.6: Fragmentation of CBZE adduct in MS/MS 
 
 
 
Figure 3.7: Tertiary structure of HSA showing CBZE binding sites detected 
in vitro 
Protein was depicted as ribbons and the modified histidine residues shown as blue spheres. 
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3.3.3 Characterisation of compound modified GSTPi 
GSTPi was used for the detection of protein binding, as it was shown to be a 
model protein for reactive metabolites due to the reactive cysteine residue it 
contains [25]. As for HSA there were no conjugates found in the mass 
spectrometric analysis of the tryptic digested peptide from GSTPi incubated 
with CBZ or 9-AC. The protein coverage for GSTPi samples incubated with 
9-AC was again lower compared to the coverage of other samples. 
For CBZE, the mass spectrometric analysis revealed a conjugation on Cys47 
at the 10:1 ratio and after a 24 hour incubation. This cysteine is located in the 
peptide 45ASCLYGQLPK54. The CBZE-modified peptide was found as a 
double charged ion at m/z 542.21 and eluted at 37.66 min. This fragment 
showed a gain in mass of 253 amu compared to the mass of the parent 
peptide (Fig. 3.9). The peptide sequence was identified by observing b and y 
ions of the fragment. The binding of CBZE to Cys47 (m/z 542.21) was 
confirmed by the detection of the modified b3 ion as well as characteristic 
CBZE fragment ions (see Fig. 3.7) 
 
 
Figure 3.8: Fragmentation of CBZE adduct in MS/MS 
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Figure 3.10: Tertiary structure of GSTPi showing CBZE binding site 
detected in vitro 
Protein depicted as ribbons and the red arrow pointing at modified cysteine residue shown in 
yellow. 
 
3.3.4 Binding of 9-AC with HSA in the presence of NaBH3CN 
To observe the possible Schiff base formation from 9-AC and HSA, the 
protein was reacted in the presence of NaBH3CN. No conjugates were 
observed in the mass spectrometric analysis of the tryptic digests of HSA. 
The protein coverage, as in previous experiments, was low. 
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3.4 Discussion 
 
The mechanism by which the immune system is activated in CBZ-induced 
hypersensitivity reactions is not clear. It has been proposed that the 
activation of the immune system results from the generation of reactive 
metabolites [32]. 
Biotransformation is crucial during the clearance of a drug. During the 
biotransformation, the less reactive parent drug is metabolised into 
intermediates that have a higher reactivity towards proteins. The drug-
modified proteins may then potentially cause an immune response, in some 
cases resulting in a cutaneous idiosyncratic ADR [33]. The detection of 
antibodies against microsomal proteins in the blood of patients that had 
suffered from CBZ-induced liver injuries suggests that CBZ or one of its 
metabolites can bind to proteins and thus trigger an immune reaction [10]. 
The liver is the main site for drug metabolism but it is questionable that the 
highly reactive metabolites will be found outside the liver [34, 35]. 
Metabolism outside the liver, generating protein reactive intermediates, might 
be more important in the activation of the immune system known to occur in 
idiosyncratic ADRs [34, 36-38]. For CBZ, Furst and colleagues showed that 
9-AC can be generated by activated human lymphocytes [19]. The binding of 
9-AC and CBZE was shown using radiolabeled compounds [20, 39]. These 
experiments only found that protein modification was possible but were 
unable to determine the residue inside the protein. 
Drugs are considered too small to be detected by the immune system. 
Therefore they would need to modify proteins in order to be immunogenic. In 
this chapter, the experiments were designed to assess protein modification 
of CBZ and its metabolites, CBZE and 9-AC. Covalent binding is described in 
the hapten hypothesis as a mechanism for drugs to become immunogenic 
(see general introduction 1.5.1). Therefore, an additional aim was to detect 
the exact binding site within the protein. For this assessment of the exact 
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protein binding site of CBZ and its metabolites CBZE and 9-AC, HSA and 
GSTPi were analysed by LC-MS/MS. HSA and GSTPi have been previously 
reported to bind drugs and drug metabolites and the modified proteins have 
been identified as activators of immune response, thus the proteins 
presented promising targets for this work [25, 40-44]. 
The results showed that no conjugates were observed in samples of HSA or 
GSTPi incubated with the parent drug CBZ. This was expected as in the 
literature covalent protein binding of CBZ was only reported in the presence 
of a metabolising enzyme [20]. This would suggest that CBZ acts as a pro-
hapten and therefore cannot covalently bind to proteins (see general 
introduction 1.5.1). CBZ as a chemically inert drug can be transformed into a 
reactive structure through the drug’s metabolism. This was also confirmed in 
the experiments of this chapter, where instead a metabolising system, 
selected metabolites were used. 
In the samples of HSA and GSTPi, conjugates with CBZE were found and 
characterised for both proteins. It was shown that CBZE forms covalent 
bonds with histidines in HSA and the highly reactive cysteine in GSTPi. 
Epoxides are considered hard electrophiles and therefore able to bind to 
histidine residues. This was observed in HSA. CBZE was found to bind to 
His146 and His338. Since both residues could be found at the same 
concentration and the same time point, no preference could be determined. 
Histidine is a nucleophilic side chain and was therefore expected to react 
with CBZE. His146 is also the most reactive of the histidine residues in HSA 
[40, 44]. 
Covalent binding of CBZE to a reactive cysteine residue (Cys47) was 
detected in GSTPi. This finding had been reported before [39]. No binding to 
a histidine residue was detected in GSTPi. 
This different selectivity of binding in GSTPi and HSA could be caused by 
different parameters at the possible binding site within the protein. These 
parameters include intrinsic chemical reactivity of amino acids and non-
covalent interaction between a molecule and the binding pocket of the 
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protein. Additionally, CBZE represents a bulky molecule. Due to this, the 
tertiary structure of the protein could influence the accessibility of potential 
binding sites. There is also only one cysteine in HSA that is not forming a 
disulphide bond (Cys34) [45]. After tryptic digestion this cysteine is located in 
a larger peptide. For further investigation of the binding of CBZE to this 
cysteine other digestion methods could be used. 
These findings also indicate the difficulties in drug design. During the 
development of a new drug, attempts to predict the protein binding 
capabilities of the drug and its metabolites are undertaken with the aim of 
minimising adverse reaction for patients treated in clinical trials with the new 
drug. The findings for CBZE indicate that binding to particular residues within 
proteins can be missed depending on the protein chosen for the 
experiments. Ideally, all proteins of the human body should be screened 
during the development of a new drug. However, this would increase the 
costs of drug development severely and would be therefore not feasible. 
Nevertheless, the conjugates of CBZE indicate a possible involvement of 
haptens formed by the main metabolite of CBZ. The immunogenicity of these 
modified proteins remains to be shown and would be a very interesting point 
for further studies. One possibility to determine whether these adducts are 
immunogenic would be the T cell proliferation assay. In this assay, the drug-
specific T cells from CBZ hypersensitive patients would be incubated in the 
presence of peptides derived from the modified proteins and the proliferation 
of the T cells would be measured. 
The binding of 9-AC and N-acetyl-lysine was proven to be a Schiff base. The 
adduct was only found to be covalent in the presence of a reducing agent 
transforming the imine into an amine, as it was reported before [20]. 
This formation of a Schiff base, in which the carbonyl carbon of the aldehyde 
group in 9-AC reacts with an amino group of a residue or the N-terminus to 
an unstable imine, should also be observable in proteins. No Schiff base 
adducts of 9-AC and an ɛ-amino group of a residue was observed even at 
high concentrations. The only conjugates observed resulted from unspecific 
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binding to the backbone of the proteins. No other conjugates were observed 
for either HSA or GSTPi. Also in the presence of a reducing agent, no 
covalent binding was observed in HSA. Higher concentrations of reducing 
agent should be used in further experiments to find the Schiff base products 
that were expected. 
The protein coverage in the samples containing 9-AC was always lower 
compared to the coverage observed in all the other samples. The reason for 
the low coverage could lie in the solubility of 9-AC in methanol and the 
protein precipitation conducted in methanol. Conjugated proteins could have 
stayed in solution and were therefore not detected. To eliminate this 
possibility, the proteins could be isolated using other precipitation methods. 
Another consideration for further studies could include the investigation of 
the immunogenicity of the non-covalent modification of peptides by 9-AC. In 
order to determine this, T cell proliferation could be examined by incubating 
T cells from CBZ hypersensitive patients with 9-AC in the presence of 
chemically fixed APCs, thus analysing the role of the p-i mechanism in the 
9-AC mediated activation of T cells during hypersensitivity reactions. 
In summary, CBZE was able to covalently modify proteins. This observation 
indicates that haptens could play a role in the pathogenesis of CBZ-induced 
hypersensitivity reactions. As all experiments were conducted in vitro, it is 
uncertain whether these modifications can also be observed in vivo. 
Therefore the presence of these adducts need to be investigated in patients 
undergoing CBZ treatment. The immunogenicity of these adducts would also 
need further investigation. Nevertheless, the role of the hapten hypothesis 
cannot be excluded and could offer an explanation for the first signal needed 
in the activation of naïve T cells according to the danger hypothesis. 
Additionally, the findings for 9-AC indicate that non-covalent binding to 
proteins might also occur during CBZ-induced hypersensitivity reactions. 
Therefore the T cell activation in patients suffering from CBZ-induced 
hypersensitivity reactions needs further investigation and should include 
methods for the detection of covalent as well as non-covalent modifications 
causing the activation.  
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4.1 Introduction 
 
Various in vivo and in vitro analyses of skin lesions from patients with drug-
induced hypersensitivity reactions have revealed the involvement of cytotoxic 
mechanisms mediated by drug-specific cytotoxic T cells [1-7]. The activation 
of those T cells can lead to widespread apoptosis [8]. It has been also shown 
that the severity of the drug-induced hypersensitivity is strongly associated 
with a high expression of cytotoxic markers [9]. The association of drug-
induced cytotoxicity with the development of drug-induced hypersensitivity 
reactions is less well studied. 
Computational toxicology is a rapidly expanding field. It combines 
methodologies from computer science bioinformatics, chemistry and 
molecular biology [10-12]. Classical experimental approaches in toxicology 
are based on in vivo testing in animal models. This approach, although 
delivering reliable results, is very time- and cost-intensive. It has also led to a 
huge backlog of chemicals to be tested. The amount of chemicals that 
require testing is growing rapidly with the discovery of new chemicals. The 
concept of computational toxicology lies in identifying chemicals that bear a 
hazard for individuals and prioritise these compounds for animal testing or 
even replace animal testing in the future [13, 14]. Utilising the in vitro-in vivo 
extrapolation paradigm, in vitro data for thousands of chemicals were 
generated by the Tox21 program which comprises several agencies in the 
United States of America including the National Toxicology Program, 
National Chemical Genomics Center, Environmental Protection Agency and 
Food and Drug Administration, to re-establish the field of predictive chemical 
toxicology [15]. 
Chemical mechanistic data provide information about the toxicity of a 
chemical based on its structure. Such information can be obtained by in vivo 
testing in animals, chemical structure-based prediction models or in vitro 
screening for endpoint toxicity. 
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Chemical structure-based prediction links the geometry and the electronic 
structure of a molecule to an activity, such as adverse health outcomes. This 
can be achieved either through statistical models, assigning scores 
according to structural similarities of a new compound or by expert systems 
utilising rules determined by scientific consensus. It has been shown that 
chemicals with ≥ 0.85 similarity (based on the Tanimoto coefficient) to active 
compounds were 30 times more likely to be active themselves compared to 
randomly chosen chemicals [16]. The Ashby-Tennant structural alerts for 
carcinogenicity are an example of an expert system incorporated in many 
software tools [17, 18]. Although both models are used for the prediction of 
toxic effects, it has been shown that they do not allow the prediction of 
complex biological phenotypes [10]. 
Recent advances in automated quantitative high-throughput screening 
(qHTS) allows the generation of vast amounts of biological data. These 
experiments range from short-term in vitro assays to various in vivo 
endpoints and allow the prediction of in vivo toxicity using statistical or 
machine learning approaches [19]. 
 
In the past, genetic studies, investigating disease-gene associations, were 
primarily focusing on one or a few target genes [20]. This approach required 
a priori information about the genes and pathways involved, meaning that a 
hypothesis of the involved mechanism needed to be generated [21]. In the 
last decade, extensive characterisation of the human genome through next-
generation DNA sequencing has allowed a better understanding of the 
impact of single nucleotide polymorphisms (SNP) on phenotypes [22]. This 
allows investigation of the association of genetic variance to toxicity in an 
unbiased approach. As the genetic associations in idiosyncratic drug 
reactions are not related to the known pathological pathways of the drug, this 
novel method may be better suited for discovering associations. 
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Complex data generated, using the different methods described, can be 
integrated in different ways. These include consensus, hierarchical and 
hybrid approaches (see Fig. 4.1) [23-26]. It has been shown that these 
approaches allow a better prediction of in vivo toxicity and allow prioritisation 
of additional testing in classical animal testing or generation of testable 
hypotheses concerning the underlying mechanism of toxicity [14, 27, 28]. 
 
 
 
Figure 4.1: Approaches for integration of chemical and biological data for 
predictive models in computational toxicology (adapted from Rusyn et al., 
2012 [29]) 
142 
 
The advanced knowledge about the genome combined with the in vivo 
studies in genetically diverse mice showed that polymorphisms can have a 
fundamental effect on disease risk after drug or toxin exposure [30]. In one 
study, it was observed that genetic variation in CD44 influenced liver injury 
caused by acetaminophen. These factors cannot be assessed or evaluated 
using established animal systems or cell lines as these are missing such 
genetic variation [31]. For the 1000 Genomes project, samples from healthy 
volunteers in 25 populations were collected and lymphoblast cell lines were 
generated (see Tab 4.1) [32]. These were generated by transforming B cells 
from participants with the Epstein-Barr virus into immortalised cell lines [33]. 
The lymphoblast cell lines were made commercially available to researchers. 
Such lymphoblasts enable in vitro testing at the population scale. The 
feasibility of the in vitro model was used to assess interindividual- and 
population-wide variability of chemically-induced toxicity phenotypes [34]. 
In chapter 2, inter-individual variability was observed in the viability of cells 
exposed to a metabolite of carbamazepine (CBZ), 9-acridinecarboxaldehyde 
(9-AC). Based on these findings, it was hypothesised, that the variability may 
be caused by genetic differences and could lead to the initiation of 
hypersensitivity reaction. Following the previous results, the aim of this 
chapter was to further investigate the inter-individual variability and inter-
population differences in cell viability of 331 lymphoblastoid cell lines 
exposed to CBZ and its metabolites. For the detection of genetic association 
with lower tolerance of CBZ and its metabolites, a genome-wide association 
study (GWAS) was to be performed using the dose-response data from the 
screening and DNA sequencing data. Candidate SNPs were to be assessed 
for potential biological plausibility and the most plausible SNP was to be 
validated in patients with CBZ-induced hypersensitivity reactions and CBZ-
tolerant controls. 
This presents a novel approach for discovering SNPs involved in the 
development of CBZ-induced hypersensitivity reactions in patients. The 
findings could also unravel the underlying mechanisms involved in these 
reactions. 
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Table 4.1: Populations from the 1000 Genomes project [32] 
Continent of origin Population description 
Africa 
Esan in Nigeria 
Gambian in Western Davison, the Gambia 
Luhya in Webuye, Kenya 
Mende in Sierra Leone 
Yoruba in Ibadan, Nigeria 
America 
African Ancestry in Southwest US 
African Caribbean in Barbados 
Colombian in Medellin, Colombia 
Mexican Ancestry in Los Angeles, California 
Peruvian in Lima, Peru 
Puerto Rican in Puerto Rico 
Asia  
East 
Chinese Dai in Xishuangbanna, China 
Han Chinese in Beijing, China 
Han Chinese South 
Japanese in Tokyo, Japan 
Kinh in Ho Chi Minh City, Vietnam 
South 
Bengali in Bangladesh 
Gujarati Indian in Houston, Texas 
Indian Telugu in the UK 
Punjab in Lahore, Pakistan 
Sri Lankan Tamil in the UK 
Europe 
Britisch from England and Scotland 
Finnish in Finland 
Iberian populations in Spain 
Utah residence with northern and western 
European ancestry 
Toscani in Italy 
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4.2 Material and Methods 
 
4.2.1 Chemicals 
CBZ and its metabolites, CBZ-10,11 epoxide (CBZE, eMolecules Inc., 
Cambridge, USA) and 9-AC (Life Chemicals, Braunschweig, Germany), were 
used in these experiments. The compounds were dissolved in dimethyl 
sulfoxide (DMSO, eMolecules Inc.) and diluted into 12 different stock 
concentrations ranging from 20 000 to 10 µM (see Tab. 4.2). 
 
Table 4.2: Serial dilution of stock concentrations 
Concentration 
(µM) 
µl added from 
dilution 
µl of DMSO 
added 
Final 
concentration 
(µM) 
20 000 2 800 from stock 0 200 
10 000 1 400 from stock 1 400 100 
3 000 420 from stock 2 380 30 
1 000 280 from 10 000 2 520 10 
300 280 from 3 000 2 520 3 
100 280 from 1 000 2 520 1 
30 280 from 300 2 520 0.3 
10 280 from 100 2 520 0.1 
 
These dilutions were aliquoted into 96-well plates and stored at -80°C until 
use in the experiment. The final concentration ranged from 200 to 0.1 µM in 
the assay. DMSO was used as negative control (0.5% v/v final 
concentration). Tetraoctylammonium bromide (eMolecules) was used as a 
positive control for cytotoxicity as described by Cho and colleagues (46 µM 
final concentration) [35]. 
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4.2.2 Cell lines and culturing 
340 immortalised lymphoblastoid cell lines from participants of the 1000 
Genome project were obtained from Coriell Cell Repositories (Camden, NJ, 
USA). These cell lines were chosen as their basal gene expression levels 
were known through RNA sequencing [36]. The cells were genotyped by 
exon targeting using NimbleGen 385K capture chip followed by Illumina 
Genome Analyzer I and II, AB SOLiD System 1.0 and 2.0 or 454 GS FLX for 
sequencing [32]. The cells were transformed into immortalised cell lines, 
using Epstein Bar viruses [33], for further scientific experiments. The cells 
were derived from 340 unrelated, healthy individuals representing four 
different populations. 78 cell lines (22.9%) were residents from Utah with 
northern and western European ancestry (CEU). 90 cell lines (26.5%) were 
Tuscan residents from Italy (TSI). 91 cell lines (26.8%) were from England 
and Scotland (GBR). 81 cell lines (23.8%) were from Nigerians, Yoruban 
from Ibadan (YRI). The cell lines were divided into 9 randomised batches for 
culturing and cytotoxic screening. 
Cells were cultured at 37°C with 5% CO2 in suspension in flasks oriented 
upright containing RPMI 1640 media (Gibco, Carlsbad, CA, USA) 
supplemented with 10% fetal calf serum (FCS, Gibco) and 0.1% penicillin-
streptomycin (Gibco). The cells were counted and viability was measured on 
five consecutive days using the Trypan blue (Sigma-Aldrich Inc.) exclusion 
method and the Cellometer Auto T4 (Nexcelom, Bioscience, Lawrence, MA, 
USA). Daily measurements were conducted to account for differences in 
cytotoxicity of lymphoblast cell lines caused by differences in baseline growth 
rate and metabolic status [37]. 
 
4.2.3 Patients 
DNA samples from 153 individuals from the DNA archive in Liverpool were 
used for the genotyping. 109 of these patients were recruited by researchers 
in Liverpool over the past two decades and 44 individuals have been 
recruited globally within the international Serious Adverse Events Consortium 
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(iSAEC). The iSAEC is a non-profit organization, comprising pharmaceutical 
companies, academic institutions and international regulatory bodies such as 
the Food and Drug Administration in the USA [38]. The main objective of the 
consortiums work is the identification of genetic variants responsible for 
severe, drug-induced reactions including severe skin rashes. The summary 
of ethnicities of the cohort used in this work can be found in table 4.3 (see 
Tab. A4.1 in appendix for individual genotype). 
 
Table 4.3: Ethnicity of patients 
Ethnicity Number of individuals 
African 1 
Asian 5 
Caribbean 1 
White 127 
Mixed 17 
Not known 2 
 
From the 109 patients who had suffered from hypersensitivity reactions: 39 
of the 109 were patients with maculopapular exanthema (MPE), 1 patient 
with acute generalised exanthematous pustulosis (AGEP), 43 patients with 
drug reaction with eosinophilia and systemic syndromes (DRESS), and 26 
patients with Steven Johnson syndrome and/or toxic epidermal necrolysis 
(SJS/TEN). The clinical phenotypes were defined as described by 
Pirmohamed and colleagues (see general introduction section 1.2.2) [39]. 
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44 were CBZ tolerant patients defined as taking CBZ for a minimum of 6 
months without any adverse effects (see Tab. 4.4). 
 
Table 4.4: Patient phenotypes and number of patients used for genotyping 
Clinical diagnosis Number of patients 
MPE 39 
AGEP 1 
DRESS 43 
SJS/TEN 26 
CBZ tolerant 44 
 
AGEP: Acute generalised exanthematous pustulosis DRESS: Drug rash with eosinophilia 
and systemic symptoms, SJS: Steven Johnson Syndrome, TEN: toxic epidermal necrolysis, 
MPE: maculopapular exanthema 
 
4.2.4 Cytotoxicity assay 
The CellTiter-Glo Luminescent Cell viability assay (Promega Cooperation, 
Madison, WI, USA) was used to assess the intracellular adenosine 
triphosphate (ATP) concentration 23 hours after exposure of the cells to the 
compounds. ATP is a marker of the metabolic activity of cells and therefore a 
marker of cytotoxicity [40].The principle of the assay is similar to the MTT 
assay as described in chapter 2. The assay was selected based on its utility 
for in vitro screening of cytotoxicity in cell type- and individual-independent 
manner as shown in cross-cell line and cross-individual experiments [37, 41]. 
It has been demonstrated in different cell lines and individuals that the assay 
does not depend on cell type or individual and therefore is not introducing 
further limitations on the experiments. 
The cells were counted and the viability measured using the Trypan blue 
exclusion method. Cell lines with a viability of 90% or higher were diluted to a 
concentration of 3x105 cells/ml. The dilutions of cells, together with the 
master plate containing the dilutions of compounds were plated in duplicates 
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into white bottom 96 well plates using a liquid handling robotic for improved 
reproducibility (Biomek3000, Beckman Coulter Inc., Irving, TX, USA). Diluted 
cells (198 µl) and compounds (2 µl) were added to a well and split into two 
wells of different plates, so that each well contained 100 µl. The plates were 
incubated for 23 hours in an incubator at 37°C and 5% CO2. After 23 hours 
the plates were taken out of the incubator and cooled down to room 
temperature before adding freshly prepared reagent. The content was mixed 
by a shaker. Plates were then incubated for 20 minutes at room temperature 
in the dark before measuring luminescence (DTX880 Multimode Detector, 
Beckman Coulter Inc.). The experiments were conducted in laboratory of 
Professor Rusyn’s group at the University of North Carolina at Chapel Hill in 
USA. 
 
4.2.5 Analysis of Single Nucleotide Polymorphism 
14 SNPs were identified as top hits in the GWAS. The HaploReg v2 online 
database was used for the SNP analysis [42]. The database allows 
submission of queries by rs-ID number of the SNP. The data obtained from 
the database include the position of the SNP in the chromosome (intronic 
and exonic) the known function of the SNP as well as SNPs that are in 
linkage disequilibrium. The information in the database was generated by 
genotyping individuals included in the 1000 Genomes project [32]. 
 
4.2.6 Dual oxidase 1 genotyping 
The genetic variants of the DUOX1 allele were genotyped using the 
rs16939743 TaqMan® SNP genotyping assay (Life Technologies Ltd., 
Paisley, UK).This SNP was selected for validation because it was the only 
potentially functunal SNP (missense mutation) and it was also found to be 
associated with the cytotoxicity in all three compounds tested. 
The TaqMan® SNP genotyping assay is a PCR assay utilising the 5’ 
exonuclease activity of AmpliTaq Gold® DNA polymerase [43, 44]. For the 
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PCR, two locus-specific primers flanking the SNP of interest and two allele-
specific oligonucleotide TaqMan® probes are included. The probes are 
labeled with a fluorescent reporter dye at the 5’ end and a non-fluorescent 
quencher with a minor groove binder at the 3’ end [45]. Minimal fluorescence 
is emitted by an intact probe, due to the close proximity of the quencher [46]. 
A signal is generated by cleaving the fluorescent reporter dye from the 5’ end 
of a probe hybridised to the target allele through the polymerase during each 
PCR cycle. The PCR primers amplify the specific locus of the DNA template. 
The cleavage of one or both dyes of the probes produces an exponentially 
increasing fluorescent signal. The use of two allele-specific probes labelled 
with two different fluorescent dyes, allows the detection of both alleles in a 
single PCR. The use of a minor groove binder enhances the allelic 
discrimination through stabilising the probe template hybridisation and 
reducing mismatch hybridisation [47]. 
 
Figure 4.2: Schematic view of probe binding and generation of allele -
specific florescent signal through cleavage of DNA polymerase  
 
The PCR was conducted in accordance with the TaqMan® protocol using the 
dry-down DNA method. Briefly, the samples were prepared in 384-well 
optical reaction plates. 20ng of DNA were dispensed into each well and left 
to dry overnight. A master mix of the reagents for the PCR was prepared in a 
5 µl volume as follows: TaqMan® universal PCR master mix (final 
concentration: 1X) and working stock of SNP genotyping assay (final 
concentration: 1X) were mixed and added up to the final volume with DNase-
free water. The plate was then placed in the thermal cycler (7900HT Fast 
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Real-Time PCR System, Applied Biosystems, Life Technologies) and the 
PCR reaction was conducted. The PCR was initiated at 95°C for 10 min 
followed by 40 cycles of denaturing at 92°C for 15 sec and annealing and 
extending at 60°C for 1 min. The fluorescence was measured by the thermal 
cycler and analysed using the SDS 2.4 software. 
 
4.2.7 Cytotoxicity assay data processing 
The data from the cytotoxicity assay were normalised to the positive and 
negative control and expressed as percentage of viability compared to the 
negative control (DMSO) [41]. 
 
4.2.7.1 Curve fitting 
A Hill equation was fitted to the normalised concentration-response titration 
points of each compound and the data from each cell line. The baseline 
(ceiling), 100% of living cells, was estimated from the lower concentration-
responses. The maximum response (floor) is fixed to 100% dead cells (from 
positive control) unless another floor was observed for the cell line. Outliers 
of the data set from each cell line were removed if they lay more than 2 
standard deviations from the estimated fit. The program also fitted a Hill 
equation to the normalised concentration-response titration points for each 
compound and the data sets of all cell lines. 
 
4.2.7.2 Effective concentration 10 
The effective concentration 10 (EC10) is the concentration at which the 
luminescence dropped to 90% of the fitted value for the lowest concentration 
used in the experiment. For estimation of EC10, a program was used, which 
had been developed in Professor Rusyn’s group at the University of North 
Carolina at Chapel Hill. In case of the EC10 dose not being within the 
concentration range, the program estimated the EC10 at 251 µM. This 
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concentration is slightly higher than the highest concentration (200 µM) used 
in the experiments. This allows for the use of the data set in further analysis 
(such as the GWAS using the Plink software). 
 
4.2.8 Statistical analysis 
The statistical analysis was conducted by Prof. Rusyn’s group using the R 
statistical software (2.10.0; R Development Core Team, Vienna, Austria). 
 
4.2.8.1 Assessing reproducibility of assays 
The Pearson correlation coefficient (ρ) between pairs of replicates was used 
to assess the reproducibility of the experiments. The two EC10 estimates for 
each cell line and each compound were used to calculate the Pearson 
correlation coefficient. In addition, ρ was calculated for each compound 
separately and for each compound against one of the other two compounds 
to investigate whether there was a correlation between them. A Kruskal-
Wallis ANOVA [48] was performed to test for significant differences the EC10 
estimates to check for batch effects. Batch effects were adjusted using the 
Combining Batches (ComBat) method developed by Johnson and colleagues 
[49]. Experimental variations without biological cause, also referred to as 
batch effects, are commonly observed in experiments that logistically require 
the sizing of different batches. These make the combination of data 
inappropriate without adjustment for these batch effects. The combination of 
data is necessary for increased statistical power. The ComBat method is 
based on parametric and nonparametric empirical Bayes frameworks to 
adjust the data for batch effects in small samples sizes and has proven 
robustness against outliers in such situations [49]. 
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4.2.8.2 Group difference 
A Kruskal-Wallis ANOVA [48] was performed to test for significant 
differences in the EC10 estimates for each compound, each compound in 
the different genders and also for each compound in different populations. 
These comparisons resulted in the multiple comparison problem. The false 
discovery rate is generally set at 0.05 level through the p-value. Through the 
screening of multiple hypothesis simultaneously, the probability of making a 
false discovery could increase far beyond the pre-set 0.05 level. Different 
approaches have been described of accounting for multiple comparisons in 
the false discovery rate. For the group differences, the Benjamini-Hochberg 
false discovery rate was used to correct for multiple comparison [50]. 
 
4.2.8.3 MAGWAS analysis 
To measure the relationship of cytotoxicity and genotype, multivariate 
ANCOVA genome-wide association software (MAGWAS) was used [51]. 
This software provides analysis tools for association studies of single 
nucleotide polymorphisms (SNP) in genetic data having multivariate 
responses and possibly, multiple covariates. The software is based on the 
multivariate analysis of covariance (MANCOVA). MANCOVA combines the 
advantages of the analysis of covariance (ANCOVA) and the multivariate 
analysis of variance (MANOVA). 
The core of all these analyses is the analysis of variance (ANOVA), which 
tests three or more groups for mean differences based on a continuous 
response variable (independent variable) measured in a scale or interval. For 
the comparison of the variance in the means of two groups, t-test can be 
utilised. Conducting multiple t-tests for the comparisons of more than two 
group means is not advisable as multiple testing would result in an inflation 
of the false discovery rate (Type I error). Therefore, ANOVA is used for such 
comparisons. 
In comparison to ANOVA, ANCOVA includes one or more covariates. 
Covariates are variables that are not part of the experimental design but can 
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have an influence on the on the outcome (dependent variable). ANCOVA 
assesses the distribution of means in the outcome within different treatment 
groups (independent variables), while statistically monitoring the influence of 
covariates and adjusting for these. Therefore, ANCOVA separates variance 
in the outcome into three groups: variance accounted for by the treatment, 
variance caused by covariates, and residual variance. The variance caused 
by covariates (covariance) is measured as a linear association between the 
covariates and the outcome. Due to this adjustment, ANCOVA reduces the 
error variance within a group and also eliminates the possibility of confounds. 
MANOVA is an extension of ANOVA and can be used for analysing multiple 
dependent variables. ANOVA can only analyse one association of one 
dependent variable. Similar to the situation of multiple t-tests, the conduction 
of multiple ANOVAs is inappropriate, as this would lead to an increase in the 
false discovery rate. Another advantage of using MANOVA over multiple 
ANOVAs is that MANOVA takes into account relationships between 
outcomes (dependent variables) by including them in one analysis. 
Therefore, analysing the data with a MANCOVA software allows the use of 
the dose response data measured instead of EC10, as well as adjusting for 
various covariates. The screening for all cell lines used in the experiments 
could not be measured at the same time and might influence the means 
depending on these circumstances, such as the day on which the cells were 
measured. 
 
“For covariates, responses were fit to the model using following formula: 
𝑌𝑖 = 𝛼 + 𝑋𝑖 + 𝐸𝑖; 
where 𝑌𝑖 is the vector of responses for the i-th cell lines, and 𝑋𝑖 contains 
effects from covariates. This regression identifies overly influential 
observations that would be used in the association analysis. 
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For phenotype, responses were modelled using the following formula: 
𝑌𝑖𝑗 = 𝛼 + 𝑋𝑖,−𝑗 + 𝐸𝑖𝑗; 
where 𝑌𝑖𝑗 is the j-th response from the i-th cell lines, and 𝑌𝑖,−𝑗 are vectors of 
responses, excluding j, from the i-th cell line. This regression identifies 
responses that do not match the rest of the dose-response curve. 
 
For this the program uses following guidelines: 
 Replace responses > 3:5 ϭ-hat away from their predicted value 
 Use original ranked responses instead if replacement > 5% 
 Use original ranked response also, if absolute skewness > 1 or 
kurtosis > 4.5” 
The information was provided by Chad Brown, the developer of the 
MAGWAS. 
 
For the MAGWAS, genotype data from each cell line comprising 1510701 
SNPs was obtained from the 1000 genome project [32]. For the quality 
control of the genotyping data, the missingness test (GENO > 0.1), minor 
allele frequency test (MAF < 0.05) and Hardy-Weinberg test (p ≤ 0.001) were 
used. The missingness test determines the quality of a marker by assessing 
the call rate for a particular SNP. In this GWAS, it was set less than 10%, 
meaning that the lowest call rate for a SNP was above 90%. This excluded 
48 SNPs. The minor allele frequency (MAF) test excludes very rare SNPs 
from the analysis. Because of their rare occurrence, these SNPs generally 
require larger sample sizes. In this GWAS, 481 379 SNPs with MAF below 
5% were excluded. The Hardy-Weinberg equilibrium (HWE) assumes that all 
frequencies of alleles and genotypes can be estimated from one generation 
to the other in the absence of migration, mutation, natural selection and 
inbreeding [52]. The HWE test is a Chi-squared test assessing how good the 
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data fit the HWE [53]. 19 169 markers were excluded based on HWE test. 
After the quality control of the data, 1 015 304 SNPs were included in the 
GWAS. Phenotype was derived as the normalised and adjusted dose-
response data for the cell lines in the MAGWAS analysis. For covariates, the 
first 10 principal components were used for to adjust for population 
stratification (see Fig. 4.3 and 4.4). Furthermore batch, gender, day, and 
batch and day were included in the model. 
 
 
 
 
 
 
 
 
Figure 4.3: Eigenvalues of first 15 principal components  
The x-axis shows the principle components and y-axis shows Eigenvalues. Eigenvalues 
represent how much variation is caused by principle component. 
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Figure 4.4: Principle component analysis  
CEU: residents from Utah with northern and western European ancestry, TSI: Tuscan 
residents from Italy, GBR: British population from England and Scotland, YRI: Nigerians, 
Yoruban from Ibadan. 
 
LocusZoom was used to visualise the genomic context for suggestive loci 
determined by MAGWAS [54]. 
P-values below 1 x 10-8 were considered genome-wide significant. This value 
derives from the Bonferroni correction [55]. Cut off of p < 10-8 was also used 
in other GWASs [56-60]. The approach for this correction is conservative; 
and therefore, p-values between 1x10-5 and 1x10-8 were also taken into 
consideration but as genome-wide suggestive. 
 
157 
 
4.2.8.4 Fisher’s exact test 
The clinical outcome of the patients was compared against the DUOX1 
genotyping data utilising the Fisher’s exact test [61]. 
 
4.2.8.5 Power calculation for SNP validation 
Based on the frequency of the rare variant of DUOX1 in European (0.01), to 
achieve 80% power with 5% alpha error and odds ratio of 5, approximately 
144 cases and 175 controls in a 1:5 ratio would need to be included. 
To determine whether the polymorphism in DUOX1 is associated with all 
hypersensitivity phenotypes, genotyping needs to be conducted in a large 
number of individuals with diverse clinical phenotypes. To assess a sample 
size for future studies to detect a statistical difference between case- and 
control group under the assumption that the frequency of the DUOX1 variant 
is 20% in patients with hypersensitivity reactions, a power calculation was 
performed with varying frequencies of the DUOX1 variant in the control 
group (see Tab. 4.5). 
Table 4.5: Number of patients required to conduct a case control study 
with varying frequencies of DUOX1 variant in a control group (frequency 
of DUOX1 variant in cases: 20%, 5% Alpha error and 80% power)  
  
Frequency of DUOX1 variant in 
control group 
Case : Control 
ratio 
Groups 
8% 
(Worldwide) 
14% 
(Asian) 
19% 
(African) 
Numbers of individuals required 
1:1 
Cases 131 615 24 641 
Controls 131 615 24 641 
1:5 
Cases 69 354 14 707 
Controls 345 1 770 73 535 
1:10 
Cases 61 321 13 465 
Controls 610 3 210 134 650 
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4.3 Results 
 
The screening was conducted in a 96-well plate format using a robotic 
system. Out of the 340 cell lines that were chosen originally for the 
experiment, 9 had low viability (<90%), and therefore cells were not used for 
the screening. The number of cells and the percentage of cell lines from 
different populations utilised in the experiments are shown in Table 4.6. 
 
Table 4.6: Screened cell lines after correction for cell viability and quality 
requirements 
Population Cell lines Percentage 
CEU 76 22.9 
YRI 81 23.3 
TSI 90 26.3 
GBR 91 27.5 
Total 331  
 
The remaining 331 cell lines were divided into random batches and screened 
against the 3 compounds. Each 96-well plate contained one cell line exposed 
to CBZ and its two metabolites, CBZE and 9-AC, together with the vehicle 
control DMSO and the positive control tetraoctylammonium bromide. 
 
4.3.1 Interindividual variability 
 
The cytotoxicity data from the ATP assay and the utilisation of strictly 
controlled conditions, allowed the investigation of variation in dose-response 
in 331 individuals of different ancestry [62]. The normalised data for each 
compound is shown in grey for each concentration and all individuals (Fig. 
4.1). The data for each individual were pooled and a logistic curve was fitted 
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(red-dashed curve). From separately performed logistic curve fits, an EC10 
was estimated for each individual cell line, shown as a histogram. In case of 
the EC10 dose not being within the concentration range, the EC10 was 
estimated at 251 µM to allow for inclusion of the data for further analysis. 
For a better comparison, the EC10s for the 3 compounds were plotted as 
box plots (see Fig. 4.5). The plots showed that the average EC10 for 9-AC 
was much lower than the EC10s for CBZ and CBZE, showing that 9-AC was 
toxic in the concentration range used in this experiment, while CBZ and 
CBZE were non-toxic. The box plots also showed that for all three 
compounds, there were individuals with higher susceptibility to the cytotoxic 
effect of each compound. 
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4.3.2 Robustness and reproducibility of qHTS data 
 
Each plate was prepared and measured in duplicate to increase the 
robustness of the data. For testing the reproducibility of the screening data, 
the two EC10 estimates from the duplicates were plotted against each other 
and pair-wise Pearson correlation among replicate plate pairs was performed 
(Fig. 4.6). For CBZ, the Pearson correlation coefficient ρ was 0.59. For 
CBZE, ρ was 0.60. This showed that there was no strong correlation 
between the EC10s of CBZ and CBZE. For 9-AC, ρ was 0.79 showing a 
much higher association between the EC10s of 9-AC. 
 
Figure 4.6: Intra-experimental reproducibility of EC10 
The EC10s from the two replicates of each experiment were plotted against each other and 
a pair-wise Pearson correlation was performed to assess the reproducibility of the outcome. 
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4.3.3 Differences between genders and populations 
 
The EC10s showed inter-individual variability. To investigate the nature of 
these differences further, the two genders as well as the four different 
populations were compared with each other. The EC10 were analysed using 
a Kruskal-Wallis ANOVA. No significant difference was observed for any of 
the three compounds (data for CBZ and CBZE not shown). Figure 4.7 shows 
the comparison of the EC10s from 9-AC for the different genders and figure 
4.8 shows the comparison of EC10s from 9-AC for the four populations. 
 
 
Figure 4.7: Comparison of EC10s from 9-AC for genders 
The EC10s of the two different genders were visualised in a box plot. A Kruskal-Wallis 
ANOVA was performed to find significant differences between the EC10s of the genders. 
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Figure 4.8: Comparison of EC10s from 9-AC for different populations 
The EC10s of the four populations were visualised in a box plot. A Kruskal-Wallis ANOVA 
was performed to investigate whether differences exist between the EC10s of the four 
populations. 
 
4.3.4 Evaluation between cytotoxicity and genotype 
 
The observation that EC10s vary by up to 2 magnitudes between individuals 
for all three compounds raised the following question: could genetic loci be 
identified that are associated with the higher susceptibility for toxicity caused 
by CBZ and its metabolites? Publicly available genotypes from the 1000 
Genomes project were used [32] and a MAGWAS was performed using the 
dose-response data as a phenotype. 
The MAGWAS revealed SNPs that were associated with the higher 
susceptibility to the cytotoxic effect caused by the compounds (see Tab. 4.7). 
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Table 4.7: Number of SNPs associated with susceptibility to  cytotoxic 
effect 
Compound 
SNPs with 
p-value 
below 1x10-4 
SNPs with 
p-value 
below 1x10-5 
SNPs with 
p-value 
below 1x10-6 
Minimum 
p-value 
CBZ 94 16 0 2.5x10-6 
CBZE 130 16 1 2.0x10-8 
9-AC 104 18 3 2.5x10-7 
For each compound MAGWAS revealed SNPs that were to varying significant degrees 
associated to the higher susceptibility of cell lines to the cytotoxic effect of compounds. 
 
For CBZ, the GWAS revealed SNP rs4772593 on chromosome 13 with the 
lowest p-value in association with susceptibility to cytotoxicity in cell lines 
(see Fig. 4.9 A). Two SNPs, rs56303447 on chromosome 5 and rs2927299 
on chromosome 16, had the lowest p-value, which indicates susceptibility to 
cytotoxicity of CBZE (see Fig. 4.10 A). Three SNPs revealed in the GWAS 
(see Fig. 4.11 A); SNP rs1624718 located on chromosome 16, rs7998181 
located on chromosome 13 and rs6984950 located on chromosome 8 were 
associated with susceptibility to 9-AC cytotoxicity. Several locus zooms were 
presented in this chapter, which were derived from Manhattan plot analysis. 
The left y-axes in the LocusZooms show the p-values for the negative 
logarithm of the p-value for each SNP (see Fig. 4.9 to 4.11). The x-axis 
shows the position of each SNP on the chromosomes as well as known 
genes in the vicinity. The right y-axis shows the recombination rate on the 
chromosome and the depicted region. The dots and their colour show the 
linkage disequilibrium of the SNP and other polymorphisms in the region of 
the chromosome. 
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Figure 4.9: Results of Genome-wide Association Study of toxicity-
genotype relationship for CBZ 
A: Manhattan plot from GWAS for the dose response data of CBZ. SNP with lowest p-value 
was located on chromosome 13 B: Locus zoom for the region of chromosome (chr) 13 
containing the most significant SNP, rs4772493. Left y-axis shows the p-value as the 
negative logarithm (-log10). Right y-axis shows the recombination rate of region 101 and 102 
Mb on the chromosome 13. X-axis shows the position of rs4772493. The dots and their 
colour show other polymorphisms in the region and their linkage disequilibrium to 
rs4772493. 
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Figure 4.10: Results of Genome-wide Association Study of toxicity-
genotype relationship for CBZE 
A: Manhattan plot from GWAS for the dose response data of CBZE. SNPs with lowest p-
value were located on chromosomes 5 and 16 B: Locus zoom for the region of chromosome 
(chr) 5 containing the most significant SNP, rs56303447, C: Locus zoom of region on 
chromosome 16 containing rs2927299. Left y-axis show p-values as the negative logarithm 
(-log10). Right y-axes show the recombination rate of regions on chromosomes. The x-axes 
show the position of SNP on chromosomes. The dots and their colour represent other 
polymorphisms in the region and their linkage disequilibrium to SNPs. 
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Figure 4.11: Results of Genome-wide Association Study of toxicity-
genotype relationship for 9-AC 
A: Manhattan plot from GWAS for the dose response data of CBZE. SNPs with lowest p-
value were located on chromosomes 8, 13 and 16 B: Locus zoom for the region of 
chromosome (chr) 16 containing rs1624718, C: Locus zoom of region on chromosome 13 
containing rs7998181. D: Locus zoom of region around rs6984950 on chromosome 8. Left 
y-axis show p-values as the negative logarithm (-log10). Right y-axes show the 
recombination rate of regions on chromosomes. The x-axes show the position of SNP on 
chromosomes. The dots and their colour represent other polymorphisms in the region and 
their linkage disequilibrium to SNPs. 
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Some SNPs were also found to have low p-values for the susceptibility to the 
cytotoxicity of all 3 compounds (see Tab. 4.8). 
 
Table 4.8: SNPs associated with susceptibility to cytotoxicity found for 
more than one compound 
SNP ID 
p-value for 
CBZ 
p-value for 
CBZE 
p-value for 
9-AC 
Function 
rs16939743 8.5x10-6 6.3x10-5 4.1x10-6 missense 
rs62048729 7.4x10-6 4.5x10-5 5.0x10-7 - 
SNP2-81896 9.8x10-5 9.3x10-6 - - 
rs73319053 5.0x10-5 4.6x10-5 - intronic 
rs7930391 3.0x10-5 2.1x10-5 - intronic 
rs4144233 6.5x10-6 - 7.1x10-5 intronic 
rs7080371 6.3x10-5 - 4.7x10-5 intronic 
rs56303447 - 2.2x10-8 3.5x10-5 5.9 kb 5’ of gene 
rs57831073 - 2.0x10-5 7.8x10-5 82 kb 5’ of gene 
 
The GWAS revealed 14 SNPs that were associated with the cytotoxic effects 
of the compounds; CBZ, CBZE, and 9-AC. 2 of these 14 SNPs were found to 
be associated with toxicity to all 3 compounds, 7 with 2 compounds, and 5 
with 1 compound. None had reached the predefined genome-wide significant 
cut off (1x10-8). SNPs located in biologically plausible genes were validated 
using samples from patients that had undergone CBZ treatment. 
 
4.3.5 SNP analysis 
The 14 SNPs, that were found genome-wide suggestive in the GWAS, were 
identified and analysed using HaploReg v2 online database (Tab. 4.9) [42]. 
From the 14 top hits found in the GWAS (see Tab 4.8), 5 were found to be in 
flanking regions of genes (rs56303447, rs57832073, rs4772493, rs6984950 
and rs7998181), 6 SNPs were in introns of genes (rs73319053, rs7930391, 
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rs4144233, rs7080371, rs2927299 and rs1624718) and one SNP was inside 
the coding region of a gene and functionally significant (rs16939743). 
It was shown that SNPs located in flanking regions of genes can have an 
influence on the transcriptional regulation [63-65]. For example, a SNP in the 
5’-flanking region of the cytochrome P450 CYP2E1 gene was reported to 
enhance its expression [66]. SNPs located in introns of genes can result in 
different splice variants of certain genes [67]. Further investigation of the 
genes located next to the SNP or intronic SNPs found in the GWAS were 
excluded for different reasons. 
In the variant of the DUOX1 gene, a thymine is exchanged with a cysteine. 
This exchange leads to the substitution of an isoleucine with a threonine in 
the DUOX1 (p.I962T) [68]. SNP rs16939743 has a minor allele frequency 
(MAF) below 1% in European populations. A MAF <1 is considered a 
mutation [69]. Because of low MAF, the GWAS chip used in the past did not 
include rs16939743 [70]. It was the only functional SNP revealed by the 
GWAS and also associated to a higher susceptibility to cytotoxicity for all 
three compounds. DUOX1 was shown to play a role in the activation of the 
immune system [71-73]. Unpublished data from lymphocyte toxicity assay 
conducted in our group suggested that during the exposure of peripheral 
blood mononuclear cells to CBZ, high levels of hydrogen peroxide might be 
generated in certain samples. This finding requires further investigation. 
DUOX1 could be responsible for these levels of hydrogen peroxide. 
Therefore it was decided to genotype the samples for their DUOX1 status. 
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4.3.6 SNP genotyping of DUOX1 
From the 109 samples that were used, the genotyping did not work in 2 
cases. 65 samples were from patients that had suffered ADRs during their 
CBZ treatment and 44 samples were from CBZ tolerant patients (Tab. 4.11). 
Only 3 patients were carriers of the rare variant of DUOX1. One was a CBZ 
tolerant patient. The other 2 were patients that had suffered from severe 
CBZ-induced hypersensitivity reactions. Interestingly enough, these two 
patients were not of European descent. One patient had Thai and English 
ancestry. The other patient had declared to be of European descent but 
principle component analysis, from previous genome-wide analysis, of the 
DNA clustered this sample with DNA samples of Indian ancestry. 
 
Table 4.11: Assessment of DUOX1 status in CBZ-treated patient samples 
from Liverpool cohort  
Clinical diagnosis Number of patients 
Number of carriers of the 
DUOX1 variant 
MPE 39 0 
DRESS 22 1 
SJS/TEN 5 1 
CBZ tolerant 44 1 
 
DRESS: Drug rash with eosinophilia and systemic symptoms, SJS: Steven Johnson 
Syndrome, TEN: toxic epidermal necrolysis, MPE: maculopapular exanthema 
 
From the 4 DNA samples of patients with non-European ancestry that 
suffered from CBZ-induced hypersensitivity reaction, 2 were carriers of the 
rs16939743 variant of DUOX1. 44 DNA samples from the ITCH study were 
genotyped to assess their DUOX1 status, including 23 samples from non-
white patients. All patients had suffered from severe hypersensitivity 
reactions while treated with CBZ. The PCR did not work for 2 of the samples.  
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The genotyping showed that 5 patients, who had previously suffered from 
CBZ-induced ADRs, were carriers of the variant of DUOX1. From these 5 
patients 4 were non-white. The other carrier of the DUOX1 variant was 
recruited in Brazil. 
Due to the diversity of populations from which the DNA samples for the 
genotyping derived, there were only a few samples in each group. No DNA 
samples from non-white, CBZ tolerant patients were available to compare 
the results of the hypersensitive patients. 
The overall outcome of the assessment of the genotyping of the DUOX1 
status in patient samples can be found in table 4.12. The full list of DNA 
samples showing genotype, phenotype and ethnicity can be found in the 
appendix (Tab. A4.1). 
 
Table 4.12: Overall outcome of genotyping of DUOX1 in patient samples  
Clinical 
diagnosis 
Number of 
patients 
Number of 
carriers of the 
DUOX1 variant 
Number of 
non-white 
samples 
Number of 
DUOX1 
variant in 
non-white 
MPE 39 0 0 0 
AGEP 1 0 0 0 
DRESS 43 3 14 3 
SJS/TEN 26 3 11 2 
CBZ tolerant 44 1 0 0 
 
DRESS: Drug rash with eosinophilia and systemic symptoms, SJS: Steven Johnson 
Syndrome, TEN: toxic epidermal necrolysis, MPE: maculopapular exanthema 
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Figure 4.12: Results of real-time PCR genotyping for DUOX1 
Scatter plot of fluorescence measured at the end of the real-time PCR for all 151 samples. 
Fluorescence was utilised to assess the genotype of SNP rs16939743 for each individual. 
 
 
4.3.7 Statistical analysis of DUOX1 genotyping 
The genotyping showed that overall 6.9% of the DRESS patients were 
carrying the rare variant of DUOX1. 11.5% of the SJS/TEN patients were 
carriers of the rare variant. The frequency for the combination of the severe, 
CBZ-induced hypersensitivity reactions (AGEP, DRESS and SJS/TEN) was 
8.6%. The Fisher’s exact test for the combined data of the genotyping 
delivered a p-value of 0.17 (one sided, 95% confidence interval: 0.46 – 190, 
see Tab. 4.13). 
For non-white patients, genotyping for DUOX1 showed that 20% of the 
patients that had suffered from severe CBZ-induced hypersensitivity 
reactions (AGEP, DRESS and SJS/TEN) were carriers of the rare variant. 
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Table 4.13: Comparison of clinical outcome against DUOX1 status  
 
Pathological phenotype 
Patient with 
severe DHRs 
Tolerant individual 
Genotyping 
Carrier of DUOX1 
variant 
6 1 
Non-carrier of 
DUOX1 variant 
64 43 
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4.4 Discussion 
 
Studying drug-induced hypersensitivity reactions in vitro is difficult as there 
are only a few animal models available. The incidence rate of 
hypersensitivity in patients is low, making the collection of samples difficult. 
Hypersensitivity reactions result from genetic variability in pathways not 
involved in the pharmacological characteristics of the drug [74]. Toxicological 
studies such as the prediction of toxicity based on the structure of the 
compound, qHTS for endpoint toxicity and in vivo animal testing are currently 
used during the development of a new drug [75, 76]. The increased number 
of black box warnings and an increase in drug withdrawal show that these 
current methods would need to be improved to predict the occurrence of 
adverse drug reactions in general and hypersensitivity reactions in particular 
[77, 78]. 
Utilizing GWASs for in vitro toxicity testing allows high-throughput risk 
assessment compared to the traditional low-throughput screening used in 
animal testing. The challenge for developing computational toxicity testing 
methods is to detect the varying susceptibility of different individuals. Lock 
and colleagues established such a new method using a population-based 
cell culture model [34]. The method was capable of finding inter-individual 
variation in toxicity and also associations between the toxicity and genetic 
differences. 
In the experiments conducted for the work of chapter 2, inter-individual 
variability in viability of PBMCs from CBZ-naïve healthy volunteers was 
observed. The hypothesis of the experiments conducted in this chapter was 
that this inter-individual variability is caused by genetic differences in the 
individuals. Additionally, it was assumed that these differences in the 
susceptibility to the toxic effect of the drug and its metabolites could play a 
vital role in the induction of hypersensitivity reactions. Therefore, the work in 
this chapter was performed to identify genetic association with the difference 
in viability and also to determine the role of these associations in 
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hypersensitive patients. The cytotoxicity caused by compounds and the 
resulting damage of cells could lead to the activation of naïve T cells through 
danger signals as described in the general introduction (see 1.5.4). 
In the study by Furst and Uetrecht, it has been shown that CBZ and CBZE 
show no toxic effect, while 9-AC has been reported to cause toxicity in vitro 
[79]. The comparison of the EC10 from 2 replicates of the same cell line 
showed better reproducibility for 9-AC than CBZ and CBZE. Nevertheless for 
all 3 compounds used, cell lines more susceptible to the cytotoxic effect were 
found for each compound. 
The comparison of the different groups in relation to gender or ethnicity did 
not reveal significant differences. This shows that the susceptibility to 
cytotoxicity of certain individuals is not gender or population specific. Rates 
for CBZ-induced hypersensitivity reactions are also the same in different 
populations and indeed different genders. 
The advantage of immortalised lymphoblast cell lines is their expression of 
metabolising enzymes. Their expression of genes encoding metabolic 
enzymes is not as high as in liver cells but lymphoblastoid cell lines still 
contain most phase I and II enzymes [80]. In comparison with primary cells, 
which may derive from the tissue of interest, the use of immortalised 
lymphoblast cell lines comes with certain limitations. These include the 
inability to detect organ specific adverse effects, the lack of other 
environmental factors such as diet or co-exposure of other drugs, and cell-
cell interactions including triggering of immune response. It was 
demonstrated however by Lock and colleagues that genotyping of 
lymphoblastoid cell lines in combination with qHTS strategies can predict the 
cytotoxicity of a compound in vitro and even accurately predict toxicity of 
toxins with similar cytotoxic mechanisms [34]. 
The GWAS revealed 14 SNPs with low p-values for higher susceptibility to 
the toxicity of the compounds. Some of these SNPs were found to be 
associated to a higher susceptibility to all 3 compounds used. None of the 
SNPs reached the predefined genome-wide significance level of p < 1x10-8. 
Nevertheless, SNPs were found that reached the pre-set genome-wide 
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suggestive level (p < 1x10-5). These SNPs therefore needed further 
investigation. The SNPs associated with a higher susceptibility to toxicity for 
more than one compound represent an interesting opportunity for further 
investigation. 
Although a large number of lymphoblastoid cell lines (N=331) were screened, 
none of the SNPs investigated reached the predefined cut-off for genome-
wide significance. A post hoc power analysis was performed using the 
G*Power software to estimate the power of the GWAS undertaken in this 
chapter [81]. The 331 samples gave an estimated power of 98% with 5x10-7 
α error probability (corrected for multiple comparisons of 1 015 304 SNPs 
using the Bonferroni approach [55]), and was able to detect a 25% difference 
in cell viability between the lowest and highest end of the spectrum, which 
presents a medium sized effect based on Cohen’s criteria (Fig. 4.13) [82]. 
Thus, our GWAS sample size of 331 was adequate to detect associations 
between SNPs and medium sized effects in viability. Considering that the 
variability in the cell viability might be a complex trait, it was estimated that 
approximately 1 818 cell lines would give a statistical power of 95% (5x10-7 α 
error) to detect an approximate 10% difference in cell viability. Therefore, 
more lymphoblastoid cell lines from the 1000 genomes project and other 
sources could be screened to find associations between genetic makers and 
small variance in viability. 
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Figure 4.13: Post hoc power analysis for achieved power of GWAS 
Power (1-β error probability; β error probability: not rejecting H0 when H0 is false) is shown 
as a function of the number of samples for small (f
2
 = 0.01 = 0.1
2
), medium (f
2
 = 0.06), and 
large (f
2
 = 0.16) effect size according to Cohen’s criteria [82]. The f statistic for MANOVA 
was chosen and the sum of the concentrations (8) and covariates (14) was used as groups 
in the power calculation to allow the power estimation for MANCOVA [83]. The α error 
probability (rejection of H0 when H0 is true) was adjusted for multiple comparisons of 
1 015 304 SNPs following the Bonferroni correction (5x10
-7
) [55]; (number of predictors: 14, 
response variables 7). 
 
Of the 14 SNPs found in the GWAS, rs16939743 the only functional SNP 
and also appeared plausible, therefore it was further investigated. The SNP 
was found to be associated with a higher rate of the cytotoxic effect of all 
three compounds. The MAF is reported by the 1000 Genome project to be 
8% worldwide, but varies greatly amongst different ethnicities (19% Africa, 
2% America, 14% Asia, and 1% Europe) [32]. It is located in the dual oxidase 
1 (DUOX1) gene [68, 84], located on the long arm of chromosome 15 
(15q15.3). The variant causes an amino acid exchange which leads to the 
missense mutation and gene product (p.I962T) [68]. DUOX1 is a member of 
the NADPH oxidase family [85]. It was shown that DUOX1 regulates the 
amount of reactive oxygen species in cells and thereby modulates cell 
signalling [86]. It can also generate hydrogen peroxide and by that plays a 
role in the activation of peroxidases involved in immune response [71, 72]. It 
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was shown that the redox signalling during the response of the innate 
immune system is DUOX1-mediated and that upon the detection of bacterial 
ligands such as lipopolysaccharides, stimulates the production of DUOX1. 
One study showed the involvement of DUOX1 in T cell signalling [73]. During 
the activation of T cell receptor (TCR), DUOX1 was found to mediate the 
signal. DUOX1 knockdown with small interfering RNA and small hairpin RNA 
led to the inhibition of TCR signalling and the production of cytokines. 
The SNP rs16939743 has variable MAF across populations and was 
included in the GWAS as the worldwide MAF is 8%. Due to the low MAF in 
European populations, the SNP has not been included into the list of 
interrogated genetic markers for different GWAS chips. Therefore it was 
decided to validate this SNP in the samples of patients with CBZ-
hypersensitivity from the Liverpool archive for several reasons: 
 The population of patients is of diverse ethnic background, including 
patients from populations with relative high MAF (African and Asian). 
 The SNP has potentially relevant functional significance, due to the 
role of DUOX1 in the immune response. 
 Unpublished data from our group showed that certain samples 
generated high levels of hydrogen peroxide during the exposure to 
CBZ. 
For validation of the finding from the GWAS, samples of CBZ treated patients 
were genotyped in order to assess their DUOX1 rs16939743 status. 
The variant of DUOX1 was only found in one CBZ tolerant patient with 
European ancestry. In non-white patients that had developed CBZ-induced 
hypersensitivity syndromes, a higher percentage of carriers of the DUOX1 
variant was found. 21.4% of the non-white patients that had suffered from 
DRESS and 18.2% of the patients that had suffered from SJS/TEN during 
their treatment with CBZ were carriers of the DUOX1 variant. Taken 
together, the frequency of DUOX1 in non-European with severe 
hypersensitivity is 20%, which is slightly higher than the MAF found in African 
populations (19%) [32]. The frequency for the combination of the severe, 
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CBZ-induced hypersensitivity reactions of all genotyped samples was 8.6% 
and the Fisher’s exact test delivered a p-value of 0.17. 
One of the limitations of the experiments conducted is that they lack the 
statistical power to detect the differences in SNP frequency among groups of 
patients of diverse ethnicity. For the different ethnicities the data had to be 
pooled as there were fewer samples included for each ethnicity. For further 
investigation, larger number of patients from non-European populations 
would be needed and ideally include CBZ-tolerant patients from the 
corresponding cohort. 
In conclusion, the role of individual susceptibility to the toxicity of CBZ and 
two of its metabolites in drug hypersensitive patients has been analysed. 
Genetic association with the susceptibility was assessed utilising a novel 
approach derived from computational toxicology. This new approach 
combined the dose-response data from in vitro cytotoxicity screening with the 
genotyping data from the lymphoblastoid cell lines in a GWAS. Following this 
approach, possible genetic markers were discovered. To analyse the role of 
inter-individual variability in the viability of cells after exposure to the 
compounds during CBZ-induced hypersensitivity reactions, the genetic 
markers were assessed for biological plausibility and the most promising 
candidate, rs16939743, was analysed by genotyping hypersensitive patients. 
This new approach represents a promising model for further investigations of 
genetic associations in hypersensitivity reaction. It was also found that the 
analysed SNP rs16939743 could play an important role in non-European 
hypersensitive patients. In European patients who had suffered from CBZ-
induced hypersensitivity, SNP rs16939743 was not detected. However, at 
this stage the role of the SNP in European patients cannot be excluded. 
Further investigations by genotyping more patients from various populations 
would need to be conducted. 
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5.1 Introduction 
 
Human leucocyte antigens (HLAs) play an important role in the predisposing 
to diseases caused by the immune system. For example certain drug-
induced hypersensitivity reactions are also associated with particular HLA 
alleles [1, 2]. 
As mentioned in the general introduction (see section 1.4), the MHC is 
located on chromosome 6, a highly polymorphic region of the human 
genome. Through efforts from various research groups, this part of the 
genome was amongst the first genomic regions to be fully sequenced. The 
MHC spans over 3.6 megabase pairs accommodating 224 gene loci. About 
60% of those are considered to be expressed and 40% are estimated to play 
a role in the immune system. A large number of HLA alleles have been 
characterised [3]. 
Initially, HLA typing was performed using serological typing [5]. Since then 
the typing methods have evolved dramatically. The first vast improvement 
was the application of PCR methods for typing. The development of next 
generation sequencing technologies was the second breakthrough, 
introducing the possibility of sequence-based HLA typing. Following these 
advances, the number of known HLA alleles has increased exponentially 
(see Fig. 5.1). 
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Figure 5.1: Known HLA alleles by year [6] 
 
The three most commonly used PCR-based HLA typing methods are: 
1. PCR utilising sequence base typing (SBT-PCR) 
2. PCR utilising sequence-specific oligonucleotides (SSO-PCR) 
3. PCR utilising sequence-specific primers (SSP-PCR) 
 
SBT-PCR for HLA typing gives the highest possible resolution compared to 
the other two methods, for which resolution is limited by the oligonucleotides 
or primers used. It also allows for the detection of undiscovered HLA alleles. 
PCR sequencing HLA typing methods have been described using a generic 
PCR amplification system [7-9]. Advances in next generation sequencing for 
DNA have made this method the current gold standard for HLA typing [10-
12]. This method is very labour and time intensive and requires special 
equipment, and specially trained personnel. Therefore such HLA typing is 
generally performed by specialised laboratories. 
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SSO-PCR HLA typing involves PCR to amplify the sequence from the HLA 
locus to be tested. This PCR product is then hybridised against a panel of 
oligonucleotide probes, which have complementary sequences of stretches 
containing known polymorphisms of the HLA alleles in question [13]. It is a 
good method for high-throughput HLA typing as many samples can be 
processed in parallel. SSO-PCR HLA typing is quite labour and time 
intensive. 
The most commonly used method in clinical immunology laboratories for 
HLA typing is the SSP-PCR approach. SSP-PCR HLA typing uses multiple 
PCR primer pairs that target only specific DNA sequences. This annealing 
therefore requires the presence of certain SNPs [14, 15]. This is achieved by 
designing the primers that are complementary to the sequence for the SNP 
at the 3’ end of the primer. The method is the fastest HLA typing method 
available with gel electrophoresis being the rate-limiting step. It utilises 
standard equipment found in a biological laboratories, such as thermal 
cyclers, gel electrophoresis facilities and ultraviolet (UV) transilluminator. The 
costs for the assay can be kept low with self-designed and optimised 
primers. The limitation of this SSP-PCR HLA typing is that the first PCR can 
only provide low- to medium-resolution results, depending on the number of 
different primers used. The second PCR can then achieve high-resolution to 
8 digits for some HLA alleles. 
The underlying molecular mechanism of HLA-associated hypersensitivity 
reactions are complex. The association of abacavir-induced hypersensitivity 
reactions and HLA-B*57:01 was first reported 2002 [1, 16] but the exact 
molecular mechanism was only discovered about a decade later [17-20]. 
Abacavir interacts with residues of amino acids within the binding groove of 
HLA-B*57:01 and thus changes the configuration of the grove, resulting in 
the presentation of altered self-peptides by HLA-B*57:01. This presentation 
of altered self-peptides leads to the activation of T cells (see general 
introduction 1.5.3). HLA screening before prescription of abacavir 
significantly reduces the incidence of hypersensitivity reactions [21, 22]. 
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For CBZ, recent studies have demonstrated an association between an 
increased risk of severe ADRs and HLA alleles [23, 24]. In Asian populations 
a strong association was found between HLA-B*15:02 and SJS/TEN [25-30]. 
In Caucasian and Japanese populations, a similar association between HLA-
A*31:01 and CBZ-induced hypersensitivity has been found [31, 32]. Other 
known associations of CBZ-induced hypersensitivity reactions and HLA 
alleles can be found in table 5.1. 
As most of these severe ADRs are otherwise unpredictable, the information 
about the HLA status is the only risk marker for patients treated with CBZ. 
The FDA and the UK regulatory agency recommend screening patients with 
Asian ancestry for HLA-B*15:02 statues before administering the CBZ [33, 
34], while the association with HLA-A*31:01 is provided for information in the 
label. 
It is therefore important to develop new reliable assays, which can be used in 
clinical practice before the start of CBZ treatment. Such assays need to 
improve the safety of the patient, be cost-effective and have a short 
turnaround time for the results. For the reduction of the time to result, assays 
which are easy to use and robust would be preferable as this allows testing 
in hospitals. 
The aim of this chapter was to validate two new SSP-PCR HLA typing 
methods. Both methods utilise one pair of specific primers to assess whether 
or not the individual is a carrier of the HLA-A*31:01 allele. 
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Table 5.1: Overview of HLA alleles found associated with CBZ-induced 
hypersensitivity reaction 
HLA allele Ethnicity Clinical manifestation Reference 
B*15:02 
Han Chinese SJS/TEN [26] 
Malaysian, Chinese SJS/TEN [30] 
Thai SJS/TEN [27] 
Diverse SJS/TEN [35] 
A*31:01 
European MPE, DRESS, SJS/TEN [31, 35] 
Han Chinese MPE [26] 
Japanese DRESS, SJS/TEN [36] 
Korean DRESS [29] 
Diverse MPE, DRESS [35] 
A*02:01 Han Chinese MPE [37] 
B*15:11 Korean SJS [29] 
B*58:01 Han Chinese MPE [37] 
DRB*03:01 Han Chinese MPE [37] 
DRB*14:05 Han Chinese MPE [37] 
 
DRESS: Drug rash with eosinophilia and systemic symptoms, SJS: Steven Johnson 
Syndrome, TEN: toxic epidermal necrolysis, MPE: maculopapular exanthema 
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5.2 Material and Methods 
 
5.2.1 Samples 
347 DNA samples from the DNA archive in Liverpool, obtained from patients 
that had received CBZ treatment were used in these experiments. The 
samples were obtained from 62 patients that had developed CBZ-induced 
hypersensitivity reactions and from 285 healthy volunteers. 
 
5.2.2 HLA typing 
For the validation of the two new methods, the HLA type of the samples used 
had to be determined by the currently most reliable methods. Therefore the 
current gold standard, high-resolution, SBT-PCR HLA typing as well as the 
proxy SNP typing were compared with the newly developed methods to be 
validated. 
 
5.2.2.1 HLA high-resolution genotyping 
The DNA of 280 patients was isolated from 10 ml venous blood using 
magnetic separation (Chemagen, Baesweiler, Germany). The DNA was 
genotyped using high-resolution, sequence based HLA-A typing performed in 
the Histogenetics laboratory (Histogenetics, New York, USA). The typing was 
performed using SBT-PCR. The sequencing primers were produced for 
locus- and group-specific amplification, especially for exon 2 and 3 of HLA-A 
[38]. 24 of these samples were from patients that had developed 
hypersensitivity reactions and 256 were from healthy volunteers [39]. 
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5.2.2.2 Proxy SNP HLA typing 
Genotyping for the rs1061235 SNP for 73 samples was performed by 
KBioscience. Complete linkage disequilibrium (r2=1) for this SNP and HLA-
A*31:01 allele had been shown previously in individuals with European 
ancestry [40]. The genotyping was performed by KBioscience utilising the 
SSP-PCR method. The primers used for the PCR are labelled with 
fluorescence resonant energy transfer (FRET) molecules, allowing the 
discrimination between two alleles in the same sample [41]. 44 of the 73 
DNA samples were obtained from patients that had suffered CBZ-induced 
hypersensitivity reactions and 29 derived from healthy volunteers. 
 
5.2.2.3 SSPGo HLA-A*31 Identification kit from Biofortuna 
The primers for the SSP-PCR were designed to align only at the specific 
sequence. It is based on the principle that only a complete match at the 3’ 
terminals leads to the amplification while the mismatch does not yield 
amplification products [42]. This approach is also referred to as Allele 
Specific Amplification as the reaction only occurs when the DNA material 
includes that particular SNP. 
The SSPGo HLA-A*31 Identification kit from Biofortuna was designed to 
assess the HLA-A*31:01 status in patients. The design of the primer was not 
revealed by the company. The kit comes in 96 well plates. Each well 
contains the dried mix of lyophilised primers, polymerase, dNTPs and buffer. 
Two sets of primers were included necessary for HLA typing as well as 
primers for an internal control gene. The internal control allows for detection 
of intrinsic problems with the DNA sample. 
The experiments were performed following the manufacturers protocol [43]. 
The SSP-PCR was performed in a thermal cycler (Veriti 96 Well Thermal 
Cycler, Applied Biosystems, Paisley, UK). 10 ng of sample DNA were added 
to each well containing the dried mix for the SSP-PCR. 
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The SSP-PCR was initiated at 94°C for 5 min. Following this, 10 cycles with 
the following parameters were performed: denaturing at 96°C for 15 s, 
annealing at 66°C for 50 s, and extending at 72°C for 30s. These 10 cycles 
were followed by 20 cycles with the setting: denaturing at 96°C for 15s, 
annealing at 64°C for 50 s, and extending at 72°C for 30 s. The samples 
were cooled to 15°C. 
The SSP-PCR product was loaded on 2% agarose (Sigma Aldrich Co, Poole, 
UK) gel containing 0.5 µg/ml ethidium bromide (Sigma Aldrich). The 
electrophoresis was done for 20 min at 10 V/cm (PowerPacTM Basic, Bio-Rad 
Laboratories Ltd., Hertfordshire, UK). Pictures of the gel were taken under 
UV light (GelVue, Syngene, Cambridge, UK) and interpreted. 
 
5.2.2.4 HLA-A*31:01 SSP genotyping 
An HLA typing method developed in the laboratory of Mary Carrington of the 
National Cancer Institute in Frederick (Maryland, USA) was also validated. 
This is a wet lab technique using side specific primers for the amplification of 
genomic DNA (SSP-PCR HLA typing method) [31].  
Primer design: 
Forward primer: gatagagcaggagaggcct 
Reverse primer: agcgcaggtcctcgttcaa 
The PCR was performed according to an optimised protocol. The difference 
between the original and the optimised protocol were: 4 µl of DNA were used 
instead of 2 µl, 0.5 µl instead of 0.2 µl of the dNTP mix and 0.5 µl instead of 
0.125 µl of polymerase were used for the master mix of each sample. 
Because of the resulting additional volume, the amount of DNase-free water 
added was reduced to 13.5 µl instead of 16.175µl. In addition the last set of 
cycles was increased from 4 cycles to 9 cycles. 
The SSP-PCR was performed in 96-well plate format. 
A PCR master mix for all samples was prepared (see Tab. 5.2). 
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Table 5.2: Master mix for HLA*A-31:01 SSP genotyping 
  per sample [µl]: 
GoTaq buffer 1x 2.5 
MgCl2 25 mM 1.5 
dNTPs 10 mM / dNTP 0.5 
Forward primer 20 µM 1.25 
Reverse primer 20 µM 1.25 
Polymerase 1 u 0.5 
DNase-free water add to 21 µl 13.5 
 
 
To 4µl of the DNA sample (20 ng/µl), master mix (21µl) was added, giving a 
reaction volume of 25 µl. The PCR was conducted in a thermal cycler (Veriti 
96 Well Thermal Cycler). 
The PCR was initiated at 95°C for 3 min. 5 cycles with the following 
parameters were performed: denaturing at 95°C for 15 s, annealing at 70°C 
for 15 s, and extending at 72°C for 30s. These 5 cycles were followed by 21 
cycles with the setting: denaturing at 95°C for 15s, annealing at 65°C for 15 
s, and extending at 72°C for 30 s. The last 9 cycles had the following 
settings: denaturing at 95°C for 15s, annealing at 55°C for 1 min, and 
extending at 72°C for 2 min. After the last cycles the samples were kept at 
72°C for 7 min before being cooled to 4°C. 
After the SSP-PCR, the product was loaded on 1.5% agarose gel containing 
0.5 µg/ml ethidium bromide. The electrophoresis was conducted at 120 V 
(PowerPacTM Basic). Pictures of the gel were taken under transilluminator 
(GelVue) and interpreted. 
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5.2.3 Statistical analysis 
HLA genotyping data from the different methods were compared using the 
Fisher’s exact test [44]. 
The positive predictive value was calculated with the following formula: 
Positive predictive value =  
∑ True positive
∑ Test outcome positive
 
 
The negative predictive value was calculated using following formula: 
Negative predictive value =  
∑ True negative
∑ Test outcome negative
  
 
The accuracy was determined according to the following formula: 
Accuracy =  
∑ True positive +  ∑ True negative
∑ Total population
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5.3 Results 
 
In these experiments the accuracy of different SSP-PCR methods was 
validated. To achieve this, DNA samples from 347 individuals, were used. 
Before the utilisation of the samples, the HLA-A*31:01 status had to be 
determined, using the current gold standard. 
High-resolution HLA typing by Histogenetics was performed for 280 
participants. Of those, 32 (11.4%) individuals were positive for the HLA-
A*31:01 allele. For one sample the HLA typing failed. The remaining 247 
(88.2%) samples were found to be negative for HLA-A*31:01. 
The proxy SNP genotyping by KBioscience was performed for 73 individuals. 
Out of these, 9 (12.3%) individuals were carriers of the HLA-A*31:01 allele 
while the remaining 64 (87.7%) were from individuals not carrying this allele. 
The HLA types for 6 samples had been determined by both methods. The 
results of these samples were compared to each other (see Tab. 5.3). The 
false negative result was from a patient with one parent of Thai origin who 
carried the HLA-A*11:33, one of the two HLA alleles with high similarity to 
A*31:01 (see Fig. 5.3). 
 
Table 5.3: Comparison of the high-resolution HLA typing against proxy 
SNP genotyping 
 
High-resolution HLA typing 
Carrier of HLA-
A*31:01 allele 
Non-carrier of HLA-
A*31:01 allele 
Proxy SNP 
genotyping 
Carrier of HLA-
A*31:01 allele 
3 1 
Non-carrier of HLA-
A*31:01 allele 
0 2 
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The HLA typing showed that in total out of the 347 genotyped individuals, 37 
(10.7%) were carriers of HLA*A-31:01 allele. 
 
5.3.1 Validation of SSPGo HLA-A*31 Identification kit 
For the validation of the SSP-PCR kit from Biofortuna 347 samples were 
utilised. Two plates were excluded because of the poor call rate; in one plate, 
94 (98%) and in the other 64 (67%) samples could not be genotyped 
because the intrinsic controls did not work. Because of the high failure rate, 
systematic issues were assumed to be the underlying reason. 
272 samples were included for further analysis. The internal control of the 
SSPGo HLA-A*31 identification kit from Biofortuna showed that the PCR had 
not worked for 35 (13.1%) samples. All 35 samples were from patients not 
carrying the HLA*A-31:01 allele. 
 
 
Figure 5.4: Outcome of SSPGo HLA-A*31 Identification kit from Biofortuna 
The picture shows an agarose gel under UV light after electrophoresis. The direction of the 
electrophoresis was from the top down. The sample A is from an individual carrying the 
HLA-A*31:01 allele. The PCR product shows two distinct bands. The upper one is the 
control band and the lower one shows the presence of the HLA-A*31:01 allele in the DNA 
sample. Sample B is from an individual negative for the HLA-A*31:01 allele. The sample 
shows only one distinct band, the control band. The PCR for sample C did not work. 
Therefore no bands are visible under the UV light. 
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To evaluate the reliability, the results obtained from the SSPGo HLA-A*31 
Identification kit were compared to the results from the high-resolution, 
sequence based HLA typing and HLA-A*31:01 proxy SNP genotyping. The 
35 samples, for which the SSP-PCR failed, were excluded from this analysis. 
For the 193 samples that were typed with the high-resolution, sequence 
based typing and included in the evaluation, the assay was in exact 
accordance with the current gold standard (see Tab. 5.4). The positive 
predictive value, the negative predictive value, and the accuracy of the kit 
from Biofortuna were found to be 100%. 
 
Table 5.4: Comparison of the high-resolution HLA typing against SSPGo 
HLA-A*31 Identification kit 
 
High-resolution HLA typing 
Carrier of HLA-
A*31:01 allele 
Non-carrier of 
HLA-A*31:01 allele 
Kit from 
Biofortuna 
Carrier of HLA-
A*31:01 allele 
31 0 
Non-carrier of 
HLA-A*31:01 allele 
0 162 
 
 
For the 44 samples typed with proxy SNP genotyping, the SSPGo kit 
produced two false negative results (see Tab. 5.5). The positive predictive 
value was 100% but the negative predictive value was 95%. 
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Table 5.5: Comparison of the results from proxy SNP genotyping against 
the SSPGo kit  
 
Proxy SNP genotyping 
Carrier of HLA-
A*31:01 allele 
Non-carrier of 
HLA-A*31:01 allele 
Kit from 
Biofortuna 
Carrier of HLA-
A*31:01 allele 
7 0 
Non-carrier of 
HLA-A*31:01 allele 
2 35 
 
5.3.2 Validation of HLA-A*31:01 SSP genotyping 
For the validation of the HLA-A*31:01 SSP genotyping following the Mary 
Carrington’s protocol, 77 samples were used. 3 were excluded as the data 
obtained for the samples were inconclusive. These samples showed a band 
for the HLA-A*31:01 allele in one experiment, but failed to replicate in a 
duplicate or vice versa. 
 
 
Figure 5.5: Outcome of HLA-A*31:01 SSP genotyping 
The picture shows an example of an agarose gel under UV light after electrophoresis. The 
direction of the electrophoresis was from top down. The sample A is from a patient not 
carrying the HLA-A*31:01 allele. No band can be visualised. Sample B is from a patient 
carrying the HLA-A*31:01 allele. The PCR product shows one distinct band for the HLA-
A*31:01 allele PCR product. 
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The results obtained from SSP-PCR HLA-A*31:01 typing were compared 
with the results from the high-resolution, sequence based HLA typing. 
For the 73 samples that were typed with the high-resolution, sequence based 
typing, 3 (4.1%) true positives and 60 (82.2%) true negatives were found by 
the SSP-PCR. The SSP-PCR also gave one (1.4%) false negative and 9 
(12.3%) false positive results (see Tab. 5.6). The positive predictive value 
was 25% and the negative predictive value was 98% for the HLA-A*31:01 
SSP genotyping. Therefore the accuracy of the SSP-PCR was 86.3%. 
 
Table 5.6: Comparison of the high-resolution HLA typing against SSP-PCR 
HLA-A typing after Mary Carrington 
 
High-resolution HLA typing 
Carrier of HLA-
A*31:01 allele 
Non-carrier of 
HLA-A*31:01 allele 
SSP-PCR 
after Mary 
Carrington 
Carrier of HLA-
A*31:01 allele 
3 9 
Non-carrier of 
HLA-A*31:01 allele 
1 60 
 
For the comparison of the SSP-PCR against the proxy SNP genotyping, 
there was only one sample available. This sample was found HLA-A*31:01 
positive from both SSP-PCR HLA typing and proxy SNP HLA typing. 
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5.4 Discussion 
 
An increasing number of studies show associations between HLA alleles and 
immune-mediated drug-induced hypersensitivity reactions [2, 16, 25, 45]. 
The most renowned example is the association of HLA-B*57:01 with 
hypersensitivity to abacavir, an antiretroviral drug used for the treatment of 
human immunodeficiency virus infection (HIV) [1, 22, 46]. It is recommended 
by FDA guidelines to test for HLA-B*57:01 before prescription. This proved to 
be cost-effective and reduced the incidence of abacavir-induced 
hypersensitivity [21, 47]. 
Information on the association between CBZ-induced hypersensitivity 
reactions and HLA-A*31:01 in Europeans [31] and Japanese [32] is included 
in the label of the drug. For the association between HLA-B*15:02 and CBZ-
induced hypersensitivity reactions in Asians [25, 26], the FDA and the UK 
regulatory agency recommend screening patients with Asian ancestry for 
their HLA-B*15:02 status before administering CBZ [33, 34]. 
HLA genes are the most polymorphic genes in the human genome. Different 
HLA types can share similarities and only differ in one SNP. For an exact 
assessment of the HLA type, high-resolution, sequence based HLA typing 
methods are required. These methods are expensive and require specialised 
laboratories with specially trained personnel. The methods are also time 
intensive. The time until the results are obtained and the treatment of a 
patient can be started can take up to several days. Therefore their utilisation 
in clinical practice is currently not feasible. In the attempt to tackle these 
issues, assays have been developed for the HLA-A*31:01 and HLA-B*15:02 
typing [48, 49]. These assays determine whether or not the patient is a 
carrier of the HLA risk allele. Therefore they utilise one set of primers in 
addition to a set of primers for a housekeeping gene. 
The SSPGo HLA-A*31 Identification kit from Biofortuna and the SSP-PCR 
protocol developed by the group of Mary Carrington follow similar 
approaches as described for B*15:02. These assays were validated to 
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assess their accuracy compared with the current gold standard and their 
practicality for clinical practice. 
The SSPGo HLA-A*31 Identification kit from Biofortuna showed results that 
were as reliable as the current gold standard. It even distinguished between 
HLA-A*31:01 and the two very similar alleles, HLA-A*02:32 and HLA-
A*11:33. This distinction can currently be only achieved using high-resolution 
sequence based HLA typing. 
The SSPGo HLA-A*31 Identification kit produced two false negatives when 
compared with the proxy SNP genotyping. Proxy SNP genotyping is not 
100% accurate, although this SNP has been reported to be in complete 
linkage disequilibrium with HLA-A*31:01 in Europeans [40]. One of the “false 
negatives” found in the comparison between SSPGo HLA-A*31 and the 
proxy SNP genotyping has been actually incorrectly assigned A*31:01 
genotype by the proxy SNP genotyping compared to the HLA high-resolution 
genotyping (see Tab 5.3). The sample was from a patient with one parent of 
Thai origin. The second sample with discordant results is of white ethnicity 
and should undergo genotyping using the HLA high-resolution sequence 
based typing to ascertain the HLA type. 
Using the Biofortuna kit was user friendly and fast, but two 96 well plates had 
to be excluded as the PCR for the housekeeping gene failed in a large 
percentage of samples (98% and 67%). The only two samples that worked 
on the plate with 98% failure rate were from one carrier of HLA-A*31:01 
genotyped in a duplicate. Such a high error rate could have been caused by 
the way in which the experiment was conducted (human error) or a result of 
some problems with the equipment, such as the UV light in the 
transilluminator or the sensitivity of the camera. In addition to the high error 
rate, there were also some issues with the positive control of the 
housekeeping gene. The PCR assay from Biofortuna did not work for 35 
(13.1%) samples. All of these samples were from patients not carrying the 
HLA-A*31:01 allele. This taken together with the previous observations 
would suggest that the primers for the control gene are not as robust as the 
SSP-PCR primer. This would need to be further investigated. 
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The validation of the SSP-PCR protocol developed by Carrington’s group 
was less accurate (positive predictive value: 25%, and negative predictive 
value: 98.4%) in comparison to the gold standard or the kit from Biofortuna. 
Another disadvantage of the method is that it does not contain a pair of 
primers for a housekeeping gene. Therefore it was not possible to determine 
whether or not the PCR worked. Further optimisation should include the use 
of an appropriate pair of primers for a housekeeping gene. 
Overall, the validation of the two newly developed methods for HLA-A*31:01 
typing found that the SSP-PCR approach presents a cheaper possibility for 
assessing the HLA type of a patient before the start of treatment. Even 
though both methods tested in this chapter would need further optimisation, 
the validation showed promising results for potential clinical application. One 
of the methods was even as accurate as the gold standard, HLA high-
resolution genotyping. However, the reliability would need to be improved. 
The methods were also more user-friendly compared to current typing 
methods, reducing the turnover time significantly and thus allow prompt 
results. The case of abacavir, demonstrates that assessing the HLA-B*57:02 
statues of a patient before drug treatment can improve the safety of patients 
[1]. The first successful method to assess a patients HLA type before the 
start of treatment was a SSP-PCR, which proved accurate, fast and reliable 
[50]. Further successful attempts to improve the turnover time included 
allele-specific PCR, real-time PCR, and flow cytometric detection using 
fluorescence coupled antibodies [51-53]. Similar approaches could be 
followed to further reduce the turnover time in assessing the HLA-A*31:01 
status of Caucasian patients before the start of CBZ therapy. The clinical use 
of HLA typing before the treatment of CBZ would vastly improve the patient’s 
safety and allow clinicians to treat their patients based on their genotype in a 
more personalised approach. 
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Chapter 6 
Final Discussion 
 
Drug-induced hypersensitivity reactions (DHRs) or Type B adverse drug 
reactions (ADRs) are not related to the known pharmacological 
characteristics of the drug. They are rare, but cause approximately 20% of all 
hospital admissions related to ADRs [1]. Although only a minority of patients 
treated with the drug suffer from DHRs, they are a major clinical issue due to 
the often high severity and mortality [2]. 
Carbamazepine (CBZ) is one of the most commonly prescribed 
anticonvulsants used to treat patients with partial seizures, trigeminal 
neuralgia and bipolar disorder. Although only a small number of patients 
treated with CBZ develop severe ADRs, skin rashes are fairly common 
affecting up to 10% of patients [3]. This requires discontinuation of therapy to 
prevent more severe DHRs. The most severe types of CBZ-induced 
hypersensitivity reactions are Steven Johnson syndrome (SJS), toxic 
epidermal necrolysis (TEN) and drug reactions with eosinophilia and 
systemic symptoms (DRESS). These reactions are not limited to the skin; 
they lead to organ dysfunction, for example in the liver. Patients suffering 
from these severe reactions are sometimes treated in intensive care units. 
The mortality rate is approximately 10% for SJS and DRESS, and 30% for 
TEN [4].  
Despite intensive research in this field, the underlying pathophysiological 
mechanisms of DHRs still remain mostly unknown. Immunogenetic T cell-
mediated mechanisms have been postulated for hypersensitivity reactions to 
several aromatic antiepileptic drugs. It has been possible to isolate drug-
specific T cells from the blood and other tissues of patients with CBZ and 
lamotrigine-induced hypersensitivity reactions [5-9]. T cell phenotypes and 
effector functions have been studied and characterised, but molecular 
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mechanisms of T cell activation in DHRs is still poorly understood. It has 
been demonstrated in in vitro studies that CBZ metabolism is not necessary 
for the activation of T cells [10]. The lack of T cell activation by dendritic cells 
presenting CBZ-modified peptides suggests non-covalent protein binding of 
stable metabolites of CBZ [10, 11]. In a study by Furst and colleagues it was 
shown that a toxic metabolite binds in a non-covalent way to peptides in vitro 
[12]. They reported that 9-acridinecarboxaldehyde (9-AC) binds to 
nucleophiles but that adduct formation was reversible under physiological 
pH. They were able to show that the adduct becomes irreversible in the 
presence of a mild reducing agent. They therefore hypothesised that the 
reversible binding of 9-AC to protein occurs via a Schiff base which is then 
reduced to the stable adduct. 
To follow on from these findings, in chapter 3, protein binding of CBZ, CBZE, 
and 9-AC was assessed, utilising mass-spectrometric methods to determine 
the binding site of the compounds. In these experiments, covalent protein 
binding was only shown for CBZE with glutathione S-transferase π (GSTPi) 
and human serum albumin (HSA). With GSTPi, CBZE was found to bind to 
the cysteine at position 47 while in HSA, CBZE was found to bind to the 
histidine at position 146 and the histidine at position 338. This represents a 
novel finding as only the binding of CBZE in GSTPi has previously been 
reported in the literature [13]. Surprisingly, the binding was found on different 
amino acids. It would be expected that the binding affinity would be to the 
same amino acids. Different positions within each protein structure as well as 
neighbouring amino acids could lead to the differences in preference. 
For 9-AC no covalent binding was observed with protein, which confirms the 
previous study by Furst and colleagues [12]. A similar approach as in the 
study, using reducing agent to transform the Schiff base into a stable 
product, was attempted for HSA but did not yield any measurable amount of 
adduct. A higher dose of reducing agent could overcome the problem and 
should be further investigated. The mass spectrometric analysis revealed 
nonspecific binding to the N-terminus of the protein backbone, which had not 
been reported previously (see Fig. A3.1 in appendix). This could indirectly 
show that a non-covalent adduct was present in the full length protein. 
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Further experiments are necessary to assess the protein binding capability of 
9-AC. 
It has been shown previously that the formation of haptens is not required to 
trigger T cell activation in CBZ-induced hypersensitivity reactions [10, 11, 
14]. A better approach for the assessment of protein binding during the 
induction of CBZ-induced ADRs could include the use of protein fragments 
mounted on HLA and thus determine the capability of CBZ or its metabolites 
to interact with proteins. 
An increasing number of studies have demonstrated a strong link between 
several drug-induced hypersensitivity reactions and specific HLA alleles [15-
17]. These findings provided a new insight into the mechanism of DHRs and 
for the first time allowed the prediction of individual patient’s risk for 
developing DHRs. The best known examples include the association 
between abacavir-induced hypersensitivity reactions and HLA-B*57:01 in all 
ethnicities [18] and CBZ-induced SJS and HLA-B*15:02 in Asian populations 
[19]. 
In Caucasians with CBZ-induced hypersensitivity reactions, two independent 
genome-wide association studies (GWAS) showed an association with HLA-
A*31:01 [20]. Unlike HLA-B15:02, HLA-A*31:01 has been associated with 
multiple phenotypes in several ethnicities. These two alleles can be used to 
predict the increased risk for developing severe hypersensitivity reactions 
[20-24]. Given the strong evidence, the FDA and UK regulatory agency 
recommend genotyping for HLA-B*15:02 before the start of CBZ treatment 
[25, 26]. 
DNA sequencing is the most reliable method for high resolution HLA typing. 
This technique is labour and time intensive and requires specialised facilities 
with trained personnel. To overcome this, several existing methods have 
been optimised to achieve rapid and simple HLA typing that can be utilised in 
general clinical laboratories [27, 28]. Biofortuna [29], a small biotechnology 
company, as well as the Carrington group [20] developed new methods for 
clinical HLA typing based on SSP-PCR. For the validation of these methods, 
clinical samples were HLA typed and the results compared to the gold 
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standard, sequence based typing. For HLA-A*31:01 carriers the Biofortuna 
kit proved to be as reliable as the current gold standard. However, a very 
high proportion of DNA samples from patients that were not carrying the 
HLA-A*31:01 allele failed to amplify. This observation may represent a 
chance finding because HLA-A*31:01 is a rare allele and only 32 out of the 
347 patients carried that allele. However, if there is such a high failure rate, 
one has to question the reliability of the method. 
The SSP-PCR HLA typing from Carrington’s group was less accurate. The 
lack of primers for a housekeeping gene made it hard to distinguish between 
samples for which the PCR did not work and samples of patients not carrying 
the HLA-A*31:01 allele. The method would therefore benefit from further 
optimisation before it can be considered for clinical use. 
Although there is strong evidence for an association between the HLA-
A*31:01 allele and CBZ-induced hypersensitivity reactions in Europeans, the 
pathogenesis is poorly understood and other genetic and non-genetic factors 
might also play a role. For example in Asians, it has been found that the 
interaction of CBZ with HLA-B*15:02 results in the stimulation of a subset of 
T cells (CD8+) [11, 19, 20]. A similar investigation of the interaction of CBZ 
with HLA-A*31:01 failed to show such stimulation [30]. It is possible that for 
Europeans at least, several rare not yet discovered genetic variants may be 
involved in CBZ-induced hypersensitivity reactions. 
CBZ is extensively metabolised in vivo. Over 30 metabolites of CBZ have 
been discovered (for more details, see metabolism of CBZ in general 
introduction 1.7.1) [31-34]. It is unknown whether the parent drug or one of 
its metabolites causes CBZ-induced adverse reactions. Therefore, the 
metabolism of CBZ could play an important role in the onset of DHRs. Phase 
I metabolism takes place mainly in the liver. Highly unstable metabolites, 
such as the hypothesised CBZ arene oxide, would react with proteins in 
close vicinity within the liver but may not be detectable outside the liver [35]. 
This would explain hypersensitivity reactions involving the liver but would not 
explain other reactions such as the cutaneous ADRs. 
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Leukocytes in particular monocytes and neutrophils, possess strong 
oxidizing properties because they contain myeloperoxidase. 
Myeloperoxidase together with hydrogen peroxide and chloride is able to 
form hypochlorous acid [36]. It was shown that drugs, such as dapson, 
sulfamethoxazole and phenytoin, can be oxidised to reactive intermediates 
[37-39]. Furst and Uetrecht found that similar metabolism for CBZ could take 
place in human blood [40]. In their in vitro studies they observed a ring 
contraction of CBZ. Although several intermediates were not detected, it was 
shown that myeloperoxidase was the metabolising enzyme. This study also 
showed that the same metabolism can occur in neutrophils but to a lesser 
extent (500-fold less) than with myeloperoxidase. Such metabolism could 
explain the occurrence of hypersensitivity reactions outside of the liver as 
reactive species were found to be bound covalently to blood cells. The cell 
damage caused by the metabolites could result in the release of danger 
signals that lead to the activation of the immune system as described in the 
danger hypothesis for T cell activation (see general introduction 1.5.4) [41]. 
In computational toxicology, a new concept for determining individual 
susceptibility to toxicity has been developed by linking toxic phenotypes to 
genetics [42]. The methodology is sensitive enough for the detection of inter-
individual variability. This new concept was utilized in chapter 4 and is a 
novel approach to detect biomarkers for risk assessment of CBZ treatment in 
patients. 
As a preliminary step towards the new approach, a T lymphoblastoid cell line 
(CCRF-CEM) and peripheral blood mononuclear cells (PBMC) from healthy 
volunteers were exposed to CBZ and its toxic metabolite 9-AC in vitro. Four 
different assays; cell viability, mitochondrial membrane permeabilisation, 
phosphatidylserine exposure and membrane integrity, and caspase 
activation assay were used to assess the cell death pathways. 
Typical characteristics of apoptosis are activation of caspases, the 
mitochondrial membrane permeabilisation and exposure of 
phosphatidylserine on the cell surface [43]. These pathological 
characteristics can be observed during other processes in the cell, including 
217 
 
other modes of cell death but also in situations that do not lead to the death 
of the cell [44-46]. Because of these findings, it is necessary to observe cell 
death with a minimum of two different assays [47, 48]. Four assays were 
used in the experiments to find the best working and feasible method for 
quantitative high-throughput screening (qHTS). For the CCRF-CEM cells all 
assays worked well and they showed that the cells exposed to 9-AC died via 
an apoptotic pathway. As expected, CBZ showed no toxic effect in the range 
of concentrations used for the experiments. Experiments using primary cells 
(PBMCs) were more difficult to perform and problems with flow cytometry, 
namely indistinct populations of living and dead cells, were encountered. 
However, similar to the results observed in T lymphoblastoid cells, the 
assays showed that the PBMCs also die via an apoptotic pathway when 
exposed to 9-AC. No toxicity of the parent drug was observed. 
In chapter 2, the inter-individual variability to cytotoxicity caused by CBZ and 
9-AC was assessed. Since the data obtained from the double staining were 
inconclusive, only the three assays measuring the viability, mitochondrial 
depolarisation, and activation of caspase, were used for the preliminary 
screening of inter-individual variability in response to CBZ and its metabolites 
in PBMCs from 20 CBZ-naïve healthy volunteers. The PMBCs showed 
variation in response to the cytotoxic effect of 9-AC. The observation of inter-
individual viability presented an interesting finding for further investigation by 
quantitative high-throughput screening (qHTS). 
It has been shown that lymphocytes from CBZ hypersensitive patients are 
more sensitive to the cytotoxicity of CBZ metabolite using a lymphocyte 
toxicity assay that included a metabolising system [49, 50]. This has led to 
the hypothesis that hypersensitivity reactions are the result of an imbalance 
between the generation and detoxification of reactive metabolites [50]. In 
order to understand the inter-individual variability in patient responses to 
drugs and prove the hypothesis, polymorphisms in various genes including 
drug metabolising enzymes, drug transporters and receptors, have been 
analysed [51-53]. These studies were unable to find associations between 
hypersensitivity reactions and an imbalance in the metabolism. 
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The findings for the flow cytometric assays of chapter 2 showed that cells of 
a single cell type would be preferable compared to a mixture of cells, 
especially with the assays relying on flow cytometry. This approach was not 
chosen for this work as cell-cell interactions, possibly occurring in the human 
blood, would be missed and therefore not fully represent the situation found 
in patients. 
As the incidence rate of CBZ-induced hypersensitivity reactions is low and 
therefore the patient samples are rare, the qHTS was conducted in 
immortalised lymphoblastoid cell lines. These cells were generated as part of 
the 1000 genome project to allow scientists to conduct experiments with a 
defined genetic diversity. It has been shown previously that lymphoblastoid 
cell lines express enzymes responsible for drug metabolism [54]. In their 
study, Siest and colleagues measured the expression of 16 drug 
metabolising enzymes as well as 13 known transcription factors in PBMCs of 
20 healthy volunteers. The drug metabolising enzymes included a variety of 
cytochrome P450s as well as GSTs. The highest expression of cytochrome 
P450s was found in T cells but was still considerably lower compared to liver 
tissue (20 to 2000 times). GST was also found to be expressed in the 
PBMCs. GST is responsible for the conjugation of reactive species during 
metabolism and leads to the renal clearance of the conjugate, which offers 
protection against toxic metabolites. This study showed that PBMCs can be 
used as a model system to study inter-individual differences in metabolism. 
In toxicology, new in vitro based assays have been tested for classifying the 
cytotoxic profile of chemicals. The current backlog of toxicity testing for 
chemicals is of great concern for regulatory committees worldwide. 
Traditional animal testing is time consuming and costly, as it requires a large 
number of laboratory animals. In addition, animal models are lacking 
interindividual variability due to their inbred nature. Recently, a program was 
formed by several governmental agencies in the United States to assess the 
implementation of qHTS using in vitro toxicity assays in the field of 
computational toxicology [55, 56]. These qHTS combined with the recent 
advances in genome sequencing, allow the consideration of interindividual 
biological variability in human health hazard. Genetic variability may have a 
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role in individual susceptibility to ADRs after exposure to toxins or drugs [57]. 
The availability of well-defined genetically diverse renewable sources of 
human cells, derived from the International HapMap and 1000 Genomes 
project allows in vitro screening on a population scale [58, 59]. 
In chapter 4, immortalised lymphoblastoid cell lines were exposed to CBZ, its 
main metabolite CBZE and one toxic metabolite 9-AC. The overall dose-
response to CBZ and CBZE demonstrated that there was no cytotoxic effect 
for the two compounds. The concentration range included the clinically 
relevant concentrations. More interesting, the individual dose-response 
revealed variability and several cell lines showed more pronounced cytotoxic 
effects from these compounds then the majority of cells. The overall dose-
response data for 9-AC showed that this metabolite is cytotoxic to all cell 
lines that were exposed to it. Some individuals were more susceptible to the 
cytotoxic effect than others. Due to the plating of cells and compounds being 
undertaken using robotics, the experimental error was minimised and 
therefore, even small differences in viability could be detected and included 
in the analysis. The screening of cell viability has been successfully used in 
the past for the prediction of cytotoxicity for known toxins and had shown 
promising results for the association of cytotoxic genotypes with observed 
phenotypes [42]. 
Following these findings, a GWAS was performed to reveal genetic variants 
that might be associated with the higher susceptibility to toxic effects. This 
GWAS revealed 14 biologically plausible SNPs with low p-values, however 
none of the SNPs reached genome-wide significance (1x10-8). Therefore 
further validation was necessary. The experiments were conducted in cell 
lines derived from CBZ-naïve individuals. To optimise the outcome, cells 
could be primed before the start of the assay. Primed T cells have a lower 
activation threshold in comparison with naïve T cells. This can be achieved 
by culturing T cells in the presence of antigen-presenting cells and 
repeatedly stimulating them with the drug of interest [60, 61]. A series of 
experiments from our department using flucloxacillin and sulfamethoxazole, 
have demonstrated that primed cells could have similar outcomes as cells 
from drug-induced hypersensitive patients [62, 63]. Furthermore, PBMCs 
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from CBZ-naïve carriers of HLA-B*15:02 were stimulated using the priming 
method and exhibited similar response to CBZ as T cells from patients that 
had suffered from CBZ-induced hypersensitivity [64]. Including primed and 
non-primed T lymphoblastoid cell lines for qHTS might allow the exploration 
of underlying changes in the cell during hypersensitivity reaction. Another 
possibility could be the inclusion of metabolising systems in the screening as 
described for the lymphocyte toxicity assay by Spielberg and colleagues [65]. 
This assay has been successfully used in the past and it was found that cells 
derived from hypersensitive patients showed higher susceptibility to toxic 
effects of the generated metabolites than the tolerant controls [49, 50]. 
The SNPs from the GWAS conducted for this work were characterised and it 
was found that only one SNP (rs16939743) in the DUOX1 gene was 
functionally relevant. This SNP was found at p-values 8.5x10-6 for CBZ, 
6.3x10-5 for CBZE, and 4.1x10-6 for 9-AC, which suggests that carriers may 
be at higher risk to develop CBZ-induced hypersensitivity reactions than non-
carriers. The SNP is a missense variation within DUOX1. DUOX1 plays a 
role in both innate and adaptive immune responses. 
Samples from CBZ-tolerant as well as from CBZ-hypersensitive patients 
were used to validate this finding and were genotyped to determine their 
DUOX1 status. The genotyping suggests that the rare minor allele variant of 
DUOX1 does not play an important role in the initiation of CBZ-induced 
hypersensitivity reactions in Europeans. Because of the low minor allele 
frequency (MAF) in Europeans (below 1%), the statistical power of the 
genotyping in patients was not sufficient to detect the difference. The variant 
of DUOX1 was only found in individuals of non-European ancestry. The 
frequency of the minor DUOX1 allele in CBZ hypersensitive patients 
detected through the genotyping conducted in the experiments of this thesis 
was similar to the highest MAF reported in 1000 Genomes project, which 
was found in populations of African ancestry. 
Because severe CBZ-induced hypersensitivity reactions are so rare even 
after two decades of recruiting patients, the number of samples from 
Caucasians in the DNA archive of the University of Liverpool was limited. 
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Furthermore, the patient cohort was heterogeneous comprising samples 
from many different ethnicities as well as different clinical phenotypes. To 
validate the effect of rare DUOX1 variants in non-Europeans, populations 
from homogeneous ethnic background would need to be genotyped together 
with ethnicity matched treated controls. 
In addition to the SNP in DUOX1 found by the GWAS conducted for this 
work, several other SNPs in close proximity of genes or in introns of several 
genes were found at increased frequency. It has been shown that SNPs in 
such locations can have an effect on gene expression or gene variant 
splicing [66, 67]. This requires further investigation. 
Following the experiments in chapter 4, another analysis of the data will be 
conducted in the future using a different software [68]. In this analysis the 
concentration of CBZ and its metabolites, at which a 10% decrease in 
viability was observed, will be utilised to determine whether there is a 
correlation with higher cytotoxicity during exposure to compounds, compared 
to the dose-response data used in the described analysis (chapter 4). This 
10% difference in viability was shown to be sufficient as the starting point of 
cytotoxicity [42]. The results of both analyses will be compared for 
verification of results from the first analysis. The cell material, which was 
collected during the experiments, will be used in future proteomic 
experiments to assess differences in protein abundance before and after the 
exposure of the compounds and to validate previous findings. 
The bridging of cytotoxic effects in vitro to the onset of CBZ-induced 
hypersensitivity reactions through danger signals leading to an immune 
response in vivo remains to be established. In the novel approach, which 
applied computational toxicology to personalised pharmacology, a possible 
new genetic marker for predicting risk for ADRs was found. This marker was 
investigated in a retrospective cohort of CBZ hypersensitive patients and 
tolerant controls. However, the majority of experiments in this thesis were 
conducted using cells from CBZ-naïve volunteers. The best approach would 
be to collect samples from patients before they receive CBZ treatment and 
store them. In case patients developed hypersensitivity reactions on 
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exposure to CBZ, new samples can be collected and compared with the pre-
treatment one. This approach however, would not be feasible because of the 
cost, logistics, ethical, and societal difficulties with sample and information 
storage. Therefore, alternative strategies should be explored. One of them 
would be to prime cells from CBZ-naïve volunteers [64]. Following this 
approach cells could be tested before and after priming, allowing the 
detection of changes in RNA expression and dose-response changes due to 
the priming. 
The cell work in this thesis was conducted in PBMCs or lymphoblastoid cell 
lines. Although they offer certain advantages including the expression of drug 
metabolising enzymes and easy withdrawal from individuals with minimally 
invasive procedures, there are also disadvantages such as the cells lacking 
organ specific properties. To overcome this absence and better understand 
the mechanisms occurring during drug-induced hypersensitivity reactions, 
samples from different tissues or model systems affected during 
hypersensitivity including the skin and liver, could be used in further 
investigations. Due to the ethical and practical issues in tissue sampling from 
healthy volunteers, model systems or engineered tissue should be used to 
produce such tissue [69]. Model systems allow further investigations as the 
example of the rat model of nevarapine-caused skin rash demonstrated [70]. 
Through this animal model researchers were able to show that 
nevirapine-induced skin rashes were immune mediated and that T cells 
played an important role [71]. It was also possible to show that a sub-set of T 
cells is sensitised and through their transfer into unexposed animals, the 
susceptibility for reactions increased. 
Further work could also include investigation of the role of danger signals 
derived from simultaneous viral infections such as reactivation of herpes 
virus (HHV) infection during the occurrence of DRESS [72, 73]. The role of 
HHV reactivation in the development of DRESS is well recognised [74, 75]. 
HHV-6 reactivation has been proposed by a Japanese consensus group for 
the diagnosis of DRESS [76]. Viral reactivation by a limited number of drugs 
has been detected in DRESS, but how these drugs induce HHV reactivation 
is not yet understood. It is still uncertain whether virus infection triggers 
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DRESS or DRESS triggers the virus reactivation [72, 75]. Findings 
supporting both hypotheses have been made [72, 77]. Further investigations 
would need to clarify the underlying mechanism and thus the role in 
hypersensitivity reactions. 
Environmental factors may also play an important role in hypersensitivity 
reactions, but these however, have not been investigated in this thesis. 
Increased knowledge of metagenomics of the human gut showed that 
different diets influence the microbiota composition [78-81]. Nermes and 
colleagues investigated the interaction of bacteria (Lactobacillus rhamnosus 
GG) with gut microbiota and the influence on humoral immunity in infants 
with atopic dermatitis for period of three months [82]. The immunoglobulin 
(Ig)-secreting cells were measured as well as the proportion of memory B 
cells in blood. In their study they were able to show that the proportion of 
memory B cells increased significantly while the number of Ig-secreting cells 
decreased. They concluded that the gut barrier function might be enhanced 
through certain probiotics, which supports the development of immune 
response and thus provides control for further infections. Further 
investigation in hypersensitivity could therefore include information on gut 
microbiome in patients and thus add some information about their lifestyle. 
Novel high-throughput technologies have made it possible to simultaneously 
examine millions of genes, transcripts, proteins, metabolites and 
microbiomes in an unbiased approach. This approach may hold a key to 
understand the mechanisms of hypersensitivity and to identify clinically 
useful prediction biomarkers [83-89]. Already, these methods, which require 
interdisciplinary collaboration, have improved the insight and understanding 
of human disease and therefore, they could also be applied for studying 
CBZ-induced hypersensitivity reactions [90]. Through these high-throughput 
technologies, vast amounts of complex and multifarious data, ranging from 
molecular to clinical, can be generated and system biology methods could be 
applied for the analysis. Several systems have been developed to overcome 
the problems of data integration [91-93]. These systems improve the analysis 
of data but there is no single standard. In a global open source partnership 
community, tranSMART was developed to establish the use of similar 
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standards for big data processing and integration [94]. The approach chosen 
by transSMART is based on the sharing of data on a cloud platform and 
allows the use of informatics-based translation of science into clinics, big 
data resource, newest and best suited analytic tools as well as experts 
opinions from all over the world. 
In conclusion, inter-individual variability in the cytotoxic response to CBZ and 
its metabolites was detected in vitro in primary cells and lymphoblastoid cell 
lines from CBZ-naïve, healthy volunteers. There is a large variability in 
susceptibility to cell death with the doses at which cytotoxicity can be 
observed varying up to 100 fold for CBZ and its two metabolites investigated 
in this work. The GWAS revealed genetic polymorphisms, which could be 
associated with the observed variability. The frequency of the candidate SNP 
in DUOX1 was not increased in European patients suffering from CBZ-
induced hypersensitivity reactions, but a higher frequency of this SNP could 
not be excluded for non-European patients. New conjugates for CBZE and 
HSA and evidence for non-covalent conjugation of 9-AC and HSA were 
found. These findings need further validation in patients that experienced 
CBZ-induced hypersensitivity reactions. Finally, new HLA typing methods 
were utilised and showed promising results but also require optimisation (see 
Fig. 6.1). 
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Figure 6.1: Contribution of present work to the field of Carbamazepine-
induced hypersensitivity reaction 
 
Recent discoveries in the field, such as the finding of HLA associations to 
hypersensitivity reactions and uncovering the exact mechanism of drug 
binding to HLA molecule in the case of abacavir, greatly improved our 
understanding of hypersensitivity reactions. Nevertheless, further 
investigations of the approaches undertaken in this study are necessary to 
confirm the association between cytotoxic susceptibility to drugs and the 
development of hypersensitivity reactions. The ultimate aim is to develop 
predictive testing to determine risk of hypersensitivity reactions in patients to 
prevent these reactions in the future and through that, to improve drug 
safety. 
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Appendix 
Plots show the staining of PBMCs with Annexin V and PI:  
 
Figure A2.1:  Staining of PBMCs with Annexin V and PI  
The experiment was performed using PBMCs from one individual. PBMCs were exposed to 
Methanol (MeOH) 9-AC (50 µM) Staurosporine (STS, 4 µM), and Cytochalasin B (CytB, 50 
µM) for 2 or 24 h. Samples were measured in flow cytometer. 
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Plots show the triple staining of PBMCs with Annexin V, PI, and a CD3+ 
specific, florescent antibody: 
 
Figure A2.2: Triple staining of PBMCs with Annexin V, PI, and T -cell 
specific, fluorescent antibody CD3
+
 
The experiment was performed using PBMCs from one individual. PBMCs were exposed to 
Methanol (MeOH) 9-AC (50 µM) Staurosporine (STS, 4 µM), and Cytochalasin B (CytB, 50 
µM) for 2 hours. The medium was replaced after 2 hours with fresh, drug-free medium for 
the rest of the 24 hours. After 24 hours of incubation, cells were stained with Annexin V and 
PI and the T-cell antibody. Samples were measured in flow cytometer. 
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Exposure of PBMCs to CBZ and 9-AC in RPMI-1640 media containing 10% 
foetal calve serum and 2 mM L-glutamine obtained from Invitrogen Ltd 
(Paisley, UK). For further description of the experimental setup see chapter 
2. 
 
Figure A2.3: Cell viability of PBMCs exposed to CBZ and 9 -AC in RPMI-
1640 
PBMCs were exposed to different concentrations of CBZ and 9-AC for 2 hours (A) and 24 
hours (B). 
 
Figure A2.4: Mitochondrial depolarisation of PBMCs exposed to CBZ and 
9-AC in RPMI-1640 
PBMCs were exposed to different concentrations of CBZ and 9-AC for 2 hours (A) and 24 
hours (B). 
234 
 
 
Figure A2.5: Measuring and apoptotic and necrotic cells of PBMCs 
exposed to CBZ and 9-AC in RPMI-1640 
PBMCs were exposed to different concentrations of CBZ and 9-AC for 2 hours (A) and 24 
hours (B). 
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Table A4.1: Samples used for DUOX1 rs16939743 genotyping  
Ctrl: control, MPE: maculopapular exanthema, AGEP: acute generalised exanthematous 
pustulosis, DRESS: drug reaction with eosinophilia and systemic syndromes SJS/TEN: 
Stevens-Johnson syndrome and/or toxic epidermal necrolysis, NK: not known 
Sample ID DUOX1 allele Phenotype Ethnicity 
C001 TT exposed ctrl WHITE 
C002 TT exposed ctrl WHITE 
C003 TT exposed ctrl WHITE 
C004 TT exposed ctrl WHITE 
C005 TT exposed ctrl WHITE 
C006 TT exposed ctrl WHITE 
C007 TT exposed ctrl WHITE 
C008 TT exposed ctrl WHITE 
C009 TT exposed ctrl WHITE 
C010 TT exposed ctrl WHITE 
C011 TT exposed ctrl WHITE 
C012 TT exposed ctrl WHITE 
C013 TT exposed ctrl WHITE 
C014 TT exposed ctrl WHITE 
C015 TT exposed ctrl WHITE 
C016 TT exposed ctrl WHITE 
C017 TT exposed ctrl WHITE 
C018 TT exposed ctrl WHITE 
C019 TT exposed ctrl WHITE 
C020 TT exposed ctrl WHITE 
C021 TT exposed ctrl WHITE 
C022 TT exposed ctrl WHITE 
C023 TT exposed ctrl WHITE 
C024 TT exposed ctrl WHITE 
C025 TT exposed ctrl WHITE 
C026 TT exposed ctrl WHITE 
C027 TT exposed ctrl WHITE 
C028 TT exposed ctrl WHITE 
C029 TT exposed ctrl WHITE 
C030 TT exposed ctrl WHITE 
C031 TC exposed ctrl WHITE 
C032 TT exposed ctrl WHITE 
C033 TT exposed ctrl WHITE 
C034 TT exposed ctrl WHITE 
C035 TT exposed ctrl WHITE 
C036 TT exposed ctrl WHITE 
C037 TT exposed ctrl WHITE 
C038 TT exposed ctrl WHITE 
C039 TT exposed ctrl WHITE 
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C040 TT exposed ctrl WHITE 
C041 TT exposed ctrl WHITE 
C042 TT exposed ctrl WHITE 
C043 TT exposed ctrl WHITE 
C044 TT exposed ctrl WHITE 
Greek TT SJS/TEN WHITE 
H001 TC DRESS White, but outlier in WGS 
H002 TT SJS WHITE 
H004 TT DRESS WHITE 
H005 TT MPE WHITE 
H006 TT DRESS WHITE 
H010 TT MPE WHITE 
H011 TT MPE WHITE 
H017 TT MPE WHITE 
H020 TT DRESS WHITE 
H021 TT DRESS WHITE 
H022 TT MPE WHITE 
H023 TT MPE WHITE 
H025 TT DRESS WHITE 
H026 TT MPE WHITE 
H027 TT MPE WHITE 
H028 TT MPE WHITE 
H029 TT MPE WHITE 
H031 TT MPE WHITE 
H033 TT MPE WHITE 
H034 TT MPE WHITE 
H035 TT MPE WHITE 
H036 TT MPE WHITE 
H037 TT MPE WHITE 
H038 TT MPE WHITE 
H039 TT MPE WHITE 
H040 TT DRESS WHITE 
H041 TT MPE WHITE 
H042 TT MPE WHITE 
H043 TT MPE WHITE 
H044 TT MPE WHITE 
H046 TT MPE WHITE 
H047 TT DRESS WHITE 
H048 TT MPE WHITE 
H049 TT DRESS WHITE 
H050 TT MPE WHITE 
H051 TT MPE WHITE 
H052 TT MPE WHITE 
H053 TT MPE WHITE 
H054 TT DRESS WHITE 
H055 TT HSS/DRESS/DIHS INDIAN 
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H056 TT MPE WHITE 
H057 TT MPE WHITE 
H058 TT MPE WHITE 
H062 TT MPE WHITE 
H063 TT DRESS WHITE 
H064 TT MPE WHITE 
H065 TT MPE WHITE 
H066 TT HSS/DRESS/DIHS ASIAN - YEMENI 
H068 TT MPE WHITE 
H069 TT MPE WHITE 
H070 TT MPE WHITE 
H071 TT DRESS WHITE 
H072 TT DRESS WHITE 
H073 TT TEN WHITE 
H074 TT MPE WHITE 
H075 TT MPE WHITE 
H076 TT DRESS WHITE 
H077 TT DRESS WHITE 
H080 TT DRESS WHITE 
HUC_0002 TT HSS/DRESS/DIHS WHITE 
HUC_0005 undetermined HSS/DRESS/DIHS WHITE 
IUB_0012 undetermined SJS BLACK AFRICAN 
LSC_0020 TT SJS/TEN WHITE 
LSC_0034 TT SJS WHITE 
LSC_0073 TT SJS/TEN PAKISTANI 
LSC_0092 TT SJS/TEN WHITE 
LSC_0093 TT HSS/DRESS/DIHS WHITE 
LSC_0094 TT SJS/TEN WHITE 
LSC_0095 TT HSS/DRESS/DIHS WHITE 
N002a TT DRESS WHITE 
N006a TT DRESS WHITE 
N008a TT DRESS WHITE 
N011a TT DRESS WHITE 
N012a TC SJS THAI-WHITE 
RPH_0012 TC TEN THAI 
RPH_0013 TT TEN VIETNAMESE 
RPH_0046 undetermined SJS BLACK CARIBBEAN 
ULP_0121 TT SJS/TEN WHITE 
ULP_0125 TT SJS/TEN WHITE 
UPP_0015 TT AGEP WHITE 
UPP_0019 TT SJS WHITE 
USP_0001 TT SJS/TEN MIXED: BLACK/WHITE/NK 
USP_0002 TC HSS/DRESS/DIHS 
MIXED: 
WHITE/BLACK/BRAZILIAN 
INDIAN 
USP_0003 TT SJS/TEN MIXED: BLACK/WHITE/NK 
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USP_0005 TT HSS/DRESS/DIHS 
MIXED: 
WHITE/BLACK/BRAZILIAN 
INDIAN 
USP_0006 TT HSS/DRESS/DIHS WHITE 
USP_0010 TT HSS/DRESS/DIHS WHITE 
USP_0011 TT HSS/DRESS/DIHS MIXED: BLACK/WHITE/NK 
USP_0012 TT HSS/DRESS/DIHS WHITE 
USP_0013 TT SJS/TEN 
MIXED: 
WHITE/BLACK/BRAZILIAN 
INDIAN 
USP_0014 TT HSS/DRESS/DIHS 
MIXED: WHITE/BRAZILIAN 
INDIAN 
USP_0015 TT SJS/TEN WHITE 
USP_0016 TT SJS/TEN WHITE 
USP_0017 TT HSS/DRESS/DIHS WHITE 
USP_0018 TT HSS/DRESS/DIHS MIXED: BLACK/WHITE 
USP_0022 TT HSS/DRESS/DIHS 
MIXED: 
WHITE/BLACK/BRAZILIAN 
INDIAN 
USP_0029 TT SJS/TEN WHITE 
USP_0030 TT SJS/TEN MIXED: WHITE/NK 
USP_0031 TT HSS/DRESS/DIHS MIXED: WHITE/NK 
USP_0034 undetermined HSS/DRESS/DIHS 
MIXED: WHITE/BRAZILIAN 
INDIAN/NK 
USP_0035 TC SJS/TEN WHITE 
USP_0036 TT SJS/TEN WHITE/NK 
USP_0037 TC HSS/DRESS/DIHS WHITE/BLACK/NK 
USP_0040 TT HSS/DRESS/DIHS NK 
USP_0044 TT SJS/TEN WHITE 
USP_0045 TT HSS/DRESS/DIHS NK 
USP_0046 TT HSS/DRESS/DIHS 
MIXED: 
WHITE/BLACK/BRAZILIAN 
INDIAN 
USP_0048 TT HSS/DRESS/DIHS MIXED: BLACK/WHITE 
 
